Electrostatic nanoparticles and uses thereof

JP2023553038A5Pending Publication Date: 2024-12-05バウマー セバスチャン +4
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023534305
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-29
Filing Date
2021-12-02
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing RNA interference (RNAi) therapies face challenges in delivering siRNA effectively to target cells due to issues such as nuclease attack, immunogenicity, and renal clearance, limiting their half-life and circulation time, and lack of targeted cell delivery mechanisms.

Method used

A method involving the formation of nanoparticles by conjugating a positively charged polypeptide, such as protamine, to a bifunctional linker, and then combining it with an antibody and negatively charged molecules like siRNA, forming a nanoparticle that self-assembles in the presence of free protamine, enhancing targeted delivery.

Benefits of technology

The nanoparticles efficiently deliver siRNA to target cells, achieving specific gene silencing and therapeutic effects with improved stability and bioavailability, applicable to various diseases including cancer and viral infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022117731000001
    Figure 2022117731000001
  • Figure 2022117731000002
    Figure 2022117731000002
  • Figure 2022117731000003
    Figure 2022117731000003
Patent Text Reader

Abstract

The present invention relates to a method for producing nanoparticles, comprising the steps of: (c) contacting an antibody with a composition comprising a first conjugate (A), wherein the first conjugate comprises a positively charged polypeptide conjugated to a bifunctional linker, and the composition is essentially free of unconjugated bifunctional linkers, thereby obtaining a second conjugate (B), wherein the second conjugate comprises a positively charged polypeptide, a bifunctional linker, and an antibody; and (d) contacting the second conjugate (B) with a positively charged polypeptide and a negatively charged molecule, thereby forming nanoparticles. The present invention also relates to nanoparticles obtained by the method of the present invention, including nanoparticles comprising (a) a positively charged polypeptide; (b) the second conjugate (B) comprising an antibody conjugated to a positively charged polypeptide; and (c) one or more negatively charged molecules. The present invention also relates to compositions comprising the nanoparticles of the present invention, and to nanoparticles or compositions of the present invention for use in therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Cross - reference to related applications This application claims the benefit of priority of Luxembourg Patent Application No. 102272 filed on December 2, 2020, European Patent Application No. 21175260.5 filed on May 21, 2021, and European Patent Application No. 21205482.9 filed on October 29, 2021, the contents of which are hereby incorporated by reference in their entirety.

[0002] Field of the Invention The present invention relates to a method for producing nanoparticles, which comprises the steps of: (c) contacting an (c) antibody with a composition comprising a first conjugate (A), wherein the first conjugate comprises a positively charged polypeptide conjugated to a bifunctional linker, and the composition essentially does not contain an unconjugated bifunctional linker, whereby a second conjugate (B) is obtained, and the second conjugate comprises a positively charged polypeptide, a bifunctional linker, and an antibody; and (d) contacting the second conjugate (B) with a positively charged polypeptide and a negatively charged molecule, thereby forming nanoparticles. The present invention also relates to the nanoparticles obtained by the method of the present invention, and to nanoparticles comprising (a) a positively charged polypeptide; (b) a second conjugate (B) comprising an antibody conjugated to the positively charged polypeptide; and (c) one or more negatively charged molecules. The present invention also relates to a composition comprising the nanoparticles of the present invention, and to the nanoparticles or composition of the present invention for use in therapy.

Background Art

[0003] Background The principle of RNA inhibition (RNAi) has shown great potential for medical application and was awarded the Nobel Prize in 2006. This method demonstrates high efficiency in inactivating mRNA of virtually any gene and subsequently silencing its expression through the selection and synthesis of gene-specific siRNA oligonucleotides. While this method has revolutionized molecular biology, translating this principle into clinical practice has proven difficult due to numerous specific problems.

[0004] siRNA oligos are attacked by nucleases, resulting in increased immunogenicity and renal clearance; therefore, the half-life and circulation time of "naked siRNA" are often far below expectations. Consequently, siRNA has been conjugated with stabilizers such as nanoparticles or capsules. While these stabilizers have increased the circulation time and bioavailability of siRNA, a target-cell determining structure remains lacking that (a) targets cells with specific surface molecules, delivers siRNA to these cells, and (b) enables target-specific translocation of anionic siRNA across anionic cell membranes.

[0005] Numerous Phase I-III clinical trials have been conducted for the treatment of neurological disorders, viral infections, and cancer, but to date, only one siRNA has been approved by the FDA. For example, patisiran (brand name Onpattro) is a drug therapy for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Hereditary transthyretin amyloidosis is a deadly rare disease that is estimated to affect 50,000 people worldwide.

[0006] To develop a modular therapeutic approach for treating oncological disorders, the inventors developed a system for coupling siRNA to antibodies against cancer cell-specific surface molecules, using a specific cationic peptide, protamine, to induce internal translocation upon binding. This system delivers siRNA to the target cancer cells, where it binds to their respective surface molecules, such as receptors, and then translocates internally in a receptor-dependent manner.

[0007] Protamine is a cationic nucleic acid-binding peptide that transports a complete set of compressed genomic DNA to the sperm head. Because it can complex with nucleic acids and facilitate nucleic acid transfer across the cell membrane, it has attracted the interest of many researchers to study its applications in transfection, targeted delivery, and gene therapy (Choi et al., 2009; Chono et al., 2008; Hansen et al., 1979; He et al., 2014; Liu, B., 2007). Protamine has been tested as a nucleic acid delivery medium and linked to various cell-deterministic targeting regions. In 2005, Song et al. (Song et al., 2005a) presented a genetic fusion protein linking a Fab fragment (F105) to the human immunodeficiency virus HIV gp 160 envelope protein with a truncated protamine peptide. The fusion protein was conjugated with an siRNA targeting the HIV gag protein, and its conjugate was able to target HIV-infected T cells and melanoma cells transfected with the HIV envelope, which are difficult to transfect. The siRNA-F105 carrier conjugate inhibited HIV replication in infected T cells. To validate the targeting principle, the same strategy was applied to target ErbB2 with a protamine-fused Erb2 single-chain antibody. While this genetic fusion of protamine and cytodeterminants was followed in numerous publications, the concept has not been successfully translated into clinical practice.

[0008] In previous studies, the inventors of the present invention conjugated the anti-EGFR monoclonal antibody (mAB) cetuximab to the cationic peptide protamine using a bispecific crosslinker, sulfo-SMCC, according to the chemical conjugation scheme described in Baumer, N. et al., 2016 Nat. Protoc. 11, 22-36, Baumer, N. et al., 2018 PLoS One 13, e0200163; and Baumer, S. et al., 2015 Clin Cancer Res 21, 1383-94. The resulting IgG-protamine conjugate molecule was able to internalize the EGF receptor and deliver siRNA to target cells.

[0009] An object of the present invention is to provide further, preferably improved, means and methods for delivering anionic molecules to target cells. [Overview of the Initiative]

[0010] overview The present invention (c) A step of contacting an antibody with a composition comprising a first conjugate (A), wherein the first conjugate comprises a positively charged polypeptide conjugated to a bifunctional linker, and the composition essentially does not contain an unconjugated bifunctional linker, thereby obtaining a second conjugate (B), the second conjugate comprising a positively charged polypeptide, a bifunctional linker, and an antibody; and (d) A step of bringing a second conjugate (B) into contact with a positively charged polypeptide and a negatively charged molecule, thereby forming nanoparticles. This relates to a method for producing nanoparticles, including [specific material / synthetic elements].

[0011] The present invention also relates to nanoparticles obtained by the method of the present invention.

[0012] The present invention (a) Positively charged polypeptides; (b) A second conjugate (B) comprising an antibody conjugated to a positively charged polypeptide via a bifunctional linker; (c) One or more negatively charged molecules and This also relates to nanoparticles containing [the specified element].

[0013] The present invention also relates to compositions containing the nanoparticles of the present invention.

[0014] The present invention also relates to the nanoparticles or compositions of the present invention for use in therapeutic applications. [Brief explanation of the drawing]

[0015] [Figure 1] Formation of multiple antibody-SMCC-protamine conjugates by applying the conjugation method published in Baumer, N. et al., 2016. (As shown in Figure 2) If excess sulfo-SMCC is not depleted after the reaction, the residual crosslinker can form multiple different conjugates from IgG, protamine-SMCC, and reactive sulfo-SMCC. Examples of unintended byproducts that can be observed by SDS-PAGE are IgG (A and B: anti-EGFR-mAB cetuximab) internally crosslinked by excess sulfo-SMCC, and simultaneously, IgG crosslinked to protamine. Furthermore, an unreducible high molecular weight IgG polymer (A) and simultaneously, IgG crosslinked to protamine, as seen in the gel (B), were observed. In extreme cases, the complexity of unintended side reactions may lead to the appearance of a cloud (B), which is formed by a mixture of all possible conjugates a-d. HC: heavy chain, LC: light chain. Omitting the depletion of unreacted SMCCs may result in the formation of unwanted by-products that could interfere with the function of the intended product (c). For example, reactive SMCCs may result in crosslinking between the light and heavy chains within a given IgG molecule (a) or crosslinking between two IgG molecules to form an IgG dimer (d). [Figure 2-1]Modification of the conjugation method published in (Baumer, N. et al., 2016). A: If excess sulfo-SMCC is not depleted after coupling sulfo-SMCC with protamine, the residual crosslinker can form multiple different conjugates from IgG and protamine-SMCC and reactive sulfo-SMCC. Instead, in the previous protocol, the antibody-SMCC-protamine conjugate was desalted after the coupling process. This step has been omitted in the new protocol (C: anti-EGFR antibody cetuximab, D: anti-IGF1R antibody ImcA12). Examples of unintended byproducts that may be observed by SDS-PAGE are highlighted with circles. B: The new conjugation protocol now includes a purification step after coupling sulfo-SMCC with protamine. Unbound sulfo-SMCC is depleted from the SMCC-protamine conjugate using a Zeba spin gel purification column that retains free sulfo-SMCC and elutes the SMCC-protamine conjugate. As a result, a distinct conjugation product is formed between SMCC-protamine and the heavy chain (HC) and light chain (LC) of the IgG antibody cetuximab (Cet;E) and ImcA12 (A12;F), which can be observed in Coomaschy-stained SDS-PAGE. HC: heavy chain, LC: light chain, P: protamine. Omission of depletion of unreacted SMCC may result in the formation of unwanted by-products that may interfere with the function of the intended product (c). For example, reactive SMCC may result in crosslinking between the light and heavy chains within a given IgG molecule (a) or crosslinking between two IgG molecules to form an IgG dimer (d). [Figure 2-2] See the explanation in Figure 2-1. [Figure 3-1]Antibody-mediated siRNA targeting KRAS in NSCLC. A: Targeting construct between the anti-EGFR monoclonal antibody (mAB) cetuximab and protamine. B: The anti-EGFR-mAB-protamine / free protamine (P / P) complex (α-EGFR-mAB) binds up to 8 moles of siRNA per mole of antibody. C: Cetuximab (anti-EGFR-mAB-)protamine / free SMCC-protamine (P / P) transports Alexa488-tagged siRNA to endosomes (white dots, upper left panel), but does not transport it to lysosomes because Alexa488-positive vesicles do not overlap with the lysosomal marker Lysotracker (white dots, upper right panel). D: NSCLC cells treated with α-EGFR-mAB-protamine / free protamine / siRNA (containing α, anti;P / P) showed silencing of KRAS expression by KRAS siRNA, but not by the control siRNA. E: Cells treated with α-EGFR-mAB-protamine / free protamine / siRNA (P / P) showed a significant reduction in colony formation by KRAS siRNA targeting the wt allele and the G12D mutant allele. F: α-EGFR-mAB-protamine / free protamine, applied systemically as a control and in a conjugate with KRAS-siRNA, was well tolerated in CD1-nude mice with sc xenografted SKLU1 and A549 cells, and α-EGFR-mAB-protamine / free protamine / KRAS-siRNA significantly inhibited tumor growth in SKLU and A549 tumors. G: Although A549 tumors were already therapeutically inhibited by cetuximab-P / P containing control (scrambled) siRNA, tumors in the KRAS siRNA-treated group were significantly lighter than in any of the control groups. Resected tumors were presented in H. Statistic: Mean + / - standard deviation for all experiments except F, for which standard error of mean (SEM) was selected. Significance: p<0.05, two-sided t-test. [Figure 3-2] See the explanation in Figure 3-1. [Figure 3-3] See the explanation in Figure 3-1. [Figure 3-4] See the explanation in Figure 3-1. [Figure 4] In NSCLC xenografts treated with KRAS knockdown, the abundance of the proliferation marker Ki67 is lower. Immunofluorescence determination of the proliferation marker Ki67 (gray dots A, C, E and G, I, K) in histological xenograft sections. In both A549 (A-F) and SK-LU1 (G-L), the number of Ki67-positive nuclei was significantly reduced in tumor histological sections treated with KRAS siRNA compared to groups treated with PBS and control siRNA carriers. [Figure 5] NSCLC xenografts exhibit a higher abundance of apoptotic cells. Immunohistochemical assignment of apoptosis in xenograft tumor sections by TUNEL assay. A-L: In both xenografted cell lines, tumors treated with KRAS siRNA carriers showed increased apoptosis rates compared to the control group. M-N: Statistics of TUNEL-positive nuclei in sections: In A549 tumors treated with EGFR-mAB-protamine / free protamine (mAB-P / P), the number of TUNEL-positive nuclei increased 2-fold compared to PBS treatment, and 3-fold in tumors treated with KRAS siRNA carriers. In SK-LU1, only EGFR-mAB-protamine / free protamine KRAS siRNA treatment resulted in a 4-fold increase in apoptotic cells. α, anti; cntr, control. [Figure 6]Rhabdomyosarcoma (RMS) cell lines can be targeted by antibody-siRNA complexes. A: Expression of cell surface receptors EGFR and IGF1R was tested in two RMS cell lines, and both IGFR1R and EGFR were expressed in both cell lines. B: Cetuximab-protamine (EGFR-mAB-P( / P / P) containing free SMCC-protamine) shuttled Alexa488-marked control siRNA to the majority of RD cells (>90% in FACS plot C), but the effect was lower in RH-30 (FACS not shown). RH-30 was instead characterized by shuttle transport of Alexa488 control siRNA by anti-IGF1R-directed GR11L-protamine(P / P). [Figure 7]Targeting of RD (fetal RMS, ERMS) cells and RH30 (alveolar RMS, ARMS) cells by siRNA knockdown of cmyc / NRAS and KRAS mediated by cetuximab-protamine / free SMCC-protamine (P / P), and PAX3 in RH30 reduced colony growth in soft agar assays. Cells were harvested and treated with 30 nM cetuximab-protamine / P (EGFR-mAB-P / P containing free SMCC) coupled to either control (scr) siRNA or two siRNAs effective against c-Myc and NRAS as shown, seeded onto soft agar in 96-well plates, cultured for 2 weeks, stained, and counted (A). The combination of two effective siRNAs reduced the number of colonies normalized to the PBS control from 87% to 63% in the control group (B). C: Treatment of RD cells with EGFR-mAB-P / P coupled to siRNA specific for either KRAS or NRAS moderately reduced NRAS expression in the respective cells. P<0.001, two-sided T test. D: The sequences GGCCTCTCACCTCAGAATTC (siPF1, SEQ ID NO:49), GCCTCTCACCTCAGAATTCA (siPF2, SEQ ID NO:50), CCTCTCACCTCAGAATTCAA (siPF3, SEQ ID NO:51) show the respective positions of siRNAs covering the breakpoint region of the fusion oncogene PAX3-Forkhead (FKHR) represented by the sequence TGGCCTCTCACCTCAGAATTCAATTCGTC (SEQ ID NO:48) (PAX3 part is light gray, FKHR part is dark gray). E: siRNA knockdown of PAX3-FKHR in RH30 cells mediated by cetuximab-protamine / P reduced colony growth in soft agar assays. Colony growth can be significantly inhibited by application of siRNA siPF2 against the breakpoint mediated by cetuximab (siRNA walking visualized in D). P<0.05, two-sided T test. [Figure 8]Antibody-siRNA-P / P complex formation can be applied to IGF1R targeting. A: Flow cytometry here shows that A673 Ewing sarcoma cells undergo internal translocation of the mouse anti-IGF1R antibody GR11L-sulfo-SMCC-protamine / P complex, such as uncoupled GR11L antibody, at 37°C. This is illustrated by the left shift of the histogram signal compared to a 4°C control that did not undergo internal translocation. B: In A673 cells, green fluorescent cytoplasmic vesicle structures consisting of Alexa Fluor 488-siRNA underwent internal translocation by GR11L-protamine containing free SMCC-P (arrow, right image), but not in the control experiment lacking antibody conjugate (left image). The internally translocated Alexa Fluor 488-siRNA is seen as white vesicle deposits (white arrow). Counterstaining of the cell nucleus by Hoechst is shown in gray as kidney-shaped structures. The area enclosed by the rectangle illustrates a magnified view of the shown cell. Scale bar, 20 μm. C: Next, the GSP complex was coupled to siRNA against mRNA of the oncogenic fusion protein EWS-FLI1, and A673 cells were treated with these complexes. As a result, EWS-FLI1 expression was downregulated in Western blot of FLI1 expression, as detected here. EWS-FLI1(E / F)-specific siRNA 2 reduced EWS-FLI1 protein expression by 80% compared to control siRNA and PBS control. Other E / F-specific siRNAs (siRNA 1 and FLI1-esiRNA) were found to have a much lower effect. EWS-FLI1 migrated as a biband of approximately 64 kDa, and actin migrated to 43 kDa. Published in (Baumer, N. et al., 2016). [Figure 9]Anti-IGF1R-mAB, A12 and Tepro for targeting Ewing's sarcoma cells. A: mABs targeting IGF1R, A12 (cixutumumab) and Tepro (teprotumumab) were expressed and purified in our laboratory and can be conjugated to protamine / P to enable binding and transport of siRNA. The IgG-protamine / P conjugate shows a proper molecular weight shift (arrow). HC = heavy chain, LC = light chain, -P = SMCC-protamine. B: Band shift assay using anti-IGF1R-mAB-protamine and different ratios of siRNA. C: Anti-IGF1R-mAB-protamine (containing free SMCC-P) shuttle-transported the control siRNA marked by Alexa488 into SKNM-C Ewing cells (white dots). [Figure 10] Breakpoint siRNA significantly reduced colony formation of Ewing SKNM-C cells compared to the control. SKNM-C cells were treated with A12 (A) or Tepro (B) conjugated to protamine / P and the indicated siRNA and subjected to a colony formation assay. E / F-siRNA is siRNA that interferes with the mRNA of EWS-Fli1 driving Ewing's sarcoma. BCL2 is siRNA against BCL2. P < 0.05, two-sided T test. [Figure 11] Cross-sectional view of an example of a nanoparticle-like structure that meets the conditions of an effective antibody-SMCC-protamine / P-siRNA or -SM-1 / RF carrier complex inferred from the experiment. An electrostatic binding bridge is formed between mABs, and some protamines are coupled to the targeting antibody and each anionic cargo, and the anionic cargo includes siRNA (A), anionic small molecules such as SM-1 / RF (B), or both (C). [Figure 12] The antibody-protamine / free protamine conjugate can bind to single-stranded antisense oligonucleotides (ASOs). The band shift assay has revealed that 1 mole of the EGFR antibody-protamine conjugate binds to 8 - 32 moles of ASO. [Figure 13] Description of the molecular composition of effective siRNA conjugates. Anti-CD20 mAB was conjugated with SMCC-protamine in a molar excess relative to mAB, as shown. The resulting conjugate mixture was then tested for its ability to conjugate siRNA. Regardless of the molar excess of the provided protamine-SMCC, the resulting siRNA conjugate ability did not differ significantly, and was in the range of approximately 16 moles of siRNA per mole of carrier conjugate. [Figure 14] The CD20-mAB rituximab-protamine / P conjugate binds to 8 moles of siRNA. A: Coomassie-stained SDS-PAGE showing anti-CD20-mAB, anti-CD20-mAB coupled to 30x SMCC-protamine, and molecular marker (M). HC=heavy chain, LC=light chain, -P=SMCC-protamine. B: Band shift assay using CD20-mAB-protamine / P with different ratios of siRNA. [Figure 15]Targeting of DLBCL cell lines with antibody-P / P-siRNA conjugates. Top panel: Selected DLBCL cell lines were tested for CD20 and CD33 expression by FACS analysis. Center panel (white dots): Alexa488-tagged siRNA was conjugated to monoclonal antibodies (both containing free SMCC-protamine) against CD20 (rituximab) and CD33 (gemtuzumab) conjugated with protamine, and each cell line was treated overnight with these compositions. The siRNA was translocated internally via the respective antibody targeting and condensed within cytoplasmic vesicle structures. Both targeting mABs (left: anti-CD20, right: anti-CD33) were shown to transport siRNA to their respective cell lines. Bottom panel: DLBCL cell lines were seeded on methylcellulose and treated with the shown antibody-protamine / P-siRNA conjugates. CD33 is highly expressed in all cell lines, and rituximab transports siRNA into intracellular vesicles, but the response to key gene knockdown, detected by colony formation ability, is poor, indicating problematic endosomal release. In contrast, gemtuzumab, targeting less expressed CD33, shows a much better response to gene knockdown: significance *p<0.01. Here, in particular, HBL-1 cells show a good response to BTK kinase knockdown, as well as to knockdown of cytoplasmic kinase SYK, and further components of the B cell receptor signaling pathway, e.g., CARD11b, CD79B, and MYD88. [Figure 16] Synthesis of polyanionic low molecular weight (SM) derivatives for electrostatic transport using monoclonal antibodies. SM-1 was conjugated to a polyanionic red fluorescent chromophore (RF) to form a low molecular weight (1.44 kDa) polyanion. [Figure 17]CD20-mAB rituximab-protamine / P conjugates and EGFR-mAB cetuximab-protamine / P conjugates bind to SM-1 / RF. A: Band shift assays using CD20-mAB-protamine / P and EGFR-mAB-protamine / P with different ratios of SM-1 / RF up to 1:32. B: Band shift assays using CD20-mAB-protamine / P and EGFR-mAB-protamine / P with different molecular excesses of SM-1 / RF up to 1:200. At least 100 moles of SM-1 / RF can be conjugated by antibody-protamine conjugates that also contain free SMCC-protamine. [Figure 18] CD20-mAB rituximab-protamine / P conjugate and EGFR-mAB cetuximab-protamine / P conjugate transport SM-1 / RF. A: CD20-positive HBL-1 DLBCL cells internalize the CD20-mAB-protamine / P / SM-1 / RF (containing free SMCC-P) complex (gray shadow, left). B: EGFR-positive A549 NSCLC cells internalize the EGFR-mAB-protamine / P / SM-1 / RF / P complex (white dots, left). [Figure 19] The EGFR-mAB cetuximab-protamine conjugate does not efficiently bind to siRNA after depletion of free SMCC-protamine by HPLC. A: Coomaschy-stained SDS-PAGE showing HPLC fractions 25-31 of anti-EGFR-mAB, anti-EGFR-mAB coupled to 32x SMCC-protamine, and anti-EGFR-mAB coupled to 32x SMCC-protamine after depletion of unbound SMCC-protamine; HC=heavy chain, LC=light chain, -P=SMCC-protamine. B: Band shift assay. [Figure 20]Colony formation assay of NSCLC cells treated with different siRNA carriers, both with and without free protamine, on soft agar. A: A549 cells treated with EGFR-mAB-protamine / P-KRAS-siRNA formed significantly fewer colonies on soft agar than cells treated with EGFR-mAB-protamine / P / control (scr)siRNA. B: SK-LU1 cells. When A549 cells (A) or SK-LU1 cells (B) were treated with an EGFR-mAB-protamine conjugate without free protamine (see Figure 19A, fractions 29 / 30), or with the same amount of SMCC-protamine alone, no difference in colony formation was observed compared to cells treated with PBS. Photographs of the colony assay and mean + / -SD values ​​from three independent experiments are shown here. Asterisks indicate statistical significance (P<0.05, two-sided t-test). [Figure 21-1] The CD33-mAB gemtuzumab-protamine conjugate does not efficiently bind to siRNA after depletion of free SMCC-protamine by HPLC. A: Coomaschy-stained SDS-PAGE showing HPLC fractions 24-30 of anti-CD33-mAB, anti-CD33-mAB coupled to 32x SMCC-protamine, and anti-CD33-mAB coupled to 32x SMCC-protamine after depletion of unbound SMCC-protamine; HC=heavy chain, LC=light chain, -P=SMCC-protamine. B: Band shift assay. C: Colony formation assay. OCI-AML2 cells treated with CD33-mAB-protamine / P-DNMT3A-siRNA (containing free SMCC-P) form significantly fewer colonies on soft agar than cells treated with CD33-mAB-protamine / P-control (scr)siRNA (containing free SMCC-P). When OCI-AML2 cells were treated with a CD33-mAB-protamine conjugate that did not contain free SMCC-protamine, no difference in colony formation was observed compared to cells treated with PBS (see A+B, fraction 30). The mean ± SD of three independent experiments are shown here. *P<0.033, two-tailed t-test. [Figure 21-2]See the explanation in Figure 21-1. [Figure 22] CD20-mAB rituximab-protamine conjugates do not efficiently bind to SM-1 / RF after depletion of free SMCC-protamine by HPLC. A: Coomaschy-stained SDS-PAGE showing HPLC fractions 19-25 / 26 of anti-CD20-mAB, anti-CD20-mAB coupled to 32x SMCC-protamine, and anti-CD20-mAB coupled to 32x SMCC-protamine at the depletion of unbound SMCC-protamine; HC=heavy chain, LC=light chain, -P=SMCC-protamine. B: Band shift assay of protamine-depleted CD20-mAB preparation (left) and protamine-containing CD20-mAB preparation (right). SMCC-protamine-depleted CD20-mAB preparations do not bind to >32 molars of SM-1 / RF. [Figure 23] The anti-IGF1R monoclonal AB IMCA-12(A12)-protamine conjugate does not efficiently bind to siRNA after depletion of free SMCC-protamine by HPLC. A: Coomaschy-stained SDS-PAGE showing HPLC fractions 15-21 of anti-IGF1R coupled to 32x SMCC-protamine and anti-IGF1R-mAB coupled to 32x SMCC-protamine after depletion of unbound SMCC-protamine; HC=heavy chain, LC=light chain, -P=SMCC-protamine. B: Band shift assay with protamine-depleted IGF1R-mAB preparation (bottom; fraction 20; see A) and SMCC-protamine-containing IGF1R-mAB preparation (top). The SMCC-protamine-depleted IGF1R-mAB preparation does not bind to 8 moles of siRNA. [Figure 24]Colony formation assay of SKNM-C Ewing sarcoma cells treated with A12 carriers, both with and without free protamine, on soft agar. SKNM-C cells treated with IGF1R(A12)-mAB-protamine / P-EWS-FLI1-siRNA containing free SMCC-P formed significantly fewer colonies on soft agar than cells treated with IGF1R(A12)-mAB-protamine / P-control(scr)siRNA containing free SMCC-P. No difference in colony formation was observed when SKNM-C cells were treated with an EGFR-mAB-protamine conjugate without free protamine. The mean + / -SD values ​​from three independent experiments are shown here. Asterisks indicate statistical significance (*P<, two-sided t-test). [Figure 25] Colony formation assay of SKNM-C Ewing sarcoma cells treated with different siRNA carriers, both with and without free SMCC-protamine, on soft agar. SKNM-C cells treated with IGF1R(A12)-mAB-protamine / P / EWS-FLI1(E / F)-siRNA containing free SMCC-P formed significantly fewer colonies on soft agar than cells treated with IGF1R(A12)-mAB-protamine / P / control (scr)siRNA containing free SMCC-P. When SKNM-C cells were treated with an EGFR-mAB-protamine conjugate containing free SMCC-protamine, or an EGFR-mAB-protamine conjugate without free SMCC-protamine (see Figure 19, fractions 29 / 30), or when the same amount of SMCC-protamine alone was used, no difference in colony formation was observed compared to cells treated with scr-siRNA (scr, scrambled). The mean + / - SD values ​​for three independent experiments are shown here. An asterisk indicates a statistically significant difference (P<0.05, two-tailed t-test). [Figure 26]Colony formation assay in soft agar of SKNM-C Ewing sarcoma cells, OCI-AML-2 leukemia cells, and A549 NSCLC cells treated with non-depleted A12 anti-IGF1R mAB or SMCC-protamine without antibody binding at the same concentration as the presumed IgG-protamine-SMCC-protamine / / free protamine / siRNA complex. A: SKNM-C cells treated with IGF1R(A12)-mAB-protamine / EWS-FLI1-siRNA / free SMCC-P formed significantly fewer colonies in soft agar than cells treated with IGF1R(A12)-mAB-protamine / control(scr)siRNA / free SMCC-P. In contrast, complexing of effective EWS-FLI1(E / F)-siRNA with SMCC-protamine alone at a concentration of 1800 nM proved ineffective (A, right). B: When SMCC-protamine was used in the AML cell line OCI-AML2 along with an effective DNMT3a siRNA without a targeting antibody, it did not inhibit colony formation. C: Finally, the same setup was tested in A549 with an effective KRAS siRNA conjugated to free SMCC-protamine, and there was no effect, and no difference from the control siRNA. The mean + / - SD of the three independent experiments are shown here. Asterisks indicate statistical significance (P<0.05, two-tailed t-test). [Figure 27] Vesicle tracking in A549 NSCLC cells. Cells treated with EGFR-mAB-protamine / free SMCC-P-Alexa488 siRNA were subjected to Lysotracker red staining. Vesicles containing Alexa488 (white dots, right panel) showed little co-localization with lysotracker staining (gray dots, center panel). [Figure 28]Internal migration of different anti-EGFR-mAB (cetuximab) preparations in EGFR-positive NSCLC cells (SK-LU1) treated with different complexes. SK-LU1 cells treated with EGFR-mAB-protamine / P / Alexa488-control siRNA containing free SMCC-protamine (white dots in the upper panel) and EGFR-mAB-protamine / P / Alexa488-control siRNA without free SMCC-protamine (lower panel). [Figure 29] Internal migration of different anti-EGFR-mAB (cetuximab) preparations in EGFR-positive NSCLC cells A549 treated with different complexes and free SMCC-protamine. A549 cells treated with EGFR-mAB-protamine / P / Alexa488-control siRNA containing free SMCC-protamine (nuclear staining in A, siRNA as white dots in D), and EGFR-mAB-protamine / P / Alexa488-control siRNA without free SMCC-protamine (B and E), as well as free SMCC-protamine (C and F). A-C: Nuclear staining using Hoechst, D-F: Green channels (white dots) illustrating the same cells as A-C, showing Alexa488-siRNA internal migration vesicles. [Figure 30] Internal migration of different anti-CD33-mAB (gemtuzumab) preparations in CD33-positive AML cells (OCI-AML2) treated with different complexes. OCI-AML2 cells treated with anti-CD33-mAB-protamine / P / Alexa488-control siRNA (A and D) containing free SMCC-protamine, anti-CD33-mAB-protamine / P / Alexa488-control siRNA (B and E) without free SMCC-protamine, and free SMCC-protamine (C and F). A-C. Nuclear staining using Hoechst (gray dots). D-F. Green channels illustrating the same cells as A-C for Alexa488-siRNA internal migration vesicles (white dots in D). [Figure 31]Internal migration of different anti-IGF1R-mAB(ImcA12) preparations in IGF1R-positive Ewing sarcoma cells (SKNM-C) treated with different complexes. SKNM-C cells treated with anti-IGF1R-mAB-protamine / P / Alexa488-control siRNA (A and D) containing free SMCC-protamine, anti-IGF1R-mAB-protamine / P / Alexa488-control siRNA (B and E) without free SMCC-protamine, and free SMCC-protamine (C and F). A-C: Nuclear staining using Hoechst; D-F: Green channels (white dots in D) illustrating the same cells as A-C, showing Alexa488-siRNA internal migration vesicles. [Figure 32] Presence of different anti-EGFR-mAB (cetuximab) preparations in EGFR-negative SKNMC cell cultures. The lower panel illustrates a magnified view of the inset in the upper panel, indicated by the white frame. A: Uncoupled cetuximab does not transport Alexa488-control siRNA to SKNMC cells. B: Cetuximab coupled to protamine does not transport Alexa488-control siRNA to SKNMC cells, and Alexa488-positive vesicle structures are present only next to cells (white dots, arrows in the upper panel) and in cell-free areas of the culture (arrows in the lower panel). C: Cetuximab coupled to protamine, which does not contain free SMCC-protamine (removed by HPLC), does not form Alexa488-positive vesicle structures. [Figure 33]EGFR-mAB cetuximab-protamine conjugates in DLS measurement. Top panel: Coomassie-stained PAGE gels illustrating different conjugates isolated or used for measurement in the bottom panel. Bottom panel: EGFR-mAB-P containing free SMCC-protamine, EGFR-mAB-P without free SMCC-protamine, and SMCC-protamine alone were incubated at room temperature for 2 hours and then measured via dynamic light scattering (DLS) with a zeta counter (MALVERN). Different peaks represent particles of different sizes (nm). The highest peak for EGFR-mAB-P / siRNA containing free SMCC-protamine is located at approximately 427 nm, while that without free SMCC-protamine is at approximately 3.2 nm, and free SMCC-protamine / siRNA produces a peak at 5.7 nm. [Figure 34] DLS measurement of EGFR-mAB cetuximab-protamine / P conjugate during 0-24 hour incubation at room temperature. siRNA monomers (approx. 1.92 nm) assemble into larger structures after mixing by the cetuximab-protamine / unbound protamine carrier system, which are then stabilized and assemble into much larger macrostructures (approx. 500 nm). After 24 hours in an unprotected environment in PBS, the macrostructures begin to partially degrade again. The numbers below indicate the measured particle size (nm). [Figure 35] Antibody-protamine / free SMCC-P(P / P) conjugates containing fluorescent Alexa488-siRNA (white dots) after overnight cell-free incubation on chamber slides. A: EGFR-mAB-P / P, B: CD20-mAB-P / P, C: CD33-mAB-P / P, D: IGF1R-mAB-P / P, 40x magnification, bar = 10 μm. E~H: Magnified views of A~D, bar = 10 μm. [Figure 36]Antibody-protamine conjugates with and without free SMCC-protamine, and SMCC-protamine alone, containing fluorescent Alexa488-siRNA (white dots), underwent overnight cell-free incubation on chamber slides. Antibody conjugates containing free SMCC-protamine: A-D. A. EGFR-mAB-P, B. CD20-mAB-P, C. CD33-mAB-P, D. IGF1R-mAB-P, E. Free SMCC-protamine. Antibody conjugates without free SMCC-protamine: F-I. F. EGFR-mAB-P, G. CD20-mAB-P, H. CD33-mAB-P, I. IGF1R-mAB-P. All at 40x magnification. [Figure 37] Fluorescence optical microscope images of antibody conjugates (A and B) and laser scan microscope (LSM) images (C and D) of a single confocal optical section. Formation of cetuximab anti-EGFR-mAB-protamine / free SMCC_P conjugates (A and C) and anti-CD20-mAB-protamine / free SMCC_P (B and D) containing fluorescent Alexa488-siRNA (white dot) during overnight cell-free incubation on chamber slides. [Figure 38] Anti-EGFR antibody-protamine conjugate containing free SMCC-protamine, containing fluorescent Alexa488-siRNA (white dots), in overnight cell-free incubation on chamber slides at different temperatures shown. [Figure 39] Conjugation of cetuximab with different ratios of antibody to SMCC-protamine. A: Detailed composition of each conjugation process. B: Coomassie-stained SDS-PAGE showing uncoupled anti-EGFR antibody cetuximab compared to the coupled conjugation product as shown in A. [Figure 40]Functional analysis of cetuximab conjugation products at different ratios of antibody to SMCC-protamine. A-F: Band shift assays using different conjugation products shown in the figure. G-L: Cell-free vesicle formation on slides when different conjugation products are incubated with Alexa488-siRNA (white dots, in particular, J). M-R: Internal migration of different cetuximab-SMCC-protamine / P / Alexa488-siRNA complexes into EGFR-positive A549 cells (white dots, arrows). S-X: Colony formation of A549 cells treated with different cetuximab-SMCC-protamine / P conjugates containing free protamine as a conjugate with control ("scr") siRNA or anti-KRAS siRNA ("KRAS"). When SMCC-protamine is used at more than 50-fold saturation, the conjugate is nonspecifically toxic. Mean + / - SD of three independent experiments are shown here. An asterisk indicates a statistically significant difference (P<0.009, two-tailed t-test). [Figure 41] Functional analysis of vesicle formation of anti-EGFR-mAB-protamine depleted of free SMCC-protamine by supplementation with different ratios of SMCC-protamine or protamine alone. Cell-free vesicle formation on slides by incubation with Alexa488-siRNA. Anti-EGFR-mAB-protamine without free SMCC-protamine does not form vesicles (white dots) as shown in the figure. When free SMCC-protamine was added stepwise, vesicle formation did not occur with 1x SMCC-protamine (A), occurred to a low degree with 10x SMCC-protamine (B), and occurred to a high degree with 32x SMCC-protamine (C). When uncoupled free protamine was added to sulfo-SMCC in a stepwise manner, vesicle formation did not occur with 1x SMCC-protamine (D), occurred to a low degree with 10x SMCC-protamine (E), and occurred to a high degree with 32x SMCC-protamine (white dot in F). [Figure 42]Formation of fluorescent Alexa488-siRNA and / or SM-1 / RF-containing anti-CD20-mAB-protamine / free SMCC-P conjugates in overnight cell-free incubation on chamber slides. A-C. Green fluorescent channel (white dots), D-F. Red fluorescent channel (gray dots). A and D. Anti-CD20-mAB-P / P containing Alexa488-siRNA, B and E. Anti-CD20-mAB-P / P containing red fluorescent SM-1 / RF, C and F. Anti-CD20-mAB-P / P containing Alexa488-siRNA and red fluorescent SM-1 / RF, 40x magnification, bar = 10 μm. [Figure 43] Formation of fluorescent Alexa488-siRNA and / or SM-1 / RF-containing anti-EGFR-mAB-protamine / free SMCC-P conjugates in overnight cell-free incubation on chamber slides. A-D: green fluorescent channels (white dots), E-H: red fluorescent channels (gray dots). A. and E. EGFR-mAB-P / P containing Alexa488-siRNA, B. and F. EGFR-mAB-P / P containing red fluorescent SM-1 / RF, C. and G. EGFR-mAB-P / P containing non-fluorescent control siRNA and red fluorescent SM-1 / RF, D. and H. EGFR-mAB-P / P containing green fluorescent Alexa488-siRNA and red fluorescent SM-1 / RF, magnification 40x, bar = 10 μm. [Figure 44] Formation of a rituximab anti-CD20-mAB-protamine / free SMCC-P conjugate containing fluorescent Alexa488-siRNA combined with SM-1 / RF in overnight cell-free incubation on a chamber slide. A-C: 40x magnification of green fluorescent channel (white dots) and red fluorescent channel (gray dots), D-L: Equimagnification of details from A-C, bar = 10 μm. In D, G, and L: gray rings illustrate Alexa488-siRNA fluorescence (arrows). In E, H, and K: gray circles illustrate red fluorescence of SM-1 / RF (arrows). In F, I, and L, the peripheral (Alexa488-siRNA, arrows) and internal red fluorescence (SM-1 / RF) of the green fluorescence (gray) can be discriminated. [Figure 45] Formation of cetuximab anti-EGFR-mAB-protamine / free SMCC-P conjugate containing green fluorescent Alexa488-siRNA combined with red fluorescent SM-1 / RF during overnight cell-free incubation on chamber slides. A-C: 40x magnification of green fluorescent channel (white and ring in A and C) and red fluorescent channel (gray circle in B and C). D: Magnified view of details from A-C, bar = 10 μm. [Figure 46] Large micelle structures formed by anti-CD20-mAB / P / free SMCC- / P (gray ring in A), SM-1 / RF (gray circle in B), and Alexa488-siRNA are visible in phase-contrast optical microscopy (B and C). Bar = 5 μm. [Figure 47] LSM images and Z-stacks of a single confocal optical section of an antibody conjugate. A: Formation of an anti-EGFR-mAB(cetuximab)-protamine / free SMCC-P conjugate containing fluorescent Alexa488-siRNA (white dot) combined with SM-1 / RF in an overnight cell-free incubation on a chamber slide. a: One level across the vesicle, b and c: Z-stacks reconstructing the 3D structure of the vesicle on both axes. B: Formation of an anti-CD20-mAB(rituximab)-protamine / P conjugate containing fluorescent Alexa488-siRNA (white ring and dot) combined with SM-1 / RF (gray shadow) in an overnight cell-free incubation on a chamber slide. d: One level across the vesicle, e and f: Z-stacks reconstructing the 3D structure of the vesicle on both axes. [Figure 48] Synthesis of polyanionic ibrutinib derivatives for electrostatic transport by monoclonal antibodies. Ibrutinib was conjugated with the Cy3.5 chromophore to form a low molecular weight (1.44 kDa) polyanion. Chemical structure of anionic ibrutinib-Cy3.5 (Cy3.5-RMA561) constructed with mAB stable vesicles linked to cationic protamine by electrostatic interaction. [Figure 49]High-resolution mass spectrometry of Cy3.5-RMA561. In a mass spectrometer, the sample was ionized and fragmented by an electron beam, and the resulting fragments were analyzed by mass-to-charge (m / z) ratio according to a specific deflection. HRMS (ESI, CH3CN / H2O): Calculated m / z for C64H62N9O15S4 3-[MH](z=3): 441.44216; Measured value: 441.44160; Calculated m / z for C64H62N9O15S4H2-[MH](z=2): 662.66687; Measured value: 662.66630; Calculated m / z for (C64H62N9O15S4H)2 4-[MH](z=4): 662.66687; Measured value: 662.66630. [Figure 50] αCD20-mAB rituximab-protamine / free protamine-SMCC conjugate and αEGFR-mAB cetuximab-protamine / free protamine-SMCC conjugate conjugate with ibrutinib-Cy3.5. A. Band shift assays using αCD20-mAB-protamine / P and αEGFR-mAB-protamine / P with ibrutinib-Cy3.5 in different ratios up to 1:32. B. Band shift assays using αCD20-mAB-protamine / free protamine-SMCC and αEGFR-mAB-protamine / free protamine-SMCC with ibrutinib-Cy3.5 in different molecular excesses up to 1:200. At least 100 moles of ibrutinib-Cy3.5 can be conjugated by antibody-protamine conjugates. α, anti. [Figure 51]The αCD20-mAB rituximab-protamine / free protamine-SMCC / ibrutinib-Cy3.5 conjugate and the αEGFR-mAB cetuximab-protamine / free protamine-SMCC conjugate induce internal translocation of ibrutinib-Cy3.5. A. CD20-positive HBL-1 DLBCL cells induce internal translocation of the αCD20-mAB-protamine / / free protamine-SMCC / ibrutinib-Cy3.5 complex. Left: nuclear staining, Right: gray dots = Cy3.5. B. EGFR-positive A549 NSCLC cells induce internal translocation of the αEGFR-mAB-protamine / / free protamine-SMCC / ibrutinib-Cy3.5 complex. Left: nuclear staining, Right: gray dots = Cy3.5. α, anti. [Figure 52] Covalent labeling of BTK kinase in vitro by ibrutinib-Cy3.5 conjugate (αCD20-mAB-P / ibrutinib-Cy3.5) transported by rituximab-protamine / free protamine-SMCC as a carrier molecule. 10⁵ cells were treated overnight with the indicated concentrations of the compound, lysed in a loading dye, and electrophoresed on a gel. For Cy3.5 luminescence in an INTAS gel imager, the gel was exposed to UV light on a SYBR Gold filter (left), then blotted for identification and incubated with anti-BTK-mAB, RTX, rituximab (right). Intracellular BTK bound to both free ibrutinib-Cy3.5 and ibrutinib-Cy3.5 conjugated with antibody-protamine. [Figure 53]αCD20-mAB(rituximab)-protamine / free protamine conjugate and αEGFR-mAB cetuximab-protamine / free protamine conjugate transport ibrutinib-Cy3.5 and inhibit colony formation more effectively than ibrutinib-Cy3.5 alone or the antibody. A. and B. Colony formation assays. HBL-1 cells (A) treated with αCD20-mAB(rituximab)-protamine / free protamine-SMCC / ibrutinib-Cy3.5 and A549 cells (B) treated with αEGFR mAB-(cetuximab)protamine / free protamine-SMCC / ibrutinib-Cy3.5 form significantly fewer colonies in methylcellulose than cells treated with PBS, uncomplexed ibrutinib-Cy3.5, or αCD20 mAB-(rituximab)protamine / free protamine-SMCC / ibrutinib-Cy3.5. The mean ± SD values ​​of three independent experiments are shown here. Asterisks indicate statistical significance (p < 0.05, two-sided t-test). α, anti. [Figure 54]The αCD20-mAB rituximab-protamine conjugate does not efficiently bind to ibrutinib-Cy3.5 after depletion of free protamine-SMCC by HPLC. A. Coomaschy-stained SDS-PAGE showing HPLC fractions 19-25 / 26 of αCD20-mAB, αCD20-mAB coupled to 32x protamine-SMCC, and αCD20-mAB coupled to 32x protamine-SMCC after depletion of unbound protamine-SMCC; HC=heavy chain, LC=light chain, -P=protamine-SMCC. B. Band shift assay of protamine-depleted αCD20-mAB preparation (left) and protamine-containing αCD20-mAB preparation (right). The protamine-SMCC-depleted αCD20-mAB preparation does not bind to >32 mol of ibrutinib-Cy3.5. C. Colony formation assay. HBL-1 cells treated with αCD20-mAB-protamine / free protamine-SMCC / ibrutinib-Cy3.5 form significantly fewer colonies on soft agar than cells treated with uncoupled ibrutinib-Cy3.5 alone or uncoupled αCD20-mAB. When HLB-1 cells were treated with the αCD20-mAB-protamine conjugate without free protamine-SMCC, no difference in colony formation was observed compared to cells treated with PBS (see A+B, fraction 25). The mean ± SD of three independent experiments are shown here. *P<0.0003, two-sided t-test. α, anti. [Figure 55]The αCD20-mAB rituximab-protamine / free protamine-SMCC conjugate efficiently coordinates and binds ibrutinib-Cy3.5, transporting it to the tumor site in vivo and significantly reducing tumor growth. A. Tumor growth and treatment plan for an NSG-HBL1 xenograft model. After transplantation, the tumor was allowed to grow to 200 mm3, and then intraperitoneal (ip) treatment was initiated twice weekly. Treatment with a rituximab-protamine / free protamine / ibrutinib-Cy3.5 1:20 complex (4 mg / kg mouse body weight or 0.625 nmol rituximab-protamine and / or 12.5 nmol ibrutinib derivative per dose) (in photographs, = rituximab-ibrutinib-Cy3.5(C) or rituximab-P / P / ibrutinib-Cy3.5(B)) significantly reduced tumor volume and growth. Tumor volume was assessed by caliper measurement on all two treatment days per week. In the group treated with the rituximab-protamine / free protamine / ibrutinib-Cy3.5 1:20 complex, tumor volume was limited to well below 1,000 mm3 and began to atrophy to 600 mm3 after three treatments, whereas all other groups showed rapid tumor growth and had to be sacrificed early according to predefined legal restrictions. C. Comparison of survival curves between treatment and control groups. Each group of 10 mice was treated with PBS, rituximab, ibrutinib standard, ibrutinib-Cy3.5, and the rituximab-protamine / free protamine / ibrutinib-Cy3.5 1:20 complex. Ibrutinib-Cy3.5 did not reduce tumor growth on day 8 after the start of treatment, and all mice had to be sacrificed according to predefined criteria, however mice treated with PBS and rituximab survived significantly longer, up to day 16. Of the 10 mice treated with ibrutinib, the last one had to be sacrificed on day 20. However, of the 10 mice treated with the rituximab-protamine / free protamine / ibrutinib-Cy3.5 1:20 complex, 5 survived until day 16 and 4 until day 20. The difference between the rituximab-protamine / free protamine / ibrutinib-Cy3.5 treatment group and the control group was assessed as p ≤ 0.03 (ANOVA).α, anti, RTX, rituximab. [Figure 56] Tumors of HBL-1 cells xenografted into NSG mice showed significant enrichment of the Cy3.5 fluorescence signal in mice treated with rituximab-protamine / free protamine-SMCC / ibrutinib-Cy3.5. Xenografted mice from the experiment shown in Figure 55 were sacrificed after reaching an intolerable tumor size, and organs and tumors were prepared and exposed to ex vivo fluorescence detection of the Cy3.5 signal by excitation at 530 nm and emission at 600 nm. Tumors from the group treated with rituximab-P / free P / ibrutinib (in the photo, =Rtx / ibrutinib-Cy3.5) (bottom panel) showed significant enrichment of the Cy3.5-dependent fluorescence signal in all parts of the tumor tissue compared to untargeted ibrutinib-Cy3.5 and standard ibrutinib, whereas in control organs, only necrotic lesions exhibiting autofluorescence were detected. The diameters of the tumor preparations shown were similar in all cases, but the fluorescence regions differed. The scale represents an arbitrary unit of fluorescence. The dotted line represents the outer circumference of each tumor. The numbers refer to the identification names of individual mice. [Figure 57] Summary of different mouse organs analyzed for Cy3.5 fluorescence from NSG mice xenografted with HBL1 mice. Xenografted mice from experiments shown in Figures 55 and 56 were sacrificed after reaching intolerable tumor size, organs and tumors were prepared, and exposed to ex vivo fluorescence detection for Cy3.5 signaling by excitation at 530 nm and emission at 600 nm. Tumors from the group treated with rituximab-P / free P / ibrutinib (in the photograph, =Rtx / ibrutinib-Cy3.5) (bottom panel) showed significant enrichment of Cy3.5-dependent fluorescence signaling compared to untargeted ibrutinib-Cy3.5. Scales represent arbitrary units of fluorescence. Organs are always oriented in the same direction (illustrated in the scheme on the right) in bright-field (top panel) and red (Cy3.5) fluorescence (bottom panel). [Figure 58]Formation of rituximab αCD20-mAB-protamine / free SMCC-protamine nanovesicles containing green fluorescent Alexa488-siRNA and / or red fluorescent ibrutinib-Cy3.5 in overnight (o / n) cell-free incubation on chamber slides. A.-C. Green fluorescent channels, D.-F. Red fluorescent channels. A. and D. αCD20-mAB-P / free P containing green Alexa488-siRNA, B. and E. αCD20-mAB-P / free P containing red fluorescent ibrutinib-Cy3.5, C. and F. αCD20-mAB-P / free P containing green Alexa488-siRNA and red ibrutinib-Cy3.5, magnification 40x, bar = 10 μm. All rituximab-protamine preparations contain unbound protamine-SMCC. α, anti. [Figure 59] Formation of cetuximab αEGFR-mAB-protamine / free protamine-SMCC conjugates containing green fluorescent Alexa488-siRNA and / or red fluorescent ibrutinib-Cy3.5 in overnight (o / n) cell-free incubation on chamber slides. A-D. Green fluorescent channel, E-H. Red fluorescent channel, A. and E. Cetuximab αEGFR-mAB-P / free protamine-SMCC containing green fluorescent Alexa488-siRNA, B. and F. Cetuximab αEGFR-mAB-P / free protamine-SMCC containing red fluorescent ibrutinib-Cy3.5, C. and G. αEGFR-mAB-P containing non-fluorescent control siRNA (scr, scrambled) and red fluorescent ibrutinib-Cy3.5, D. and H. αEGFR-mAB-P containing non-fluorescent Alexa488-siRNA and red fluorescent ibrutinib-Cy3.5, magnification 40x, bar = 10 μm. All cetuximab protamine preparations contain unbound protamine-SMCC. α, anti. [Figure 60]Formation of cetuximab αEGFR-mAB-protamine / free protamine-SMCC conjugates (A-B) and rituximab anti-CD20-mAB-protamine / free protamine-SMCC conjugates (C-D) containing green fluorescent Alexa488-siRNA combined with red fluorescent ibrutinib-Cy3.5 in overnight (o / n) cell-free incubation on chamber slides. Magnification of green and red fluorescent channels is 40x. In A and C, the peripheral green fluorescence (Alexa488-siRNA) is visible, and in B and D, the internal red fluorescence (ibrutinib-Cy3.5) is visible. All antibody-protamine preparations contain unbound protamine-SMCC. [Figure 61] Determination of particle size in different complex formations of αCD20-mAB rituximab / free protamine-SMCC with siRNA and ibrutinib-Cy3.5. Average diameters (nm) are shown in AB-E. Zetaview measurements of the shown complexes were performed at 1 and 2 hours after the start of incubation. The average vesicle size (nm), determined by the average diameter of each particle illustrated in the histograms B-E, is shown here. All rituximab-protamine preparations contain unbound protamine-SMCC. α, anti. [Figure 62-1]A: The αCD20-mAB rituximab-protamine / free protamine-SMCC (αCD20-mAB-P / P) conjugate binds to ibrutinib-Alexa488. Band shift assay using αCD20-mAB-protamine / P with ibrutinib-Alexa488 in different ratios up to 1:2. α, anti. B: Because the anionic charge of the Alexa488 molecule is limited to -2 (arrow), the interaction between the polycationic protamine conjugate and Alexa488 was found to be weaker than the interaction with Cy3.5, which has a net charge of -4. The ibrutinib conjugated to Alexa488 and the protamine conjugate resulted in a coupling ratio of only 2:1. However, the complexation of ibrutinib-Alexa488 with αCD20-mAB rituximab-protamine / free protamine-SMCC (αCD20-mAB-P / P) was successful. C~H: Stability after self-assembly of αCD20-mAB-protamine, free protamine, and ibrutinib-Cy3.5 in a 1:20 ratio for 1 hour, followed by incubation for 24 hours in PBS (C, D) and under challenging conditions, such as cell culture medium RPMI / 10%FCS (E, F) and PBS / 50%FCS (G, H). C, E, G: Cy3.5 fluorescence, D, F, H: phase contrast. α, anti. [Figure 62-2] See the explanation in Figure 62-1. [Figure 63] Charged ibrutinib-Cy3.5 forms stable nanoparticles with different mABs conjugated to protamine, whereas uncharged ibrutinib (trade name: imbruvica) does not. Charged ibrutinib-Cy3.5 was loaded onto each antibody carrier containing free SMCC-protamine, conjugated to protamine via SMCC, compared to uncharged ibrutinib. Only the ibrutinib samples conjugated to Cy3.5 showed high-density nanoparticle formation, while uncharged ibrutinib did not. Anti-EGFR antibodies (A-D), anti-CD33 antibodies (E-H), and anti-IGF1R antibodies (I-L) were tested in Cy3.5-dependent fluorescence microscopy (top) and phase contrast (bottom). α, anti. [Figure 64] Cross-sectional view of an ideal example of a nanoparticle-like structure that satisfies the conditions for an effective antibody-protamine-protamine-siRNA or -ibrutinib-Cy3.5 carrier complex inferred from experiments. Not shown at a constant scale. Electrostatic crosslinks are formed between mAB, and several protamines are coupled to the targeting antibody and their respective anionic cargoes, the anionic cargoes containing siRNA (A), ibrutinib-Cy3.5 (B), or both (C). [Figure 65] Electrostatic nanoparticle formation by αCD20-mAB-protamine / free protamine-ibrutinib-Cy3.5. Anionic ibrutinib-Cy3.5 was loaded onto a carrier antibody-protamine conjugate in a 1:20 ratio and applied to glass slides treated with cell cultures for fluorescence microscopy (A, B) or to a copper grid for electron microscopy negatively stained with tungsten phosphate (C). Here, electrostatic loading resulted in the formation of numerous aggregates, with larger aggregates exhibiting strong Cy3.5 fluorescence (A) and being visible in optical microscopy using an embossed dynamic filter to illustrate the 3D structure by contrast enhancement (B). In transmission electron microscopy (C), negative staining yielded nearly the same particle size range, but revealed the presence of numerous smaller vesicles (C) that were undetectable in optical microscopy. α, anti. [Figure 66]Cellular targeting of Bruton kinase BTK by ibrutinib-Cy3.5 conjugated with αCD20-mAB-P / P. A-F: Fluorescence microscopy of HBL1 DLBCL cells treated with the targeting conjugate and control, showing significant intracellular enrichment of the Cy3.5 signal. G: Lysates from cells treated with the targeting conjugate and control for 72 hours were subjected to SDS-PAGE and irradiated for the Cy3.5 signal. Here, a distinct 70 kDa band identified as BTK by parallel immunoblotting is covalently marked by ibrutinib-Cy3.5, indicating binding of the ibrutinib-Cy3.5 derivative and thus demonstrating its functionality. Fluorescence microscopy of HBL1 DLBCL cells pretreated with ibrutinib-BodyPie (green, N and P) does not show intracellular enrichment of Cy3.5 signaling after αCD20-mAB-P / P-ibrutinib-Cy3.5 treatment (M compared to L, anti-α). [Figure 67]Physiological and functional significance of BTK inactivation by αCD20-mAB-protamine / free protamine-ibrutinib-Cy3.5 treatment in DLBCL cell lines. A: HBL1 cells were treated with the respective conjugates shown for 72 hours, lysed, and subjected to SDS-PAGE, as well as Western blotting for phosphorylated BTK (pBTK), total BTK (tBTK), phosphorylated ERK (p-ERK), total ERK (t-ERK), and actin as a loading control. Here, untargeted ibrutinib-Cy3.5 inhibited BTK phosphorylation to a slightly less extent than αCD20-mAB-protamine-ibrutinib-Cy3.5, and the difference in expected downstream phosphorylation targets such as ERK was more evident: here, only ibrutinib-Cy3.5 treatment mediated by αCD20-mAB-P / P was able to reduce ERK phosphorylation. B: In the colony formation assay, untargeted ibrutinib-Cy3.5 moderately reduced colony growth in HBL1 cells, while specific targeting of ibrutinib-Cy3.5 by αCD20-mAB-P / P reduced the colony growth reduction to less than 30%. To demonstrate the importance of free protamine within the conjugate construct, it was depleted from the conjugate mixture. The application of this combination did not reveal a greater reduction in colony formation than ibrutinib-Cy3.5 alone, and therefore the antibody conjugate had lost its targeting ability (B, rightmost bar). α, anti. [Figure 68]Induction of BTK-targeted apoptosis in DLBCL cell line HBL1 by treatment with ibrutinib-Cy3.5 conjugated with αCD20-mAB-P / P. HBL1 cells were treated with each conjugate shown for 72 hours and subjected to annexin V staining. In particular, in cells treated with ibrutinib-Cy3.5 conjugated with αCD20-mAB-P / P, apoptotic cells were detected by flow cytometry, with annexin V expression (upper panel, X axis) indicating a significant increase in internalized ibrutinib-Cy3.5 fluorescence (Y axis, upper panel). Values ​​from the upper right and lower right gates were counted. Lower panel: Summarizes annexin V-positive cells from three independent experiments. P<0.05, two-sided t-test. α, anti. [Figure 69] Systemic treatment with αIGF1R-mAB-protamine / free protamine-siRNA-protamine nanocarriers inhibits the growth of Ewing sarcoma xenograft tumors by knockdown of oncogenic EWS-FLI1 translocation products. A. Treatment scheme for in vivo experiments. Nanoparticles were administered intraperitoneally as shown. B-C. Results of systemic in vivo application of targeted nanocarriers to SK-N-MC xenograft tumors. B. Tumor growth curves of SK-N-MC treated with αIGF1R-mAB teprotumumab ("Tepro")-protamine / PsiRNA nanoparticles (mean + / - SEM; two-sided t-test, *p<0.05). C. Gravimetric statistics of tumors resected at the end of the experiment (mean + SD, two-sided t-test, *p<0.05). α, anti. [Figure 70] Nanoparticles formed by carrier antibody-protamine / free protamine and siRNA exhibited a nearly neutral surface charge. As described elsewhere, the nanoparticles were allowed to form for 2 hours and subjected to dynamic light scattering (DLS) analysis (Malvern Zeta-sizer). Particle sizes ranged from 350 to 750 nm, with the indicated deviations depending on the different antibody conjugation preparations. More importantly, the zeta potential of the particle surface was only slightly negative to neutral. [Figure 71]Deciphering the prerequisites for effective nanoparticle formation between anti-EGFR-mAB-SMCC-protamine conjugate and free SMCC-protamine and siRNA. A-G. Vesicle formation by 60 nM αEGFR-mAB-P in the presence of 32x SMCC-protamine and Alexa488-control siRNA in increasing molar ratios (1:0.6-1:40) relative to antibody concentration. Vesicle formation can be observed with 5-10x molar excess of siRNA (D-E). Top panel: Fluorescence microscopy of Alexa488-siRNA-positive vesicles. Bottom panel: Phase contrast of the same preparation as the top panel. α, anti. [Figure 72] Nanoparticles formed by αEGFR-mAB-protamine / free protamine-Alexa488-siRNA are stable under serum-containing conditions. A-B. Stability after self-assembly of αEGFR-mAB-protamine, free protamine, and Alexa488-siRNA in a 1:10 ratio for 2 hours, followed by incubation in PBS (A) and PBS / 50% FCS (B) for 24 hours. α, anti. [Figure 73] Serum stability of αCD20-mAB-protamine / free P-ibrutinib-Cy3.5 nanocarrier. A-F. Stability after self-assembly of αCD20-mAB-protamine, free protamine, and ibrutinib-Cy3.5 in a 1:20 ratio for 2 hours, followed by incubation for 24 hours (A-C) or 72 hours (D-F) in PBS (A, D) and challenging conditions, such as cell culture medium RPMI / 10%FCS (B, E) and PBS / 50%FCS (C, F). A-F: Cy3.5 fluorescence microscopy. α, anti. [Figure 74]pH stability of siRNA nanocarriers constructed with three different targeting antibodies. Nanocarriers formed with αEGFR-mAB-protamine / free protamine (top panel), αIGF1R-mAB-protamine / free protamine (center panel), and αCD33-mAB-protamine / free protamine (bottom panel), each with a 10-fold molar excess of siRNA, were formed at RT for 2 hours under standard conditions and then diluted 30-fold by volume with their respective buffers for 24-hour pH stability tests on chamber slides. The slides were then washed, mounted, and subjected to fluorescence microscopy. The nanocarriers were shown to be stable at pH values ​​between 5.2 and 8.0 and tended to aggregate at lower pH values. [Figure 75] pH stability of nanocarriers constructed with αCD20-mAB-protamine / free protamine and ibrutinib-Cy3.5. Nanocarriers formed with αCD20-mAB-protamine / free protamine and 20-fold molar excess ibrutinib-Cy3.5 were formed under standard conditions at RT for 2 hours and then diluted to 30-fold volumes of each buffer for 24-hour pH stability tests on chamber slides. The slides were then washed, mounted, and subjected to fluorescence microscopy. The nanocarriers were shown to be stable at pH values ​​of 5.8–8.0 and tended to disintegrate at lower pH values. α, anti. [Figure 76] Immunolabeling of targeting IgG antibody within αEGFR-mAB-P / free protamine-siRNA nanocarriers. Nanocarriers were formed by self-assembly over 2 hours (αEGFR-P / free protamine + Alexa488-siRNA (green in A and D)), immobilized overnight on treated glass surfaces (A, E), stained with αhIgG-Alexa647 (A-C), rinsed with PBS, mounted with DAKO fluorescent mounting medium, and subjected to fluorescence microscopy. The nanocarrier structures show significant staining of the targeting αEGFR antibody with Alexa647 only in the surface region (B-C). F. Schematic diagram of the staining method. α, antibody. [Figure 77]Immunolabeling of targeting IgG antibody within αIGF1R-mAB-P / free protamine siRNA nanocarriers. Nanocarriers were formed by self-assembly over 2 hours (teprotumumab-protamine + Alexa488-siRNA (green)), immobilized overnight on a treated glass surface (A, D), stained with αhIgG-Alexa647 (A-C), rinsed with PBS, mounted with DAKO fluorescent mounting medium, and subjected to fluorescence microscopy. The nanocarrier structure showed significant staining of Alexa647 with the targeting teprotumumab antibody only in the surface region (B-C). F. Schematic diagram of the staining method. α, antibody. [Figure 78-1] Visualization of free protamine within nanocarrier complexes. Here, we used an αEGFR-mAB-protamine preparation depleted of free protamine by size exclusion chromatography, and this preparation reconstituted with free protamine tagged with a Cy3 chromophore. A: Protamine was conjugated to a Cy3-NHS ester according to the manufacturer's recommendations and purified by spin column. The resulting protamine-Cy3 showed strong Cy3-dependent fluorescence and was enriched comparably with the unconjugated material, and was therefore reconstituted with antibody-protamine in a typical 32-fold molar excess (B). siRNA nanocarriers formed with this reconstituted material and untagged siRNA showed a strong Cy3-dependent fluorescence signal of protamine in the lumen of the nanostructure (C). In contrast, the same nanostructure stained for the α-human IgG signal with αhIgG-Alexa 647 antibody showed a peripheral structure positively stained for the antibody site (D). E: Merged and enlarged view of the highlighted parts of C and D. F: Enlarged view of the highlighted part of E. α, anti. [Figure 78-2] See the explanation in Figure 78-1. [Figure 79] Synthesis of cyanine-conjugated inhibitors, gefitinib, gemcitabine, and venetoclax. [Figure 80] An extension of the concept to a simpler and less expensive polyanionic molecular part. [Modes for carrying out the invention]

[0016] Detailed explanation The inventors of this application have surprisingly found that a modification of the conjugation protocol for antibody-protamine conjugates described in Baumer, N. et al., 2016 Nat. Protoc. 11, 22-36 results in the formation of nanoparticles containing the antibody-protamine conjugate and a negatively charged cargo molecule to be delivered to the target.

[0017] The formation of composite nanoparticles containing a targeting moiety chemically conjugated to protamine, free protamine, and a negatively charged cargo molecule such as siRNA may be used for cell-type-specific therapeutic delivery of siRNA and other effector drugs that can selectively block carcinogenic pathways.

[0018] In the conjugation protocol of the present invention, two steps were modified. First, the conjugation step for antibody-protamine generation was carried out with the antibody and an SMCC-protamine conjugate that is essentially free of sulfo-SMCC. In the protocol described by Baumer, N. et al., 2016 Nat. Protoc. 11, 22-36, free sulfo-SMCC was present in this conjugation step and was only removed after the conjugation step. Second, for the step of loading siRNA onto the antibody-protamine conjugate, the antibody-SMCC conjugate and the siRNA were brought into contact with each other in the presence of a specific amount of free protamine. Surprisingly, macroparticles containing the antibody-protamine conjugate, free protamine, and siRNA are formed by this modified protocol.

[0019] The inventors of this application have, even more surprisingly, found that such nanoparticles provide more efficient siRNA binding and transport compared to conjugates generated using the previously described protocol (Baumer, N. et al., 2016 Nat. Protoc. 11, 22-36).

[0020] The nanostructures generated by the method of the present invention are much larger than linear single antibody-protamine-siRNA complexes and can be detected as vesicular structures by optical microscopy. The inventors of the present invention have found that a specific amount of unbound protamine is required to form these nanoparticles and efficiently target each cell. Subsequently, knockdown of the intended target (onco) gene is specifically carried out. As shown in Examples 6, 15, and 18-21, the positively charged nanostructures (micelles) can also function as carriers for other negatively charged small molecules, as the small molecules were also efficiently transported to each cell in a target-specific manner. Through this approach, therapeutic molecules such as siRNA not only function to form electrostatic nanostructures but are also encapsulated within the nanostructures.

[0021] Since most cancer types in the advanced and metastatic stages are not effectively curable at the time this invention was created, there is a strong need for new, more effective, and more tolerable treatment options. Nanoparticles composed of a targeting moiety, such as an antibody specific to cancer cells, chemically bound SMCC-protamine, and free protamine can transport negatively charged molecules, such as siRNA and other small molecules, that would otherwise not be taken up by eukaryotic cells. In particular, since siRNA can be targeted to any gene, this system has the potential to be applied to a number of diseases, such as cancer, neurodegeneration, and viral infections.

[0022] Accordingly, the present application relates to a method for producing nanoparticles, comprising the steps of (c) contacting an antibody with a composition comprising a first conjugate (A), wherein the first conjugate comprises a positively charged polypeptide conjugated to a bifunctional linker, and the composition essentially does not contain an unconjugated bifunctional linker, thereby obtaining a second conjugate (B), the second conjugate comprising a positively charged polypeptide, a bifunctional linker, and an antibody; and (d) contacting the second conjugate (B), a positively charged polypeptide, and a negatively charged molecule, thereby forming nanoparticles.

[0023] "First conjugate" means a conjugate comprising, or preferably comprising, a positively charged polypeptide conjugated to a bifunctional linker, as used herein.

[0024] In the method of the present disclosure, (c) is a conjugation step in which an antibody is conjugated to a first conjugate. In contrast to the method previously described by Baumer, N. et al., 2016 Nat. Protoc. 11, 22-36, the composition comprising the first conjugate used in this step essentially does not contain an unconjugated bifunctional linker. In accordance with this, the conjugation of step (c) is preferably carried out in a composition essentially that does not contain an unconjugated bifunctional linker.

[0025] In step (c), the first conjugate is preferably in a molar excess compared to the antibody, i.e., preferably there are more first conjugate molecules than antibody molecules. In some embodiments, the molar ratio of the first conjugate to the antibody in step (c) is at least about 10:1, preferably at least about 15:1, and preferably at least about 20:1. In some embodiments, the molar ratio of the first conjugate to the antibody is up to about 50:1, preferably up to about 45:1, and preferably up to about 40:1. In some embodiments, the molar ratio of the first conjugate to the antibody in step (c) is in the range of about 10:1 to 50:1, preferably about 15:1 to about 45:1, and preferably about 20:1 to about 40:1. In a preferred embodiment, the molar ratio of the first conjugate to the antibody is approximately 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1, 37:1, 38:1, 39:1, and 40:1.

[0026] In the method of this disclosure, in step (d), the second conjugate, the positively charged polypeptide, and the negatively charged molecule are brought into contact with each other. Although we do not wish to be constrained by theory, the three components are thought to self-assemble to form nanoparticles. Here, the second conjugate is the second conjugate formed in step (c).

[0027] With respect to step (d), when referring to a positively charged polypeptide, the expression encompasses both the free positively charged polypeptide and a conjugate of a positively charged polypeptide, such as a positively charged polypeptide conjugated to a linker. The positively charged polypeptide in step (d) may be the first conjugate in step (c), or it may be a different molecule from the first conjugate in step (c). For example, with respect to step (d), the term positively charged polypeptide may encompass both (free) protamine and SMCC-protamine. With respect to step (d), the term also encompasses mixtures of different positively charged polypeptides, such as a mixture of a positively charged polypeptide and a conjugate of a positively charged polypeptide.

[0028] In some embodiments, the positively charged polypeptide of step (d) is the first conjugate of step (c). As an exemplary example, the positively charged polypeptide of step (d) is SMCC-protamine, and the first conjugate of step (c) is also SMCC-protamine. If the positively charged polypeptide of step (d) is the first conjugate of step (c), the composition formed in step (c) can be used in step (d) without the step of separating the second conjugate formed in step (c) from the "residual" positively charged polypeptide (in this case, including the "residual" first conjugate).

[0029] In some embodiments, the positively charged polypeptide of step (d) is different from the first conjugate of step (c). For example, the positively charged polypeptide of step (d) is (free) protamine, while the first conjugate of step (c) is SMCC-protamine. In such cases, the method may include a step after step (c) and / or before step (d) in which the second conjugate is separated from the first conjugate. The method may also include the addition of the positively charged polypeptide in and / or before step (d).

[0030] With respect to step (d), preferred positively charged polypeptides include, but are not limited to, protamine, SMCC-protamine, histone subunits, histone subunits conjugated to SMCC, or mixtures thereof. Protamine, SMCC-protamine, or mixtures thereof are preferred, and protamine or SMCC-protamine are more preferred.

[0031] In step (d), the positively charged polypeptide is preferably in molar excess compared to the second conjugate, i.e., preferably there are more positively charged polypeptide molecules than second conjugate molecules. In some embodiments, the molar ratio of the positively charged polypeptide to the second conjugate in step (d) is at least about 10:1, preferably at least about 15:1, and preferably at least about 20:1. In some embodiments, the molar ratio of the positively charged polypeptide to the second conjugate is up to about 50:1, preferably up to about 45:1, and preferably up to about 40:1. In some embodiments, the molar ratio of the positively charged polypeptide to the second conjugate in step (d) is in the range of about 10:1 to 50:1, preferably about 15:1 to about 45:1, and preferably about 20:1 to about 40:1. In a preferred embodiment, the molar ratio of the positively charged polypeptide to the second conjugate is approximately 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1, 37:1, 38:1, 39:1, and 40:1.

[0032] In step (d), the negatively charged molecules are preferably in molar excess compared to the second conjugate, i.e., preferably there are more negatively charged molecules than second conjugate molecules. In some embodiments, the molar ratio of the positively charged polypeptide to the second conjugate in step (d) is at least about 10:1, at least about 15:1, at least about 20:1, at least about 25:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 70:1, at least about 100:1, at least about 150:1, at least about 200:1, at least about 250:1, at least about 300:1, at least about 400:1, or at least about 500:1.

[0033] In step (d), the negatively charged molecules are preferably equimolar or in molar excess compared to the positively charged polypeptides, i.e., preferably, the negatively charged molecules are present in approximately the same number or more than the positively charged polypeptide molecules. In some embodiments, the molar ratio of negatively charged molecules to positively charged polypeptides in step (d) is at least about 1:1, at least about 2:1, at least about 3:1, at least about 4:1, at least about 5:1, at least about 6:1, at least about 7:1, at least about 8:1, at least about 9:1, at least about 100:1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90:1, or at least about 100:1.

[0034] The methods of the present disclosure can be carried out over a wide range of temperatures. The embodiments of the present application show that nanoparticles can be formed at about 4°C, at room temperature, and at 37°C. Accordingly, it is conceivable that the methods of the present disclosure, for example, steps (c) and / or (d), can be carried out at temperatures of about 1°C to about 60°C, preferably about 2°C to about 50°C, preferably about 3°C ​​to about 40°C, and more preferably about 4°C to about 37°C. Accordingly, step (d) can be carried out at temperatures of about 1°C to about 60°C, preferably about 2°C to about 50°C, preferably about 3°C ​​to about 40°C, and more preferably about 4°C to about 37°C.

[0035] Step (d) is preferably envisioned to include an incubation step that enables the formation of nanoparticles. The incubation step is preferably carried out for at least about 1 hour, preferably at least about 1.5 hours, preferably at least about 2 hours. The incubation step is preferably carried out for up to about 48 hours, preferably up to about 24 hours, preferably up to about 18 hours, preferably up to about 12 hours, preferably up to about 10 hours, preferably up to about 9 hours, preferably up to about 8 hours, preferably up to about 7 hours, preferably up to about 6 hours. The incubation step is preferably carried out for about 1 hour to about 48 hours, preferably about 1 hour to about 24 hours, preferably about 1 hour to about 18 hours, preferably about 1 hour to about 12 hours, preferably about 1 hour to about 10 hours, preferably about 1 hour to about 9 hours, preferably about 1.5 hours to about 8 hours, preferably about 1.5 hours to about 7 hours, preferably about 2 hours to about 6 hours. While we do not wish to be constrained by theory, it is believed that optimal results can be achieved in an incubation period of approximately 2 to 6 hours. Therefore, in a preferred embodiment, the process is approximately 2 to 6 hours, for example, approximately 2 hours, approximately 2.1 hours, approximately 2.2 hours, approximately 2.3 hours, approximately 2.4 hours, approximately 2.5 hours, approximately 2.6 hours, approximately 2.7 hours, approximately 2.8 hours, approximately 2.9 hours, approximately 3 hours, approximately 3.1 hours, approximately 3.2 hours, approximately 3.3 hours, approximately 3.4 hours, approximately 3.5 hours, approximately 3.6 hours, approximately 3.7 hours, approximately 3.8 hours, approximately 3. This includes incubation periods of approximately 0.9 hours, 4 hours, 4.1 hours, 4.2 hours, 4.3 hours, 4.4 hours, 4.5 hours, 4.6 hours, 4.7 hours, 4.8 hours, 4.9 hours, 5 hours, 5.1 hours, 5.2 hours, 5.3 hours, 5.4 hours, 5.5 hours, 5.6 hours, 5.7 hours, 5.8 hours, 5.9 hours, and 6 hours.

[0036] The method of the present disclosure may further include, prior to step (c), a step of (a) conjugating a positively charged polypeptide into a bifunctional linker, and (b) removing the unconjugated linker.

[0037] The term "remove the unconjugated linker" means, as used herein, any appropriate step for separating the conjugate of the positively charged polypeptide and the bifunctional linker (i.e., the first conjugate) from the unconjugated linker. Such methods are well known to those skilled in the art and include, but are not limited to, filtration, dialysis, gel filtration, chromatography, or electrophoresis.

[0038] The terms “conjugation” or “conjugate” as used herein refer to the joining of two or more molecules by any type of covalent bond, including but not limited to chemical conjugation. Thus, a conjugation may include the conjugation of at least a portion of a linker to a polypeptide. This joining may be achieved via different reactive groups or via the same reactive groups.

[0039] Functional groups on polypeptides that can be targeted for crosslinking include primary amines, sulfhydryls, carbonyls, hydroxyls, carbohydrates, carboxylic acids, and the like, preferably via amines and / or sulfhydryls and / or carboxyls. In some embodiments, the conjugation of the linker to the polypeptide is achieved via the NH2 group of the polypeptide. In some embodiments, the conjugation of the linker to the polypeptide is achieved via the thiol group of the polypeptide. In some embodiments, the conjugation of the linker to the polypeptide is achieved via the carboxyl group of the polypeptide. Methods for chemically conjugating a linker (or crosslinking agent) to a polypeptide are well known to those skilled in the art.

[0040] The method of the present disclosure may further include a step of purifying the antibody prior to step (c). Such a purification step may be a desalting step. Such desalting methods are well known to those skilled in the art and include, but are not limited to, gel filtration or dialysis.

[0041] The method of the present disclosure may further include a step of separating and / or recovering the nanoparticles obtained in step (c) from the components of the production environment. Preferably, after separation and / or recovery, the nanoparticles are free from or substantially free from all other components originating from the production environment. The contaminants from the production environment are typically materials that interfere with the use of the nanoparticles, specifically their therapeutic use, and may include free second conjugates (i.e., second conjugates not contained in the nanoparticles), free (i.e., not contained in the nanoparticles) positively charged polypeptides, or free (i.e., not contained in the nanoparticles) negatively charged molecules. The nanoparticles may constitute, for example, at least about 5% by weight, at least about 10% by weight, at least about 15% by weight, at least about 20% by weight, at least about 25% by weight, at least about 30% by weight, at least about 35% by weight, at least about 40% by weight, or at least about 45% by weight of the total protein in a given sample. In a preferred embodiment, the nanoparticles constitute at least about 50% by weight, at least about 55% by weight, at least about 60% by weight, at least about 65% by weight, at least about 70% by weight, at least about 75% by weight, at least about 80% by weight, or at least about 85% by weight of the total protein in a given sample. In a preferred embodiment, the nanoparticles constitute at least about 90% by weight, at least about 91% by weight, at least about 92% by weight, at least about 93% by weight, at least about 94% by weight, at least about 95% by weight, at least about 96% by weight, at least about 97% by weight, at least about 98% by weight, or at least about 99% by weight of the total protein in a given sample. It is understood that the isolated nanoparticles may constitute, depending on the circumstances, about 5% to about 99.9% by weight or about 100% by weight of the total protein content.

[0042] The method disclosed herein may include the following steps: Optional: (a) A step of conjugating a positively charged polypeptide into a bifunctional linker; Optional: (b) a step to remove an unconjugated bifunctional linker; Optional: A step to purify antibodies; (c) A step of contacting an antibody with a composition comprising a first conjugate (A), wherein the first conjugate comprises a positively charged polypeptide conjugated to a bifunctional linker, and the composition essentially does not contain an unconjugated bifunctional linker, thereby obtaining a second conjugate (B), the second conjugate comprising a positively charged polypeptide, a bifunctional linker, and an antibody; Optional: A step to determine the protein content; An optional step; preferably, evaluating antibody functionality via flow cytometry; (d) A step of contacting a second conjugate (B) with a positively charged polypeptide and a negatively charged molecule to form nanoparticles; and / or A step of recovering and / or isolating optional nanoparticles.

[0043] The term "polypeptide" as used herein refers to a compound consisting of a single chain of amino acid residues linked by peptide bonds. The term "protein" as used herein may be synonymous with the term "polypeptide," or may further refer to a complex of two or more polypeptides. A polypeptide may contain at least about 10, at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, at least about 100, at least about 150, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400, at least about 450, at least about 500, at least about 600, at least about 700, or more amino acids.

[0044] Polypeptides, as used herein, preferably consist of naturally occurring and / or protein-constituting amino acids. However, peptide mimes in which amino acids and / or peptide bonds are substituted with functional analogs are also included in the present invention. The term polypeptide also includes and does not exclude modifications of polypeptides, such as glycosylation, acetylation, phosphorylation, etc. Such modifications are well described in basic reference books and more detailed monographs, as well as in research literature.

[0045] The term "positively charged polypeptide" means a polypeptide that has a net positive charge at or near physiological pH (e.g., in solutions having a pH of 4-10, 5-9, or 6-8) and is preferably capable of binding to nucleic acids or negatively charged small molecules by electrostatic interactions. Carriers in this class include, but are not limited to, protamines, histones, or histone subunits. Preferably, such a positively charged polypeptide has a net charge of at least 2+, preferably at least 3+, preferably at least 4+, preferably at least 5+, preferably at least 6+, preferably at least 7+, preferably at least 8+, preferably at least 9+, preferably at least 10+, preferably at least 11+, preferably at least 12+, preferably at least 13+, preferably at least 14+, preferably at least 15+, preferably at least 16+, preferably at least 17+, preferably at least 18+, preferably at least 19+, and preferably at least 20+. The term "positively charged polypeptide" can encompass both free (i.e., unconjugated) polypeptides and conjugated polypeptides, such as polypeptides conjugated to a linker.

[0046] Preferred positively charged polypeptides according to this disclosure include protamines. Protamines are small, strongly basic proteins whose positively charged amino acid groups (specifically, arginine) are generally arranged in clusters and, due to their polycationic nature, neutralize the negative charge of nucleic acids. The term “protamine” as used herein includes any protamine amino acid sequence obtained from or derived from natural or biological sources, e.g., fragments thereof, and polymeric forms or fragments thereof of such amino acid sequences. Protamines may be of natural origin or may be produced by recombinant methods. The use of recombinant methods may allow for the production of multiple copies of protamine or modification of the molecular size and amino acid sequence of protamine. Corresponding compounds may be chemically synthesized. When artificial protamines are synthesized, the methods used may include, for example, the substitution of amino acid residues having undesirable functions of natural protamine (e.g., DNA condensation) for other suitable amino acids. In general, the protamines of this disclosure may be of or derived from any species. The protamines of this disclosure may be derived from mammals, birds, amphibians, reptiles, or fish. The protamines of this disclosure may be of or derived from any species selected from the group consisting of humans, dogs, cats, mice, rats, horses, cattle, pigs, goats, chickens, sheep, donkeys, rabbits, alpacas, llamas, geese, oxen, turkeys, salmon, etc., preferably humans or salmon. The protamines of this disclosure may be mixtures of different protamines. Preferred protamines include salmon protamine. Preferred protamines include human protamine. A preferred protamine contains, or preferably consists of, a sequence having at least about 80%, preferably at least about 85%, preferably at least about 90%, and preferably at least about 95% sequence identity with respect to the salmon protamine shown in SEQ ID NO: 53. A preferred protamine contains, or preferably consists of, the salmon protamine shown in SEQ ID NO: 53.A preferred protamine contains, or preferably consists of, a sequence having at least about 80%, preferably at least about 85%, preferably at least about 90%, and preferably at least about 95% sequence identity with respect to human protamine 1 shown in SEQ ID NO: 55. A preferred protamine contains, or preferably consists of, human protamine 1 shown in SEQ ID NO: 55.

[0047] As mentioned above, protamine is a strongly positively charged protein that immediately interacts with negatively charged nucleic acids such as siRNA. Although we do not wish to be constrained by theory, it is thought that the uptake of the complex into the cell is mediated via receptor-mediated endocytosis. Furthermore, it is thought that the antibody binds to the receptor, and the nanoparticles are translocated internally via endocytosis in clathrin-coated pits. Furthermore, vesicles are transported into the cell, where siRNA can be released from the nanoparticles and enter the RNAi pathway.

[0048] More preferred positively charged polypeptides according to this disclosure include histones or histone subunits. Histones are small DNA-binding proteins present in chromatin that have a high proportion of positively charged amino acids (lysine and arginine) that bind to DNA independently of nucleotide sequences and enable it to fold into nucleosomes. The term "histone" as used herein includes any histone amino acid sequence obtained from or derived from natural or biological sources, e.g., histone subunits, fragments thereof, and polymeric forms of said amino acid sequences, or fragments thereof. Histones H2, H3, and H4 are particularly suitable. In general, histones according to this disclosure may be of or derived from any species. Histones according to this disclosure may be derived from mammals, birds, amphibians, reptiles, or fish. The histones of this disclosure may be from any species selected from the group consisting of humans, dogs, cats, mice, rats, horses, cattle, pigs, goats, chickens, sheep, donkeys, rabbits, alpacas, llamas, geese, cattle, turkeys, salmon, etc., preferably from humans, or derived therefrom. The histones of this disclosure may be mixtures of different histones or histone subunits. Preferred histones include human histones. Preferred histones contain, or preferably consist of, a sequence having at least about 80%, preferably at least about 85%, preferably at least about 90%, preferably at least about 95%, preferably at least about 98%, preferably at least about 99% sequence identity with respect to human histone H2 shown in SEQ ID NO: 56. Preferred histones contain, or preferably consist of, human histone H2 shown in SEQ ID NO: 56. A preferred histone contains, or preferably consists of, a sequence having at least about 80%, preferably at least about 85%, preferably at least about 90%, preferably at least about 95% sequence identity with respect to the human histone H2-derived peptide shown in SEQ ID NO:57.Preferred histones include, or preferably consist of, the human histone H2-derived peptide shown in SEQ ID NO: 57. Preferred histones include, or preferably consist of, a sequence having at least about 80%, preferably at least about 85%, preferably at least about 90%, and preferably at least about 95% sequence identity with respect to the human histone H2-derived peptide shown in SEQ ID NO: 58. Preferred histones include, or preferably consist of, the human histone H2-derived peptide shown in SEQ ID NO: 58.

[0049] "Linker" as used herein may mean a crosslinker or crosslinking agent containing at least two functional groups in a free (i.e., unconjugated) form. In one embodiment, the methods of the present invention include homobifunctional or heterobifunctional crosslinking agents having functional groups including, but not limited to, carbodiimides, carbonyls, imide esters, isosinates, maleimides, N-hydroxysuccinimide (NHS) esters, sulfo-NHS esters, PFP esters, hydroxymethylphosphines, aryl azides, pyridyl disulfites, and vinyl sulfones. The bonds they form include, but are not limited to, amide bonds, disulfide bonds, hydrazine bonds, thioether bonds, and ester bonds. Functional groups that can be targeted by the linker or crosslinking agent for crosslinking include primary amines, sulfhydryls, carbonyls, hydroxyls, carbohydrates, carboxyls, etc., preferably amines and sulfhydryls, most preferably sulfhydryls. Preferably, the linker does not contain cleavable disulfide bonds (SS). In one embodiment, the linker includes a pH-dependent cleavable side. The linker may be water-soluble, permeable to cell membranes, have varying spacer arm lengths, be spontaneously reactive, or contain photoreactive groups. Furthermore, the linker may be labeled or tagged.

[0050] In one embodiment, the linker may be directly conjugated to the antibody and the positively charged polypeptide, one example of which is a sulfo-SMCC linker. Examples of crosslinking agents include, but are not limited to, N-hydroxysulfosuccinimide (sulfo-NHS), sulfosuccinimidyl(perfluoro-didobenzamide)ethyl-1,3'-dithiopropionate (sulfo-SFAD), succinimidyl 4-formylbenzoate (SFB), succinimidyl 4-hydrazinonicotinateacetonehydrazone (SANH), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N-succinimidyl 3-(2-pyridyldithio)-propionate (SPDP), 2-iminothiolane (Trout's reagent), N-succinimidyl(acetylthio)acetate (SATA), and 3[2-pyridyldithio]propionylhydrazide (PDPH), or any other linkers that are publicly available and known to those skilled in the art.

[0051] A "heterofunctional" linker refers to a linker in which the targeted functional groups are mutually different. In one embodiment, the linker includes an amine and sulfhydryl, or an amine and hydroxyl, preferably an amine and sulfhydryl, as the functional groups targeted for crosslinking. In another embodiment, the method of the present invention includes a linker containing an amine and sulfhydryl as the functional groups targeted for crosslinking. In yet another embodiment, the method of the present invention includes a heterobifunctional linker that does not contain cleavable sites, for example, one that does not have cleavable disulfide bonds (SS). Preferred heterofunctional linkers include, for example, α-maleimideacetoxy-succinimide (AMAS), N(4-[p-azidosalicylamide]butyl)-3'-(2'-pyridyldithio)propionamide (APDP*), (β-maleimidopropionic acid)hydrazide·TFA (BMPH), (β-maleimidopropyloxy)succinimide (BMPS), ε-maleimidocaproic acid (EMCA), (ε-maleimidocaproyloxy)succinimide (EMCS), (γ-maleimidobutyryloxy)succinimide (GMBS), κ-maleimidoundecanoic acid (KMUA), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidecaproate) (LC-SMCC), succinimidyl-6-(3'-[ 2-Pyridyl-dithio]propionamide)hexanoate (LC-SPDP), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), succinimidyl-3-(bromoacetamide)propionate (SBAP), succinimidyl (4-iodoacetyl)aminobenzoate (SIAB), succinimidyliodoacetate (SIA), succinimidyl 4-(ρ-maleimidophenyl)butyrate (SMPB), NHS-PEG24-maleimide SM (PEG24), NHS-PEG12-mariemide (SM[PEG]12), NHS-PEG8-mariemide (SM[PEG]8), NHS-PEG6-maleimide (SM(PEG)6), NHS-PEG4-mariemide (SM[PEG]4), NHS-PEG2-mariemide (SM[PEG]2),Succinimidyl 4-(N-maleimido-methyl)cyclohexane-carboxylate (SMCC), succinimidyliodoacetate (SIA), succinimidyl (4-iodoacetyl)aminobenzoate (SIAB), (ε-maleimidocaproyloxy)sulfosuccinimidate (sulfo-EMCS), succinimidyl-3-(2-pyridyldithio)propionate (SPDP), succinimidyl-6-(β-maleimidopropionamide)hexanoate (SMPH), N-(γ-maleimidobutryloxy)sulfosuccinimidate (sulfo-GMBS), -(κ-maleimidoundecanoyloxy)sulfosuccinimidate (sulfo-KMUS), sulfosuccinimidyl 6-(α-methyl-α-[2-pyridyldithio]-toluamide)hexanoate (sulfo-LC-SMPT), sulfos These are cunimidyl 6-(3'-[2-pyridyl-dithio]propionamide) hexanoate (sulfo-LC-SPDP), maleimidobenzoyl-hydroxysulfosuccinimide ester (sulfo-MBS), sulfosuccinimidyl (4-iodoacetyl)aminobenzoate (sulfo-SIAB), sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC), sulfosuccinimidyl 4-(p-maleimidophenyl) butyrate (sulfo-SMPB), N,N-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), and sulfo-NHS-(2-6-[biotinamide]-2-(p-azidobezamide)) (sulfo-SBED). Heterobifunctional linkers are preferred in the method of the present invention.

[0052] In some embodiments, the method of the present invention includes a heterobifunctional linker that is sulfo-SMCC.

[0053] "Unconjugated bifunctional linker" means a bifunctional linker in which both functional groups are not conjugated, as used herein. In some embodiments, the unconjugated bifunctional linker is not conjugated to a positively charged polypeptide. In some embodiments, the unconjugated bifunctional linker is not conjugated to an antibody.

[0054] The term "essentially free of unconjugated bifunctional linkers" means, as used herein, that it is preferable that unconjugated bifunctional linkers are not present in the composition, but that it is possible for the compositions according to this disclosure to have very small amounts of unconjugated bifunctional linkers, preferably such amounts not substantially affect the advantageous use of such composition. In some embodiments, a composition containing a first conjugate that is essentially free of unconjugated linkers contains at least about 10 times more first conjugate molecules than unconjugated linker molecules. Accordingly, a first conjugate that is essentially free of unconjugated linkers has a molar ratio of the first conjugate to the unconjugated linker of preferably about 10:1 or more, preferably about 20:1 or more, preferably about 50:1 or more, preferably about 100:1 or more, preferably about 200:1 or more, preferably about 500:1 or more, preferably about 1000:1 or more, preferably about 2000:1 or more, preferably about 5000:1 or more, preferably about 10000:1 or more. In some embodiments, a composition that initially contained the first conjugate and the unconjugated bifunctional linker, having undergone a purification step, such as a desalting step, which can completely or partially remove the unconjugated bifunctional linker, is considered a composition that is essentially free of unconjugated bifunctional linkers.

[0055] The definition of the term "antibody" includes forms such as monoclonal antibodies, chimeric antibodies, single-chain antibodies, humanized antibodies, and human antibodies. In addition to full-length antibodies, the definition also includes antibody derivatives and antibody fragments, such as Fab fragments, among others. Antibody fragments or derivatives include F(ab')2 fragments, Fv fragments, scFv fragments, or single-domain antibodies, such as domain antibodies or nanobodies, single variable-domain antibodies, or immunoglobulin single variable domains containing only one variable domain, which may be VHH, VH, or VL, that specifically binds to an antigen or epitope independently of other V regions or domains. The term also includes diabody or dual-affinity re-targeting (DART) antibodies. Further possibilities include "mini-bodies," "Fc DART," and "IgG DART," exemplified by structures such as (bispecific) single-chain diabodies, tandem diabodies (Tandab), (VH-VL-CH3)2, (scFv-CH3)2, or (scFv-CH3-scFv)2, as well as multi-bodies, such as triabodies. Immunoglobulin single variable domains include not only isolated antibody single variable domain polypeptides but also larger polypeptides containing one or more monomers of antibody single variable domain polypeptide sequences.

[0056] Furthermore, the term “antibody” also refers to derivatives or variants of the antibodies described herein that exhibit the same specificity as the antibodies described herein, as used herein. Examples of “antibody variants” include humanized variants of non-human antibodies, “affinity-mature” antibodies, and antibody variants with altered effector functions (see, for example, U.S. Patent No. 5,648,260).

[0057] The term "antibody" includes different classes (i.e., IgA, IgG, IgM, IgD, and IgE) as well as subclasses (e.g., IgG1, IgG2, etc.) of immunoglobulins (Ig). Derivatives of antibodies, as included in the definition of the term antibody in the sense of this invention, include molecular modifications such as glycosylation, acetylation, phosphorylation, disulfide bond formation, farnesylation, hydroxylation, methylation, or esterification.

[0058] Functional antibody fragments include constructs containing the domain of the F(ab')2 fragment, the Fab fragment, scFv, or a single immunoglobulin variable domain, or single-domain antibody polypeptides, such as a single heavy chain variable domain or a single light chain variable domain, and also include the other antibody fragments described herein. F(ab')2 or Fab may be modified to minimize or completely eliminate intermolecular disulfide interactions occurring between the CH1 domain and the CL domain.

[0059] The term “human” antibody should be understood, as used herein, to mean that the antibody or its functional fragment contains an amino acid sequence found in the human germline antibody repertoire. Therefore, for the purposes of this specification, an antibody or fragment may be considered “human” if it consists of such a human germline amino acid sequence, i.e., if the amino acid sequence of the antibody or its functional fragment is identical to an expressed human germline amino acid sequence. An antibody or its functional fragment may also be considered “human” if it consists of a sequence that does not deviate more than expected due to imprinting of somatic high-frequency mutations from its nearest human germline sequence. Furthermore, antibodies from many non-human mammals, such as rodents, e.g., mice and rats, contain the VH CDR3 amino acid sequence, which may also be expected to be present in the expressed human antibody repertoire. Any such sequence of human or non-human origin that may be expected to be present in the expressed human repertoire will also be considered “human” for the purposes of this invention. Therefore, the term "human antibody" includes antibodies having variable and constant regions substantially corresponding to human germline immunoglobulin sequences known in the art, such as those described by Kabat et al. (1991) 'Sequences of Proteins of Immunological Interest, 5th Ed.', National Institutes of Health).

[0060] The human antibodies of this disclosure may contain amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro, or by somatic mutation in vivo) in, for example, CDRs, specifically CDR3. The human antibodies may have at least one, two, three, four, five, or more positions substituted with amino acid residues not encoded by human germline immunoglobulin sequences.

[0061] Non-human antibodies and human antibodies or their functional fragments are preferably monoclonal. Preparing monoclonal human antibodies is particularly difficult. In contrast to fusions of mouse B cells and immortalized cell lines, fusions of human B cells and immortalized cell lines are not viable. Therefore, human monoclonal antibodies represent overcoming a significant technical hurdle that is generally recognized to exist in the field of antibody technology. The monoclonal nature of an antibody makes it particularly suitable for use as a therapeutic agent, as it exists as a single, homogeneous molecular species that can be well-characterized, reproducibly produced, and purified. These factors result in a product whose biological activity can be predicted with high accuracy, which is crucial if such a molecule is intended to obtain regulatory approval for therapeutic administration in humans. The term “monoclonal antibody” as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies; that is, the individual antibodies constituting the population are identical, except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation) that may be present in trace amounts. Monoclonal antibodies are highly specific to a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations, which typically contain different antibodies against different determinants (epitopes), each monoclonal antibody is specific to a single determinant on the antigen. In addition to specificity, monoclonal antibodies have the advantage of being synthesized from hybridoma cultures that are free from contamination with other immunoglobulins. The modifier "monoclonal" indicates a characteristic of the antibody that it is obtained from a substantially homogeneous antibody population, and should not be interpreted as requiring antibody production by a specific method. For example, monoclonal antibodies used in this invention may be produced by the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or by the recombinant DNA method (see, for example, U.S. Patent No. 4,816,567)."Monoclonal antibodies" may be isolated from a phage antibody library using techniques such as those described in Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991).

[0062] It is particularly preferable that the monoclonal antibody or the corresponding functional fragment is a human antibody or the corresponding functional fragment. When designing antibody drugs for therapeutic administration to humans, it is highly advantageous that the antibody is of human origin. After administration to a human patient, the human antibody or its functional fragment will likely not induce a strong immunogenic response by the patient's immune system; that is, it will not be recognized as a foreign substance that is a non-human protein. In other words, no host antibodies against the therapeutic antibody, i.e., the patient's antibodies, will be produced, which would inhibit the activity of the therapeutic antibody and / or accelerate its elimination from the patient's body, thus hindering the exertion of the desired therapeutic effect.

[0063] According to a further aspect of the present invention, the antibody may be an immunoglobulin. According to a further aspect of the present invention, the antibody may be an IgG antibody. The IgG isotype includes not only the variable antibody regions of the heavy and light chains responsible for highly discriminative antigen recognition and binding, but also the constant regions of the heavy and light chains of the antibody polypeptide that are normally present in "naturally" produced antibodies, and in some cases even modifications at one or more sites by carbohydrates. Such glycosylation is generally a feature of the IgG format and is located in the constant region, which includes the so-called Fc region of the complete antibody, known to induce various effector functions in vivo. Furthermore, the Fc region mediates the binding of IgG to the Fc receptor and also facilitates the homing of IgG to inflammatory tissue, for example, at sites where the presence of the Fc receptor is increased. Advantageously, the IgG antibody may be an IgG1 antibody or an IgG4 antibody, and these formats are preferred because their mechanisms of action in vivo are particularly well understood and characterized. This is especially true for the IgG1 antibody.

[0064] According to a further aspect of the present invention, the functional fragment of the antibody may preferably be scFv, single-domain antibody, Fv, VHH antibody, diabody, tandem diabody, Fab, Fab', or F(ab)2. These formats can generally be divided into two subclasses: those consisting of a single polypeptide chain and those containing at least two polypeptide chains. Members of the former subclass include scFv (containing one VH region and one VL region ligated to a single polypeptide chain via a polypeptide linker); and single-domain antibodies (containing a single antibody variable region), such as VHH antibodies (containing a single VH region). Members of the latter subclass include: Fv (containing one VH region and one VL region as separate polypeptide chains non-covalently associated with each other); diabody (containing two non-covalently associated polypeptide chains, each containing two antibody variable regions (typically one VH and one VL per polypeptide chain), with the two polypeptide chains arranged in a head-to-tail conformation to produce a bivalent antibody molecule); tandem diabody (containing four covalently linked immunoglobulin variable regions (VH and VL regions) with two different specificities, and twice the size of the aforementioned diabody) This includes a bispecific single-chain Fv antibody that forms a dimer; (containing itself the entire antibody light chain, including the VL region and the entire light chain constant region, as one polypeptide chain, and a portion of the antibody heavy chain, including the complete VH region and a portion of the heavy chain constant region, as another polypeptide chain, with the two polypeptide chains intermolecularly connected via interchain disulfide bonds) Fab; Fab' (similar to the above Fab except that an additional reduced disulfide bond is included in the antibody heavy chain); and F(ab)2 (containing two Fab' molecules, each Fab' molecule linked to the other Fab' molecule via interchain disulfide bonds). In general, the above types of functional antibody fragments described herein allow for great flexibility in individualizing the pharmacodynamic properties of an antibody desired for therapeutic administration, for example, in the event of an imminent specific emergency.For example, when treating tissues known to have insufficient angiogenesis (e.g., joints), it may be desirable to reduce the size of the administered antibody to increase the degree of tissue penetration. In some situations, it may be desirable to increase the rate at which therapeutic antibodies are eliminated from the body, and this rate can generally be accelerated by reducing the size of the administered antibody. An antibody fragment is defined for the purposes of this invention as a functional antibody fragment, insofar as it maintains the specific binding characteristics to the epitope / target of the parent antibody, for example, as long as it specifically binds to CD33, EGFR, IGF1R, or CD20, or as long as it is an antibody that targets other cell surface structures that have the ability to move internally upon antibody binding.

[0065] According to a further aspect of the present invention, the antibody may include a CL domain. According to a further aspect of the present invention, the antibody may include a CH1 domain. According to a further aspect of the present invention, the antibody may include a CH2 domain. According to a further aspect of the present invention, the antibody may include a CH3 domain. According to a further aspect of the present invention, the antibody may include the entire light chain. According to a further aspect of the present invention, the antibody may include the entire heavy chain.

[0066] According to further aspects of the present invention, the antibody or its functional fragment may exist in the form of monovalent, monospecific; polyvalent, monospecific, specifically bivalent, monospecific; or polyvalent, multispecific, specifically bivalent, bispecific. Generally, polyvalent, monospecific, specifically bivalent, monospecific antibodies, such as the complete human IgG described herein, may have a therapeutic advantage in that the neutralization produced by such an antibody is enhanced by the avidity effect, i.e., the binding of the same antibody to multiple molecules of the same antigen, here for example, CD33, EGFR, IGF1R, or CD20. Some types of monovalent, monospecific antibody fragments are as described above (e.g., scFv, Fv, VHH, or single-domain antibodies).

[0067] Antibodies or their functional fragments can be derivatized, for example, by organic polymers, with one or more molecules of polyethylene glycol ("PEG") and / or polyvinylpyrrolidone ("PVP"). As is known in the art, such derivatization may be advantageous for modulating the pharmacokinetic properties of the antibody or its functional fragment. Particularly preferred are PEG molecules derivatized as PEG-maleimides, which enable site-specific conjugation with the antibody or its functional fragment via the sulfhydryl group of a cysteine ​​amino acid. Of these, particularly preferred are 20kD and / or 40kD PEG-maleimides, either branched or linear. It may be particularly advantageous to increase the effective molecular weight of smaller human antibody fragments, such as scFv fragments, by coupling them with one or more PEG molecules, specifically PEG-maleimide molecules.

[0068] Chimeric antibodies (immunoglobulins) in which a portion of the heavy chain and / or light chain is identical or homologous to a corresponding sequence of an antibody derived from a particular species or belonging to a particular antibody class or subclass, and the remainder of the chain is identical or homologous to a corresponding sequence of an antibody derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, are included in the antibodies of this disclosure insofar as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). Chimeric antibodies of interest as used herein include "primatized" antibodies that contain a variable domain antigen-binding sequence derived from a non-human primate (e.g., Old World monkeys, apes, etc.) and a human constant region sequence.

[0069] The “humanized” form of a non-human (e.g., mouse) antibody is a chimeric immunoglobulin, immunoglobulin chain, or fragment thereof (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding subsequences of the antibody) that is predominantly human and contains minimal sequences derived from non-human immunoglobulins. For the most part, a humanized antibody is a human immunoglobulin (recipient antibody) in which residues derived from the recipient’s hypervariable region (CDR) are replaced with residues derived from the hypervariable region (donor antibody) of a non-human species, e.g., mouse, rat, or rabbit, to achieve the desired specificity, affinity, and capacity. In some cases, Fv framework region (FR) residues of human immunoglobulin are replaced with corresponding non-human residues. Furthermore, “humanized antibodies” may also include residues not found in either the recipient antibody or the donor antibody, as used herein. These modifications are made to further improve and optimize the performance of the antibody. Humanized antibodies, ideally, include at least a portion of the constant region (Fc) of immunoglobulins, typically that of human immunoglobulins. For further details, see Jones et al., Nature, 321:522-525 (1986); Reichmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992).

[0070] Preferred antibodies are those that bind to cell surface molecules, preferably cell surface domains, and that interlocate internally in a receptor-dependent manner, such as anti-CD33 antibodies, anti-EGFR antibodies, anti-IGF1R antibodies, or anti-CD20 antibodies. Preferred antibodies are selected from the group consisting of cetuximab, gemtuzumab, xixutumumab, teprotumumab, GR11L, and rituximab. Further antibodies that bind to cell surface domains and interlocate internally in a receptor-dependent manner are disclosed in LU 92353 A, which is incorporated by reference.

[0071] The preferred antibody comprises a VH domain containing the following three heavy chain CDRs and a VL domain containing the following three light chain CDRs: CDR-H1 having sequence GFSLTNYG (SEQ ID NO:1), CDR-H2 having sequence IWSGGNT (SEQ ID NO:2), sequence CDR-H3 having TIFF2023553038000001.tif4128, CDR-L1 having sequence QSIGTN (SEQ ID NO:4), CDR-L2 having sequence YAS, and CDR-L3 having sequence QQNNNWPTT (SEQ ID NO:5). Preferred antibodies include a VH domain having the sequence described in SEQ ID NO:6 and a VL domain having the sequence described in SEQ ID NO:7. Preferred antibodies include a heavy chain having the sequence described in SEQ ID NO:8 and a light chain having the sequence described in SEQ ID NO:9.

[0072] Preferred antibodies include a VH domain containing the following three heavy chain CDRs and a VL domain containing the following three light chain CDRs: CDR-H1 having the sequence GYTITDSN (SEQ ID NO: 10), CDR-H2 having the sequence IYPYNGGT (SEQ ID NO: 11), CDR-H3 having the sequence VNGNPWLAY (SEQ ID NO: 12), CDR-L1 having the sequence ESLDNYGIRF (SEQ ID NO: 13), CDR-L2 having the sequence AAS, and CDR-L3 having the sequence QQTKEVPWS (SEQ ID NO: 14). Preferred antibodies include a VH domain having the sequence described in SEQ ID NO: 15 and a VL domain having the sequence described in SEQ ID NO: 16. Preferred antibodies include a heavy chain having the sequence described in SEQ ID NO: 17 and a light chain having the sequence described in SEQ ID NO: 18. A preferred antibody comprises a heavy chain having the sequence described in SEQ ID NO:65 and a light chain having the sequence described in SEQ ID NO:18.

[0073] The preferred antibody comprises a VH domain containing the following three heavy chain CDRs and a VL domain containing the following three light chain CDRs: CDR-H1 having sequence GGTFSSYAIS (SEQ ID NO: 19), sequence CDR-H2 containing TIFF2023553038000002.tif4128, array CDR-H3 containing TIFF2023553038000003.tif4128, array CDR-L1 having TIFF2023553038000004.tif4128, CDR-L2 having sequence GENKRPS (SEQ ID NO:23), and CDR-L3 having sequence KSRDGSGQHLV (SEQ ID NO:24). Preferred antibodies include a VH domain having the sequence described in SEQ ID NO:25 and a VL domain having the sequence described in SEQ ID NO:26. Preferred antibodies include a heavy chain having the sequence described in SEQ ID NO:27 and a light chain having the sequence described in SEQ ID NO:28.

[0074] The preferred antibody comprises a VH domain containing the following three heavy chain CDRs and a VL domain containing the following three light chain CDRs: CDR-H1 having sequence GFTFSSYG (SEQ ID NO: 29), CDR-H2 having sequence IWFDGSST (SEQ ID NO: 30), sequence CDR-H3 having TIFF2023553038000005.tif4128, CDR-L1 having sequence QSVSSY (SEQ ID NO:32), CDR-L2 having sequence IWFDGSST (SEQ ID NO:33), and CDR-L3 having sequence QQRSKWPPWT (SEQ ID NO:34). Preferred antibodies include a VH domain having the sequence described in SEQ ID NO:35 and a VL domain having the sequence described in SEQ ID NO:36. Preferred antibodies include a heavy chain having the sequence described in SEQ ID NO:37 and a light chain having the sequence described in SEQ ID NO:38.

[0075] The preferred antibody comprises a VH domain containing the following three heavy chain CDRs and a VL domain containing the following three light chain CDRs: CDR-H1 having sequence GYTFTSYN (SEQ ID NO: 39), CDR-H2 having sequence IYPGNGDT (SEQ ID NO: 40), sequence CDR-H3 having TIFF2023553038000006.tif4128, CDR-L1 having sequence SSVSYI (SEQ ID NO:42), CDR-L2 having sequence ATS, and CDR-L3 having sequence QQWTSNPPT (SEQ ID NO:43). Preferred antibodies include a VH domain having the sequence described in SEQ ID NO:44 and a VL domain having the sequence described in SEQ ID NO:45. Preferred antibodies include a heavy chain having the sequence described in SEQ ID NO:46 and a light chain having the sequence described in SEQ ID NO:47.

[0076] "Cell surface domain" means any protein on the cell surface, as used herein. Cell surface domains also include cell surface antigens. It further includes any recognizable epitopes on the cell surface of a cell. Preferably, the epitope or protein is cell type specific, as it is present only in certain cell types. In one embodiment, the cell surface domain is present on cancer cells. Potential cell surface targets include CD19, CD20, CD22, CD25, CD30, CD33, CD40, CD56, CD64, CD70, CD74, CD79, CD105, CD138, CD174, CD205, CD227, CD326, CD340, MUC16, GPNMB, PSMA, Cripto, ED-B, TMEFF2, EphB2, EphA2, FAP Av, integrins, mesothelin, EGFR, TAG-72, GD2, CAIX, and / or 5T4. Other possible cell surface domains include CD52, CD3, CD117, CD99, CD34, CD44, CD117, CA15-3, CA-125, CA27-29, EpCAM, fetal carcinoma antigen, melanoma antigen 1 (MART1) recognized by T cells, and trophoblast glycoprotein (TPBG). The cell surface molecules according to the present invention are preferably expressed in cells that are sensitive to therapeutic treatment with negatively charged molecules.

[0077] Preferably, such cell surface domains are CD33, EGFR, IGF1R, and CD20. The cell surface domains can also provide epitopes to which the antibody according to the present invention can bind.

[0078] In accordance with the foregoing, the term “epitope” defines an antigenic determinant that is specifically bound to / identified by an antibody as defined herein. An antibody can specifically bind to / interact with a conformational epitope or serial epitope specific to the target structure.

[0079] In a preferred embodiment, the antibodies of this disclosure are specific to cancer-associated antigens. As used herein, “cancer-associated antigen” or “tumor-associated antigen,” which may be used interchangeably herein, generally refers to any antigen associated with cancer cells or tumor cells, i.e., present in the same or greater proportions than on normal cells. Such antigens may be relatively tumor-specific, with expression limited to the surface of malignant cells, but may also be found on non-malignant cells. In one embodiment, the antibodies of this disclosure bind to cancer-associated antigens.

[0080] The term "internal migration," as used in this invention, refers to endocytosis, in which molecules such as proteins are phagocytosed by the cell membrane and drawn into the cell. Specifically, the cell surface domain to which the binding domain binds undergoes internal migration. Methods for measuring this internal migration are disclosed in the embodiments of this application. Alternatively, for example, such a process can be observed by time-lapse microscopy in which the receptor of interest and the cell membrane are double-stained. Preferably, nanoparticles containing antibodies capable of binding to cell surface molecules undergo internal migration when bound to the cell surface molecules.

[0081] "Second conjugate (B)" means a conjugate comprising, or preferably comprising, an antibody disclosed herein, a positively charged polypeptide disclosed herein, and preferably a bifunctional linker disclosed herein, as used herein. Here, the positively charged polypeptide and the antibody are preferably interconnected via a bifunctional linker.

[0082] The term "negatively charged molecule" refers to a molecule that has a net positive charge at or near the physiological pH (e.g., in a solution with a pH of 4-10, 5-9, or 6-8) and can preferably bind to positively charged polypeptides, such as protamines or histones, by electrostatic interactions. Preferred negatively charged molecules are nucleic acids and negatively charged small molecules. Preferably, such negatively charged molecules have a net charge of at least 2-, preferably at least 3-, preferably at least 4-, preferably at least 5-, preferably at least 6-, preferably at least 7-, preferably at least 8-, preferably at least 9-, or preferably at least 10-.

[0083] Where used herein, the terms “nucleotide sequence,” “polynucleotide,” “nucleic acid,” and “nucleic acid molecule” are interchangeable and refer to any or a combination of unbranched nucleotides, ribonucleotides, or deoxyribonucleotides, which are polymers of any length. Nucleic acid sequences may include both sense and antisense strands of DNA, cDNA, genomic DNA, RNA, such as mRNA, siRNA, synthetic and mixed polymers, or may contain non-natural nucleotide bases or derivatives of nucleotide bases, as readily understood by those skilled in the art. Furthermore, non-limiting examples of such nucleic acids include, but are not limited to, any type of RNA interference (RNAi), which may be single-stranded or double-stranded, that performs gene cessation and / or gene knockdown, e.g., gene knockdown of message (mRNA) by degradation or translation arrest of mRNA, inhibition of tRNA and rRNA function or epigenetic effect; activity of small RNAs on DNA, such as short (or small) interfering RNA (siRNA), small hairpin RNA (shRNA), siRNA prepared by endribonuclease (esiRNA), antisense oligonucleotides, microRNAs, and non-coding RNAs, and Dicer substrate siRNA. Preferred nucleic acids are siRNA, esiRNA antisense oligonucleotides, or miRNAs, with siRNA being the most preferred. In some embodiments, preferably, when the nucleic acid is double-stranded, the nucleic acid has about 18 to about 25 bp. In some embodiments, preferably, when the nucleic acid is single-stranded, the nucleic acid has about 18 to about 25 nt.

[0084] The nucleic acids used in this invention affect target cells. For example, by providing nucleic acid molecules, the expression of a specific molecule or protein in target cells is decreased or increased. Preferably, the use of nucleic acid molecules reduces the expression of a specific molecular protein.

[0085] The nucleic acids described herein include siRNA molecules designed to target, suppress, or block the expression of genes or proteins associated with cancer or involved in the development and / or progression of cancer.

[0086] Preferred nucleic acid molecules are preferably selected from siRNA, esiRNA, antisense oligonucleotides, or miRNAs that are specific to KRAS, BRAF, PIK3CA, PAX3-FKHR, EWS-FLI1, c-MYC, TP53, DNMT3A, IDH1, NPM1, or FLT3. More preferably are siRNAs specific to KRAS, BRAF, PIK3CA, PAX3-FKHR, EWS-FLI1, c-MYC, TP53, DNMT3A, IDH1, NPM1, or FLT3. Such siRNAs are known to those skilled in the art, and exemplary examples of such siRNAs are shown in the table below. TIFF2023553038000007.tif53148

[0087] Preferred nucleic acids of the present disclosure also include one or more targets, preferably a mixture of different siRNAs for a single target. For example, nucleic acids of the present disclosure may include a mixture of siRNAs that are specific to a target selected from the group consisting of KRAS, BRAF, PIK3CA, PAX3-FKHR, EWS-FLI1, c-MYC, TP53, DNMT3A, IDH1, NPM1, and FLT3.

[0088] The negatively charged molecule according to the present invention may be a molecule that is not a nucleic acid. Such a molecule may be a low molecular weight, preferably an organic low molecular weight. The negatively charged molecule may have a molecular weight of about 20 kDa or less, preferably about 15 kDa or less, or about 10 kDa or less. The negatively charged molecule may have a molecular weight of about 9 kDa or less, about 8 kDa or less, about 7 kDa or less, about 6 kDa or less, about 5 kDa or less, about 4 kDa or less, about 3 kDa or less, or about 2 kDa or less. As an exemplary example, the negatively charged molecule may be a drug and / or prodrug. The drug and / or prodrug may be conjugated to a negatively charged moiety. For example, the drug may be ibrutinib conjugated to a negatively charged moiety, e.g., Cy3.5 or Alexa488. However, the drug may be conjugated to other negatively charged moieties. Suitable negatively charged moieties for conjugation are known to those skilled in the art. Examples of suitable negatively charged moieties include (poly)sulfonated aryls (e.g., as co-ligands of transition metals), (poly)sulfonated dyes (e.g., quinoa dyes), mono / di / trisulfates, (poly)sulfates of monosaccharides or branched oligosaccharides, and oligopeptides from glutamic acid or aspartic acid. Drugs and / or prodrugs may have a negative net charge without being conjugated to an additional moiety. An exemplary example of a drug with a negative net charge is remdesivir triphosphate. Those skilled in the art will understand that the above examples are for illustrative purposes only and that many other negatively charged molecules may be used in connection with the present invention.

[0089] As used herein, "ibrutinib" (IUPAC name: 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidine-1-yl]piperidine-1-yl]propa-2-en-1-one, CAS number: 936563-96-1) relates to a molecule having the following structure (in its free form): TIFF2023553038000008.tif51128

[0090] As used herein, "remdesivir triphosphate" (IUPAC name [[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]phosphonohydrogen phosphate, CAS number: 1355149-45-9) relates to a molecule having the following structure. TIFF2023553038000009.tif51128

[0091] The present application also relates to nanoparticles. Such nanoparticles are preferably obtained by the methods described herein. The nanoparticles of the present invention may comprise (a) preferably a positively charged polypeptide as disclosed herein; (b) preferably a second conjugate (B) comprising an antibody conjugated to the positively charged polypeptide via a bifunctional linker; and (c) preferably one or more negatively charged molecules as disclosed herein.

[0092] While we do not wish to be constrained by theory, it is conceivable that the positively charged polypeptide, the second conjugate, and one or more negatively charged molecules are not uniformly distributed within the particle. Instead, in some embodiments, the second conjugate is concentrated in the outer portion of the nanoparticle. In some embodiments, one or more negatively charged molecules are concentrated in the inner portion of the nanoparticle. In some embodiments, the positively charged polypeptide is concentrated in the outer portion of the nanoparticle. In some embodiments, the positively charged polypeptide is concentrated in the inner portion of the nanoparticle. Thus, the nanoparticles of the present invention can form vesicle-like structures in which the second conjugate is mainly located in the outer portion and the negatively charged molecules are concentrated in or encapsulated in the inner portion of the nanoparticle. While we do not wish to be constrained by theory, it is conceivable that such structures protect the negatively charged molecules and thus increase their stability. Furthermore, it is conceivable that at least a portion, or even all, of the nanoparticles can migrate internally when bound to a cell via the second conjugate.

[0093] In some embodiments, the nanoparticles of the Disclosure have an average diameter of at least about 0.05 μm. In some embodiments, the nanoparticles of the Disclosure have an average diameter of at least about 0.1 μm. In some embodiments, the average diameter of the nanoparticles is at least about 0.2 μm. In some embodiments, the nanoparticles of the Disclosure have an average diameter in the range of about 0.05 μm to about 10 μm, preferably about 0.1 μm to about 10 μm, and preferably about 0.2 μm to about 5 μm. The average diameter of the nanoparticles of the Disclosure may be in the range of about 0.3 μm to about 4 μm, about 0.4 μm to about 3 μm, or about 0.5 μm to about 2 μm. The average diameter of the nanoparticles can be determined by any method suitable for determining particle size, such as dynamic light scattering and microscopic analysis. A preferred method for determining particle size is microscopic analysis, preferably by transmission optical microscopy.

[0094] The present invention further relates to compositions comprising nanoparticles of the present invention and / or nanoparticles obtained by the method of the present invention.

[0095] The present invention further relates to pharmaceutical compositions comprising nanoparticles of the present invention and / or nanoparticles obtained by the method of the present invention.

[0096] In the compositions of the present disclosure, for example, the pharmaceutical compositions of the present disclosure, at least about 10% of the second conjugate contained in the composition may be contained in nanoparticles. In a preferred embodiment, at least 20%, preferably at least 30%, preferably at least 40%, preferably at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%, preferably at least 98%, preferably at least 99% of the second conjugate contained in the composition is contained in nanoparticles. In a preferred embodiment, the composition is essentially free of the second conjugate not contained in nanoparticles.

[0097] In the compositions of the present disclosure, for example, the pharmaceutical compositions of the present disclosure, at least about 10% of the positively charged polypeptides contained in the composition may be contained in nanoparticles. In a preferred embodiment, at least 20%, preferably at least 30%, preferably at least 40%, preferably at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%, preferably at least 98%, and preferably at least 99% of the positively charged polypeptides contained in the composition are contained in nanoparticles. In a preferred embodiment, the composition is essentially free of positively charged polypeptides not contained in nanoparticles.

[0098] In the compositions of the present disclosure, for example, the pharmaceutical compositions of the present disclosure, at least about 10% of the negatively charged molecules contained in the composition may be contained in nanoparticles. In a preferred embodiment, at least 20%, preferably at least 30%, preferably at least 40%, preferably at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%, preferably at least 98%, and preferably at least 99% of the negatively charged molecules contained in the composition are contained in nanoparticles. In a preferred embodiment, the composition is essentially free of negatively charged molecules that are not contained in nanoparticles.

[0099] The term “pharmaceutical composition” relates to a composition for administration to a patient, preferably a human patient. A pharmaceutical composition or formulation is generally in a form that allows the biological activity of the active ingredient to be effective and can therefore be administered to a subject for the therapeutic use described herein. Generally, a pharmaceutical composition comprises a suitable (i.e., pharmaceutically acceptable) formulation of a carrier, stabilizer, and / or excipient. Examples of suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by EW Martin. Such a composition contains a therapeutically effective amount of the above molecules, preferably in a purified form, together with a suitable amount of carrier, in order to provide a form for appropriate administration to a patient. The formulation should be adapted to a mode of administration.

[0100] In one embodiment, the pharmaceutical composition is a composition for parenteral, transdermal, intracavitary, intra-arterial, subarachnoid, and / or intranasal administration, or for direct injection into tissue. Specifically, the composition is intended to be administered to a patient via infusion or injection. Administration of a suitable composition can be carried out by various methods, for example, intravenous, intraperitoneal, subcutaneous, intramuscular, topical, or intradermal administration. The composition of the present invention may further comprise a pharmaceutically acceptable carrier. Examples of suitable pharmaceutical carriers are well known in the art and include buffered saline solutions, water, emulsions, e.g., oil / water emulsions, various types of wetting agents, sterile solutions, liposomes, etc. Compositions comprising such carriers can be formulated by well known conventional methods.

[0101] In aspects of the present invention, the term “therapeutably effective amount” means an amount of the molecule of the present invention and / or a molecule obtained by the method of the present invention that is effective for treating cancer-related diseases. Preferred dosages and preferred methods of administration are such that, after administration, an effective amount of the molecule of the present invention and / or a molecule obtained by the method of the present invention is present in the blood. The administration schedule may be adjusted by observing the disease state, analyzing serum levels of molecules that reduce the expression of target molecules in clinical tests, and then accordingly extending or shortening the administration interval, for example, from twice or once per week to once every two weeks, once every three weeks, once every four weeks, etc. In the case of cancer, a therapeutically effective amount of the molecule or composition disclosed herein is one that can reduce the number of cancer cells; reduce tumor size; inhibit (i.e., delay and / or discontinue) the invasion of cancer cells into peripheral organs; inhibit (i.e., delay and / or discontinue) tumor metastasis; inhibit tumor growth; and / or alleviate one or more of the symptoms associated with cancer.

[0102] In another embodiment, the pharmaceutical composition is suitable for administration in combination with an additional drug, i.e., as part of a combination therapy. In a combination therapy, the active agent may optionally be contained in the same pharmaceutical composition as the molecule of the present invention, or in a different pharmaceutical composition. In the latter case, the other pharmaceutical composition is suitable for administration before, concurrently with, or after administration of the pharmaceutical composition containing the molecule of the present invention. The additional drug or pharmaceutical composition may be a non-proteinogenic compound or a proteinogenic compound. In the case where the additional drug is a proteinogenic compound, it is advantageous that the proteinogenic compound may provide an activation signal for immune effector cells. Preferably, the proteinogenic or non-proteinogenic compound may be administered concurrently or concurrently with the molecule (or preparation) of the present invention as defined herein, the vector as defined herein, or the host as defined herein.

[0103] Pharmaceutical compositions can be administered to the subject in appropriate doses. The medication plan is determined by the attending physician and clinical factors. As is well known in the medical field, the dosage for any one patient depends on many factors, such as the patient's size, body surface area, age, the specific compound being administered, sex, time and route of administration, overall health condition, and other drugs being administered concurrently.

[0104] Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils, e.g., olive oil, and injectable organic esters, e.g., ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions, or suspensions, e.g., saline and buffering media. Parenteral media include sodium chloride solutions, ringer's dextrose, dextrose, and sodium chloride, Ringer's lactate, or non-volatile oils. Intravenous media include liquids and nutritional supplements, electrolyte supplements (e.g., those based on ringer's dextrose), etc. Preservatives and other additives, e.g., antimicrobial agents, antioxidants, chelating agents, inert gases, etc., may also be present. Furthermore, the pharmaceutical compositions according to the present invention may include proteinaceous carriers, e.g., preferably of human origin, serum albumin or immunoglobulin. The pharmaceutical compositions according to the present invention are expected to include, depending on the intended use of the pharmaceutical composition, further biological activators in addition to the aforementioned molecules. Such agents may include drugs that act on the gastrointestinal system, drugs that act as cell division inhibitors, drugs that prevent hyperuricemia, drugs that inhibit immune responses (e.g., corticosteroids), drugs that modulate inflammatory responses, drugs that act on the cardiovascular system, and / or agents such as cytokines known in the art.

[0105] For example, outcome measures for analyzing the effects of the nanoparticles of the present invention and / or nanoparticles obtained by the methods of the present invention in cancer treatment may be selected from, for example, pharmacodynamics, immunogenicity, and the potential to reduce tumor size, and these may be measured, for example, by MRI imaging and patient-reported outcomes.

[0106] Another major challenge in the development of drugs, such as pharmaceutical compositions according to the present invention, is the predictable modulation of pharmacodynamic properties. For this purpose, a pharmacodynamic profile of a drug candidate is established, i.e., a profile of pharmacodynamic property parameters that influence the ability of a particular drug to treat a given condition. Pharmacodynamic parameters of a drug that influence the ability of a drug to treat a particular disease entity include, but are not limited to, half-life, volume of distribution, first-pass metabolism in the liver, and the degree of serum binding. The efficacy of a given drug may be influenced by each of the above parameters. "Half-life" means the time it takes for 50% of an administered drug to be eliminated by biological processes, such as metabolism and excretion. "First-pass metabolism in the liver" means the tendency of a drug to be metabolized when it first comes into contact with the liver, i.e., when it first passes through the liver. "Volume of distribution" means the degree to which a drug is retained in various compartments of the body, such as intracellular and extracellular spaces, tissues and organs, and the distribution of the drug in these compartments.

[0107] "Degree of serum binding" refers to the tendency of a drug to interact with and bind to serum proteins, such as albumin, which can lead to a decrease or loss of the drug's biological activity.

[0108] Pharmacodynamic parameters also include bioavailability, lag time (Tlag), Tmax, absorption rate, and / or Cmax for a given amount of drug administered. "Bioavailability" refers to the amount of drug in the blood compartment. "Lag time" refers to the delay between drug administration and its detection and measurability in the blood or plasma. "Tmax" is the time to reach the maximum blood concentration of a drug; absorption is defined as the movement of the drug from the administration site into the systemic circulation. "Cmax" is the maximum blood concentration achievable by a given drug. The time it takes to reach the concentration of a drug in the blood or tissues required for its biological effect is influenced by all of these parameters.

[0109] The term "toxicity," as used herein, refers to the toxic effects of a drug that manifest as adverse events or serious adverse events. These secondary events may refer to a general lack of tolerance and / or local lack of tolerance to the drug after administration. Toxicity may also include teratogenic or carcinogenic effects caused by the drug.

[0110] The terms “safety,” “in vivo safety,” or “tolerability” define the administration of a drug that does not induce serious adverse events immediately after administration (local tolerance) and during the longer period of drug use, as used herein. “Safety,” “in vivo safety,” or “tolerability” may be evaluated, for example, at regular intervals during the treatment and follow-up period. Measurements may include clinical evaluations, e.g., organ symptoms and screening for laboratory abnormalities. Clinical evaluations may be performed for deviations from normal findings, recorded / coded according to NCI-CTC and / or MedDRA criteria. Organ symptoms may include, for example, criteria such as allergy / immunology, blood / bone marrow, cardiac arrhythmias, and coagulation, as shown in the Common Terminology Criteria for adverse events v3.0 (CTCAE). Laboratory parameters that may be tested include, for example, hematology, clinical chemistry, coagulation profiles, and urinalysis, as well as testing of other body fluids, e.g., serum, plasma, lymph, or cerebrospinal fluid, and alcohol (liquor). Accordingly, safety can be assessed by measuring laboratory parameters and recording adverse events, for example, by physical examination, imaging techniques (i.e., ultrasound, X-ray, CT scan, magnetic resonance imaging (MRI), other measures by technical devices (i.e., electrocardiogram), and vital signs. The term “effective and non-toxic dose” means, as used herein, a tolerable dose of the molecule and / or molecule obtained by the method of the present invention, preferably an antibody as defined herein, that is sufficiently high to cure or stabilize the disease of interest without or essentially without major toxic effects. Such an effective and non-toxic dose may be determined, for example, by dose-escalation studies described in the Art, and should be below the dose that induces a serious adverse side effect (dose-limiting toxicity, DLT).

[0111] The pharmaceutical compositions of the present invention may have various formulations. (These formulations may also be referred to herein as “composition of matter,” “composition,” or “solution.”) The formulations may preferably be in various physical states, such as liquid formulations, frozen formulations, lyophilized formulations, freeze-dried formulations, spray-dried formulations, and reconstituted formulations, with liquid and frozen formulations being preferred.

[0112] "Liquid formulation" means a composition found as a liquid, characterized by the free movement of its constituent molecules within itself, but without a tendency to separate at room temperature, as used herein. Liquid formulations include aqueous and non-aqueous liquids, with aqueous formulations being preferred. An aqueous formulation is a formulation in which the solvent or primary solvent is water, preferably water for injection (WFI). The dissolution of the molecules of the present invention in the formulation and / or the molecules obtained by the method of the present invention may be uniform or heterogeneous, and as stated above, uniformity is preferred.

[0113] Any suitable non-aqueous liquid may be used, provided that it provides stability to the formulation of the present invention. Preferably, the non-aqueous liquid is a hydrophilic liquid. Examples of suitable non-aqueous liquids include glycerol; dimethyl sulfoxide (DMSO); polydimethylsiloxane (PMS); ethylene glycols, e.g., ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol ("PEG") 200, PEG300, and PEG400; and propylene glycols, e.g., dipropylene glycol, tripropylene glycol, polypropylene glycol ("PPG") 425, and PPG 725.

[0114] "Mixed aqueous / non-aqueous liquid formulation" means a liquid formulation containing a mixture of water, preferably WFI, and an additional liquid composition, as used herein.

[0115] As used herein, “formulation” or “composition” is a mixture of the molecules of the present invention and / or molecules obtained by the method of the present invention (i.e., active drug / substance) and further chemical substances and / or additives required for a pharmaceutical product, preferably in a liquid state. Formulations of the present invention include pharmaceutical formulations.

[0116] The preparation of a pharmaceutical formulation involves a process in which different chemical substances, including an active drug, are combined to produce a final pharmaceutical product, such as a pharmaceutical composition. The active drug in the formulation of the present invention is the nanoparticles of the present invention and / or nanoparticles obtained by the method of the present invention.

[0117] In certain embodiments, the nanoparticles of the present invention and / or the nanoparticles obtained by the methods of the present invention can be formulated in an essentially pure and / or essentially homogeneous manner (i.e., substantially free from contaminants, such as proteins, which may be product-related impurities and / or process-related impurities). The term "essentially pure" means a composition containing at least about 80% by weight, preferably about 90% by weight, preferably at least about 95% by weight, more preferably at least about 97% by weight, or most preferably at least about 98% by weight. The term "essentially homogeneous" means a composition containing at least about 99% by weight, preferably the compound in monomeric form, excluding the mass of various stabilizers and water in the solution.

[0118] A “stable” formulation is one in which the molecules of the present invention and / or molecules obtained by the method of the present invention inherently retain their physical and / or chemical stability and / or biological activity during storage and / or, preferably, show no substantial signs of aggregation, precipitation, fragmentation, degradation, and / or denaturation compared to a control sample, as measured by visual inspection of color and / or clarity, or by UV light scattering or size exclusion chromatography. Various further analytical techniques for measuring protein stability are available in the art and are outlined, for example, in Peptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, NY, Pubs. (1991) and Jones, A. Adv. Drug Delivery Rev. 10:29-90 (1993).

[0119] "In storage," as used herein, means that after preparation, the formulation is packaged for storage in either a liquid form, a frozen state, or a dry form for later reconstitution into a liquid form or other form, rather than being used immediately after preparation.

[0120] The "subject" according to the present invention is a vertebrate, preferably a mammal, and more preferably a human subject.

[0121] "Vertebrates" include fish, birds, amphibians, reptiles, and mammals, which are all vertebrates.

[0122] "Mammals" include dogs, cats, horses, rats, mice, apes, rabbits, cows, pigs, sheep, and preferably, humans. Humans may also be referred to by the term patient.

[0123] The present invention further relates to nanoparticles obtained by the method of the present invention, or to the nanoparticles of the present invention and / or to the pharmaceutical compositions of the present invention, for use in therapy. The therapeutic use is preferably in a method of treating cancer in a subject.

[0124] The terms “cancer” and “cancerous” as used in this invention typically refer to a condition in vertebrates, preferably mammals, and more preferably humans, characterized by uncontrolled cell proliferation.

[0125] Cancers are classified according to the type of cell from which the tumor cells are similar and therefore presumed to be the origin of the tumor. These types include cell tumors, sarcomas, hematological cancers, germ cell tumors, and blastomas.

[0126] When referred to herein, "cytoma" may include cancers of epithelial origin.

[0127] When used herein, "sarcoma" may include cancers arising from cells of mesenchymal (connective tissue) origin.

[0128] When referred to herein, “blood cancer” may include a class of cancers arising from hematopoietic cells that leave the bone marrow and tend to mature in the lymph nodes and blood, respectively. When referred to herein as leukemia, it may include bone marrow-derived cells that typically mature in the bloodstream. When referred to herein as lymphoma, it may include bone marrow-derived cells that typically mature in the lymphatic system.

[0129] When referred to herein, "germ cell tumors" may include cancers of pluripotent cell origin, most commonly found in the testes or ovaries.

[0130] When referred to herein, "blastoma" may include cancers originating from immature "progenitor" cells or embryonic tissue.

[0131] Molecules obtained by the process of the present invention, or molecules obtained by the present invention and / or methods of the present invention, may be used in methods for treating cancer, where cancer may be selected from the group consisting of lung cancer, e.g., non-small cell lung cancer; sarcoma, e.g., rhabdomyosarcoma or Ewing's sarcoma; colorectal cancer; hematological cancer, e.g., leukemia or lymphoma, e.g., acute myeloid leukemia (AML) or diffuse large B-cell lymphoma (DLBLC).

[0132] The term “treatment” means, as used herein, alleviating, reducing, stabilizing, or inhibiting the progression of a disease or disorder, such as cancer.

[0133] The present invention further relates to nanoparticles obtained by the process of the present invention, or to the nanoparticles of the present invention, or to the pharmaceutical composition of the present invention, used in a method for inhibiting and / or regulating tumor growth in a subject.

[0134] A “tumor” or “neoplasm” is a mass of abnormal tissue resulting from the abnormal proliferation or division of cells. The proliferation of neoplastic cells exceeds and does not coordinate with the proliferation of the surrounding normal tissue. However, tumors in the sense of the present invention also include leukemia and carcinoma in situ. A tumor can be benign, premalignant, or malignant. In a preferred embodiment, the tumor is premalignant or malignant. Most preferably, the tumor is malignant.

[0135] The present invention further relates to nanoparticles obtained by the method of the present invention, or to the nanoparticles of the present invention, or to the (pharmaceutical) composition of the present invention, for delivering nucleic acid molecules to tumor sites in a subject.

[0136] In one embodiment of the present invention, nanoparticles obtained by the process of the present invention, or nanoparticles of the present invention, or pharmaceutical compositions of the present invention for use of the present invention, include siRNA selected from the group consisting of siRNAs against KRAS, BRAF, PIK3CA, PAX3-FKHR, EWS-FLI1, c-MYC, TP53, DNMT3A, IDH1, NPM1, and FLT3. The siRNA of the present invention can target KRAS, BRAF, PIK3CA, PAX3-FKHR, EWS-FLI1, c-MYC, TP53, DNMT3A, IDH1, NPM1, or FLT3. Preferably, the siRNA reduces the expression of KRAS, BRAF, PIK3CA, PAX3-FKHR, EWS-FLI1, c-MYC, TP53, DNMT3A, IDH1, NPM1, or FLT3 in cells. Preferably, the expression of these targets is reduced.

[0137] "siRNA targeting a specific target" refers to a target recognized by a particular siRNA. siRNA can be constructed in various ways. For example, siRNA may target mRNA.

[0138] In general, siRNA design is known to those skilled in the art. See, for example, Reynolds et al. (Reynolds et al., (2004) "Rational siRNA design for RNA interference" Nature Biotechnology 22, 326-330) or Judge et al. (Judge et al., 2006) "Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo" Molecular Therapy (2006) 13, 494-505) or Sioud and Leirdal (Sioud and Leirdal (2004) "Potential design rules and enzymatic synthesis of siRNAs" Methods Mol Biol. 2004; 252: 457-69).

[0139] The terms "expression" or "gene expression" refer to the transcription of a particular gene or gene construct. Specifically, "expression" or "gene expression" refers to the transcription of a gene or gene construct into structural RNA (rRNA, tRNA) or mRNA, with or without subsequent translation into a protein. This process involves the transcription of DNA and the processing of the resulting mRNA product. The mRNA is then translated into a peptide / polypeptide chain, which is ultimately folded into the final peptide / polypeptide / protein. Protein expression is commonly used by proteomics researchers to indicate the presence and measurement of the abundance of one or more proteins in a particular cell or tissue. Protein expression in cells can be measured by various means, for example, by immunohistochemistry or Western blot analysis. The results obtained should be evaluated in comparison to healthy cells or a control standard. Cells with lower expression show decreased staining, for example, in intensity, when compared to control cells. Cells with higher expression show increased staining, for example, in intensity, when compared to control cells under the same conditions. mRNA expression can also be measured, for example, by RT-PCR. Here, cells with lower expression will show a greater number of amplification cycles before a detectable signal is detected, for example, compared to control cells under the same conditions. Various techniques for determining the expression of proteins and mRNA in cells are known to those skilled in the art.

[0140] For example, cells may be present in the blood, liver, stomach, mouth, skin, lungs, lymphatic system, spleen, bladder, pancreas, bone marrow, brain, kidneys, intestines, gallbladder, larynx, or pharynx of the subject.

[0141] In one embodiment, nanoparticles obtained by the method of the present invention, or nanoparticles of the present invention, or pharmaceutical compositions of the present invention are used in accordance with the present invention, wherein the subject is a mammal, preferably a human.

[0142] The present invention also relates to a kit comprising one or more coupling buffers / reagents and protocols suitable for carrying out the method of the present invention.

[0143] In one embodiment, the kit comprises one or more coupling buffers / reagents and protocols suitable for carrying out the method of the present invention.

[0144] The present invention relates to a kit comprising a suitable buffer / reagent and protocol for carrying out the method of the present invention, and optionally comprising, for example, means for purifying or concentrating the molecule of the present invention or the molecule obtained by the method of the present invention, and / or means for washing the molecule, and / or means for storing the molecule. Accordingly, the molecule and additional means are preferably packaged together in one sealed package or kit.

[0145] The present invention also relates to a kit comprising the nanoparticles of the present invention and / or nanoparticles obtained by the method of the present invention.

[0146] The present invention relates to a kit comprising nanoparticles of the present invention and / or nanoparticles obtained by the method of the present invention, and / or optionally comprising means for purifying or concentrating the molecules, and / or means for washing the molecules, and / or means for storing the molecules. Accordingly, the molecules and additional means are preferably packaged together in one sealed package or kit.

[0147] The parts of the kit (or "kit of parts") of the present invention may be individually packaged in vials or bottles, or they may be packaged together in a container or multi-container unit. The kit is manufactured preferably according to standard methods known to those skilled in the art.

[0148] The kit of the present invention may optionally include one or more labeled containers. Suitable containers include, for example, bottles, vials, and test tubes. Containers may be made of a variety of materials such as glass or plastic, and are preferably sterile. Containers hold a composition containing an active ingredient or a buffer, which is effective for the method of the present invention. Further containers may hold a suitable buffer (e.g., a reaction buffer) that allows a particular reaction to occur. It is also conceivable that containers may include those holding a variety of buffers, e.g., reaction buffers, and / or buffers for the purification of the molecules of the present invention and / or molecules obtained by the method of the present invention. The active agent in the composition is preferably a molecule obtained by the method of the present invention, or a molecule of the present invention, or a pharmaceutical composition of the present invention.

[0149] The kit may also include instructions for carrying out the method of the present invention in accordance with the method and use of the present invention. The kit may further include a label or imprint indicating that the contents may be used for reinforcing and / or for the nanoparticles of the present invention.

[0150] The kit of the present invention may further include, for example, buffers, vials, controls, stabilizers, and instructions to assist those skilled in the art in the preparation or use of the nanoparticles of the present invention.

[0151] Furthermore, the present invention also relates to the use of the nanoparticles of the present invention, or nanoparticles obtained by the method of the present invention, or pharmaceutical compositions of the present invention in the treatment, preferably in the treatment of cancer in a subject.

[0152] The present invention also relates to a method for treating cancer in a subject, comprising the step of administering to the subject a therapeutically effective amount of the nanoparticles of the present invention, or nanoparticles obtained by the method of the present invention, or a pharmaceutical composition of the present invention.

[0153] The term "administration" means the administration of a therapeutically or diagnostically effective dose of the nanoparticles of the present invention to a subject. Various administration routes are possible, as described above.

[0154] The present invention also relates to the use of the nanoparticles of the present invention, or nanoparticles obtained by the method of the present invention, or pharmaceutical compositions of the present invention for the preparation of pharmaceuticals, for example, pharmaceuticals effective in the treatment of cancer.

[0155] Unless otherwise specified, the following terms used in this document, including in the descriptions and claims, have the definitions given below.

[0156] Those skilled in the art will be able to recognize or verify, using only routine experimental methods, many equivalents of the specific embodiments of the present invention described herein. Such equivalents shall be included in the present invention.

[0157] As used herein, the singular forms “a,” “an,” and “the” include multiple references unless the context clearly indicates otherwise. Thus, for example, a reference to “reagent” includes one or more of such different reagents, and a reference to “method” includes a reference to equivalent steps and methods known to those skilled in the art, which may be modified or substituted for the methods described herein.

[0158] Unless otherwise indicated, the term “at least” preceding a set of components should be understood to refer to all of those components.

[0159] When used herein, the terms "and / or" include the meanings of "and," "or," and "all or any other combination of the components connected by the terms."

[0160] The terms “about” or “approximately” mean, as used herein, within 20%, preferably within 10%, and more preferably within 5% of a given value or range. However, it also includes the specific number; for example, about 20 includes 20.

[0161] In this specification and the following claims, unless the context otherwise requires, the word “comprise,” and variations such as “comprises” and “comprising,” will be understood to mean that a specified integer or process, or group of integers or processes, is included, and not that any other integer or process, or group of integers or processes, is excluded. When used herein, the term “comprising” may be replaced by the terms “containing” or “including,” or, when used herein, by the term “having.”

[0162] As used herein, “consisting of” excludes any component, process, or ingredient not specified in the claims. As used herein, “essentially consisting of” does not exclude materials or processes that do not substantially affect the basic and novel features of the claims.

[0163] In each instance herein, any of the terms “including,” “essentially consisting of,” and “consisting of” may be substituted for any of the other two terms. Any such substitution is conceived herein.

[0164] The present invention is not limited to the specific methodologies, protocols, materials, reagents, and substances described herein, and should therefore be understood to be subject to change. The terminology used herein is for illustrative purposes only and is not intended to limit the scope of the present invention as defined solely by the claims.

[0165] All documents referenced in the text of this specification (e.g., all patents, patent applications, scientific publications, manufacturer specifications, instructions, etc.) are incorporated herein by reference in their entirety. Nothing in this specification should be construed as an acknowledgment that the present invention does not have prior rights to such disclosures due to prior art. In the event that any material incorporated by reference conflicts with or is inconsistent with this specification, this specification shall prevail over such material.

[0166] The present invention is further illustrated by the following sections:

[0167] Item 1. (c) A method for producing nanoparticles, comprising the steps of: (c) contacting an antibody with a composition comprising a first conjugate (A), wherein the first conjugate comprises a positively charged polypeptide conjugated to a bifunctional linker, and the composition essentially does not contain an unconjugated bifunctional linker, thereby obtaining a second conjugate (B), the second conjugate comprising a positively charged polypeptide, a bifunctional linker, and an antibody; and (d) contacting the second conjugate (B), a positively charged polypeptide, and a negatively charged molecule, thereby forming nanoparticles.

[0168] Item 2. The method of Item 1, comprising the steps of (a) conjugating a positively charged polypeptide into a bifunctional linker; and (b) removing the unconjugated bifunctional linker, prior to step (c).

[0169] Item 3. The method of item 1 or 2, wherein the antibody is purified before step (c).

[0170] Item 4. The method according to any one of the preceding items, further comprising the recovery of nanoparticles.

[0171] The method according to any one of the preceding paragraphs, wherein in step (c), the first conjugate is in molar excess relative to the antibody.

[0172] Item 6. The method of any one of the preceding items, wherein in step (d), the positively charged polypeptide is in molar excess compared to the second conjugate (B).

[0173] Item 7. The method of any one of the preceding items, wherein in step (d), the negatively charged molecule is in molar excess compared to the second conjugate (B).

[0174] Item 8. The method according to any one of the preceding items, wherein in step (d), there is a molar excess of negatively charged molecules compared to positively charged polypeptides.

[0175] Item 9. The method according to any one of the preceding items, wherein in step (c), the molar ratio of the first conjugate (A) to the antibody is at least about 10:1.

[0176] Item 10. The method according to any one of the preceding items, wherein in step (c), the molar ratio of the first conjugate (A) to the antibody is approximately 10:1 to approximately 50:1.

[0177] Item 11. The method according to any one of the preceding items, wherein in step (d), the molar ratio of the positively charged polypeptide to the second conjugate (B) is at least about 10:1.

[0178] Item 12. The method according to any one of the preceding items, wherein in step (d), the molar ratio of the positively charged polypeptide to the second conjugate (B) is approximately 10:1 to approximately 50:1.

[0179] Item 13. The method according to any one of the preceding items, wherein in step (d), the molar ratio of the negatively charged molecule to the second conjugate is at least about 1:1.

[0180] Item 14. The method according to any one of the preceding items, wherein in step (d), nanoparticles are formed by self-assembly.

[0181] Item 15. The method according to any one of the preceding items, wherein step (d) includes incubation at approximately 4 to 37°C.

[0182] Item 16. The method according to any one of the preceding items, wherein step (d) includes incubation for at least about 1 hour.

[0183] Item 17. The method according to any one of the preceding items, wherein in the second conjugate, a positively charged polypeptide and an antibody are interconnected via a bifunctional linker.

[0184] Item 18. The method according to any one of the preceding items, wherein the antibody comprises a heavy chain and a light chain.

[0185] Item 19. The method according to any one of the preceding items, wherein the antibody is specific to a cell surface molecule.

[0186] Item 20. The method of Item 19, wherein cell surface molecules can be moved into the cell upon antibody binding.

[0187] Item 21. The method of item 19 or 20, wherein the cell surface molecule is expressed in cells that are sensitive to therapeutic treatment with a negatively charged molecule.

[0188] Item 22. The method according to any one of the preceding items, wherein the antibody is specific to a cancer-associated antigen.

[0189] Item 23. The method according to any one of the preceding items, wherein the antibody is specific to CD33, EGFR, IGF1R, or CD20.

[0190] Item 24. The method according to any one of the preceding items, wherein the antibody is gemtuzumab, cetuximab, cyclotumumab, teprotumumab, GR11L, or rituximab.

[0191] Item 25. Antibodies The method according to any one of the above items, comprising a CDR sequence selected from the group consisting of TIFF2023553038000010.tif114169.

[0192] Item 26. The method according to any one of the preceding items, wherein the antibody has VH sequences and VL sequences selected from the group consisting of a. SEQ ID NO: 6 and 7; b. SEQ ID NO: 15 and 16; c. SEQ ID NO: 25 and 26; d. SEQ ID NO: 35 and 36; and e. SEQ ID NO: 44 and 45.

[0193] Item 27. The method according to any one of the preceding items, wherein the antibody has heavy chain sequences and light chain sequences selected from the group consisting of a. SEQ ID NO: 8 and 9; b. SEQ ID NO: 17 and 18; c. SEQ ID NO: 27 and 28; d. SEQ ID NO: 37 and 38; e. SEQ ID NO: 46 and 47; and f. SEQ ID NO: 65 and 18.

[0194] Article 28. The method according to any one of the preceding articles, wherein the negatively charged molecule is a nucleic acid.

[0195] Item 29. The method of item 28, wherein the nucleic acid is a double-stranded nucleic acid.

[0196] Item 30. The method of item 28, wherein the nucleic acid is a single-stranded nucleic acid.

[0197] Item 31. A method according to any one of items 28-30, wherein the nucleic acid has approximately 18-25 bp.

[0198] Item 32. The method according to any one of items 28-30, wherein the nucleic acid has approximately 18-25 nt.

[0199] Item 33. The method according to any one of the preceding items, wherein the negatively charged molecule is DNA or RNA.

[0200] Item 34. The method according to any one of the preceding items, wherein the negatively charged molecule is siRNA, esiRNA, shRNA, antisense oligonucleotide, or miRNA.

[0201] Item 35. The method according to any one of the preceding items, wherein the negatively charged molecule is an siRNA specific to KRAS, BRAF, PIK3CA, PAX3-FKHR, EWS-FLI1, c-MYC, TP53, DNMT3A, IDH1, NPM1, or FLT3.

[0202] Item 36. The method according to any one of the preceding items, wherein the negatively charged molecule is preferably a mixture of one or more target-specific siRNAs selected from the group consisting of KRAS, BRAF, PIK3CA, PAX3-FKHR, EWS-FLI1, c-MYC, TP53, DNMT3A, IDH1, NPM1, and FLT3.

[0203] Item 37. The method according to any one of the preceding items, wherein the negatively charged molecule has a molecular weight of approximately 20 kDa or less.

[0204] Item 38. The method according to any one of the preceding items, wherein the negatively charged molecule has a charge of at least 2-.

[0205] Item 39. The method according to any one of the preceding items, wherein the positively charged polypeptide is a protamine or a histone.

[0206] Item 40. The method according to any one of the preceding items, wherein the bifunctional linker is a heterobifunctional linker.

[0207] Item 41. The method according to any one of the preceding items, wherein the bifunctional linker is sulfo-SMCC.

[0208] Item 42. Nanoparticles obtained by any one of the methods described in the preceding items.

[0209] Item 43. Nanoparticle comprising (a) a positively charged polypeptide; (b) a second conjugate (B) comprising an antibody conjugated to the positively charged polypeptide; and (c) one or more negatively charged molecules.

[0210] Item 44. Nanoparticles of item 42 or 43, wherein a positively charged polypeptide is concentrated in the outer and / or inner portions of the nanoparticle.

[0211] Item 45. A nanoparticle according to any one of items 42-44, wherein the second conjugate is concentrated in the outer portion of the nanoparticle.

[0212] Item 46. A nanoparticle according to any one of items 42 to 45, wherein one or more negatively charged molecules are concentrated in the inner portion of the nanoparticle.

[0213] Item 47. Nanoparticles according to any one of items 42 to 46, wherein the nanoparticles have an average diameter of approximately 0.05 μm to approximately 10 μm.

[0214] Item 48. A nanoparticle according to any one of items 42-47, wherein in the second conjugate, a positively charged polypeptide and an antibody are interconnected via a bifunctional linker.

[0215] Item 49. Nanoparticles of any one of items 42-48, comprising a heavy chain and a light chain of antibody.

[0216] Item 50. Nanoparticles of any one of items 42-49, wherein the antibody is specific to a cell surface molecule.

[0217] Item 51. The method of item 50, wherein cell surface molecules can be moved into the cell upon antibody binding.

[0218] Item 52. Nanoparticles of item 50 or 51, wherein the cell surface molecule is expressed on cells that are sensitive to therapeutic treatment with negatively charged molecules.

[0219] Item 53. Nanoparticles of any one of items 42-52, wherein the antibody is specific to a cancer-associated antigen.

[0220] Item 54. The nanoparticle according to any one of Items 42 to 53, wherein the antibody is specific for CD33, EGFR, IGF1R, or CD20.

[0221] Item 55. The nanoparticle according to any one of Items 42 to 54, wherein the antibody is gemtuzumab, cetuximab, cixutumumab, teprotumumab, GR11L, or rituximab.

[0222] Item 56. The antibody is The nanoparticle according to any one of Items 42 to 55, having a CDR sequence selected from the group consisting of TIFF2023553038000011.tif114169.

[0223] Item 57. The nanoparticle according to any one of Items 42 to 56, wherein the antibody has a VH sequence and a VL sequence selected from the group consisting of: a. SEQ ID NO:6 and 7; b. SEQ ID NO:15 and 16; c. SEQ ID NO:25 and 26; d. SEQ ID NO:35 and 36; and e. SEQ ID NO:44 and 45.

[0224] Item 58. The nanoparticle according to any one of Items 42 to 57, wherein the antibody has a heavy chain sequence and a light chain sequence selected from the group consisting of: a. SEQ ID NO:8 and 9; b. SEQ ID NO:17 and 18; c. SEQ ID NO:27 and 28; d. SEQ ID NO:37 and 38; e. SEQ ID NO:46 and 47; and f. SEQ ID NO:65 and 18.

[0225] Item 59. The nanoparticle according to any one of Items 42 to 58, wherein the negatively charged molecule is a nucleic acid.

[0226] Item 60. The nanoparticle according to any one of Items 42 to 59, wherein the nucleic acid is a double-stranded nucleic acid.

[0227] Item 61. The nanoparticle according to any one of Items 42 to 60, wherein the nucleic acid is a single-stranded nucleic acid.

[0228] Item 62. The nanoparticle of any one of Items 42 to 61, wherein the nucleic acid has about 18 to about 25 bp.

[0229] Item 63. The nanoparticle of any one of Items 42 to 62, wherein the single-stranded nucleic acid has about 18 to about 25 nt.

[0230] Item 64. The nanoparticle of any one of Items 42 to 63, wherein the negatively charged molecule is DNA or RNA.

[0231] Item 65. The nanoparticle of any one of Items 42 to 64, wherein the negatively charged molecule is siRNA, esiRNA, shRNA, antisense oligonucleotide, or miRNA.

[0232] Item 66. The nanoparticle of any one of Items 42 to 65, wherein the negatively charged molecule is siRNA specific to KRAS, BRAF, PIK3CA, PAX3-FKHR, EWS-FLI1, c-MYC, TP53, DNMT3A, IDH1, NPM1, or FLT3.

[0233] Item 67. The nanoparticle of any one of Items 42 to 66, wherein the negatively charged molecule is preferably a mixture of siRNAs specific to one or more targets selected from the group consisting of KRAS, BRAF, PIK3CA, PAX3-FKHR, EWS-FLI1, c-MYC, TP53, DNMT3A, IDH1, NPM1, and FLT3.

[0234] Item 68. The nanoparticle of any one of Items 42 to 67, wherein the negatively charged molecule has a molecular weight of about 20 kDa or less.

[0235] Item 69. The nanoparticle of any one of Items 42 to 68, wherein the negatively charged molecule has at least a 2- charge.

[0236] Item 70. The nanoparticle of any one of Items 42 to 69, wherein the positively charged polypeptide is protamine or histone.

[0237] Item 71. Nanoparticles of any one of items 42-70, wherein the bifunctional linker is a heterobifunctional linker.

[0238] Item 72. Nanoparticles of any one of items 42 to 71, wherein the bifunctional linker is sulfo-SMCC.

[0239] Item 73. A composition comprising nanoparticles of any one of items 42 to 72.

[0240] Item 74. A composition of item 73, which is a pharmaceutical composition.

[0241] Item 75. Nanoparticles of any one of items 42 to 72 or compositions of item 73 or 74 for use in therapeutic purposes.

[0242] Item 76. Nanoparticles or compositions for use in item 75, the use of which is in the treatment of cancer.

[0243] Item 77. Nanoparticles or compositions for use in item 75, the use of which is in the treatment of solid tumors.

[0244] Item 78. Nanoparticles or compositions for use in Item 75, wherein the use is for use in the treatment of cancer selected from the group consisting of lung cancer, sarcoma, colorectal cancer, and hematological cancer.

[0245] Item 79. A kit comprising nanoparticles of any one of items 42-72 or a composition of item 73 or 74.

[0246] Item 80. A negatively charged molecule is a drug and / or prodrug, e.g., remdesivir triphosphate, in the manner of any one of items 1 to 41 or any one of items 42 to 72.

[0247] Item 81. A method according to any one of items 1 to 41 or a nanoparticle according to any one of items 42 to 72, wherein a negatively charged molecule is conjugated to a moiety having a negative net charge, for example, Cy3.5 or Alexa488, and is a drug and / or prodrug, for example, ibrutinib.

Example

[0248] The following examples illustrate the present invention. These examples should not be construed as limiting the scope of the present invention. The examples are included for illustrative purposes, and the present invention is limited only by the claims.

[0249] Example 1: Modification of the conjugation protocol The inventors were puzzled by conjugates having unintended properties in SDS-PAGE electrophoresis obtained when performing chemical conjugation between a selected carrier antibody, sulfo-SMCC, and protamine, as published in Baumer, N. et al., 2016; Baumer, N. et al., 2018; Baumer, S. et al., 2015. For example, the phenomenon of IgG conjugates that were found to be no longer reducible by reducing agents such as DTT, DTE, β-mercaptoethanol, or TCEP was frequently observed (Figure 1, A and B, refer to gel a for illustration). Next, conjugates showing a much higher molecular weight than intended, representing dimers or multimers of cross-linked IgG, some containing additional protamine and some not, were observed (Figure 1C, Brief description of the drawings, refer to gel B for illustration). In extreme cases, all the complexities of these side reactions probably result in the cloud-like appearance of the resulting conjugates caused by all mixtures of these conjugates a - d in Figure 1B.

[0250] Conversely, the intended conjugate was a molecule that retained native disulfide bonds inside and outside the peptides HC and LC, and did not undergo additional internal crosslinking operations, but had numerous protamines crosslinked to the light chain (LC) and heavy chain (HC), the formulation marked with C in Figure 1.

[0251] Accordingly, the inventors modified the conjugation protocol by introducing an additional purification step after the amino-terminal activation of the protamine peptide with sulfo-SMCC. The resulting product was purified by gel chromatography to separate the activated SMCC-protamine from the excess free sulfo-SMCC, which still retained activity. From this step onward, antibody conjugation was carried out with a homogeneous solution of pure SMCC-protamine, free from residual crosslinker contamination (Figure 2).

[0252] Accordingly, all experiments shown in the following examples were carried out by following a “new” SMCC depletion protocol. The resulting complexes showed significant improvements in terms of uniformity during electrophoresis, targeting performance, and functional efficacy.

[0253] Therefore, all findings presented here were obtained using therapeutic agents synthesized by a new manufacturing process, not the formulations published in Baumer, N. et al., 2016; Baumer, N. et al., 2018; and Baumer, S. et al., 2015.

[0254] Example 2: Oncogene inactivation in non-small cell lung cancer using an unpublished modified conjugation protocol Next, EGFR-expressing non-small cell lung cancer cell lines (NSCLC) were targeted with cetuximab-protamine. Here, cetuximab-protamine was able to bind 8 moles of siRNA per mole of cetuximab-protamine (Figure 3A, B), delivering the siRNA to early endosomes in a receptor-dependent manner (Figure 3C). In vitro, in NSCLC cell lines, KRAS was effectively silenced after treatment with anti-EGFR-mAB-protamine conjugated with siRNA against KRAS (Figure 3D). Conjugated cetuximab loaded with control siRNA had a small effect on cell proliferation, colony formation, tumor growth, and tumor weight in cetuximab-sensitive A549 cells and CD1 nude mice, which is consistent with randomized clinical trials using cetuximab in NSCLC patients. However, this effect was significantly amplified by the use of KRAS siRNA. See Figures 3E and F (right panel). Cetuximab-resistant SK-LU1 cells tolerated cetuximab-control siRNA much better, but here again, colony growth and tumor growth were significantly inhibited by KRAS siRNA (Figure 3E and F, left panel).

[0255] Next, the effect of systemic anti-EGFR-mAB-siRNA treatment on the expression of the proliferation marker Ki67 was investigated by immunofluorescence in frozen sections (A549 tumor) and paraffin sections (SK-LU-1 tumor). In A549 (Figure 4A-D) and SK-LU-1 (Figure 4G-J) tumors treated with PBS or anti-EGFR-mAB-control siRNA, Ki67 staining was extensive in the Hoechst-stained nuclei of each tumor cell. Conversely, tumors treated with anti-EGFR-mAB-KRAS-siRNA showed far fewer proliferating cells exhibiting Ki67 staining (Figure 4E-F and 2K-L).

[0256] Systemic anti-EGFR-mAB-siRNA application can induce tumor growth retardation not only through reduced tumor tissue proliferation but also through increased apoptosis. Furthermore, induction of apoptosis is naturally a desirable effect of cancer drugs that can potentially actively reduce tumor size. We aimed to investigate the abundance of apoptotic cells by ex vivo TUNEL (terminal deoxynucleotidyltransferase dUTP nick end labeling) staining of each tumor tissue to reveal nuclear DNA fragmentation as an indicator of apoptosis. After peroxidase staining development, tumor sections treated with the control showed a doubling of TUNEL-positive nuclei in A549 tumors treated with anti-EGFR-mAB-control siRNA (Figure 5C-D) compared to PBS treatment (Figure 5A-B), and a further doubling when the carrier contained KRAS siRNA (see Figure 5E-F for examples, and Figure 5M for statistics). Apoptotic signaling made it impossible to distinguish between SK-LU1 tumors treated with PBS (Figures 5G-H) and those treated with anti-EGFR-mAB-control siRNA (Figures 5I-J). However, when KRAS-siRNA was conjugated to an antibody carrier and applied to xenograft tumors, the number of TUNEL-positive nuclei increased fourfold (Figures 5K-L and 5N).

[0257] In summary, the significant reduction in tumor size following treatment with anti-EGFR-mAB-KRAS siRNA can be explained by a combination of decreased proliferation and increased apoptosis in each tumor.

[0258] Furthermore, the inventors also take advantage of the fact that EGFR is surface-expressed in sarcomas (see Herrmann et al., 2010 and the following chapter). Since the inventors' system utilizes the antibody not as an active anticancer agent, but as a component of a shuttle system carrying oncogene-specific effector siRNA, the observation that cetuximab was ineffective as a monotherapy in the first clinical trials in sarcomas (Ha et al., 2013) is irrelevant to the inventors' objectives.

[0259] Example 3: Targeting of oncogenes in rhabdomyosarcoma Rhabdomyosarcoma (RMS) is an invasive soft tissue sarcoma that originates from immature myoblasts and primarily occurs in children and young adults. Pediatric RMS is divided into two main categories based on its histological appearance: approximately two-thirds are fetal RMS (ERMS), which has a better prognosis, and one-third are the more invasive alveolar RMS (ARMS) (Stevens, 2005). To date, no common genetic lesions of diagnostic value have been found in ERMS, except for the accumulation of 11p15 heterozygosity loss (Chen et al., 2013). Targeting key drivers of ARMS is more likely to have therapeutic impact. The genetic lesions that characterize alveolar rhabdomyosarcoma (ARMS) are fusions of PAX3-FKHR or PAX7-FKHR due to t(1;13) or t(2;13) chromosomal translocations. Therefore, targeting the PAX-FKHR fusion gene and its transcripts may be a specific and effective means of inhibiting malignant proliferation and inducing apoptosis in ARMS cells. Inhibition of oncogenic fusion proteins or mutant proteins has been found to be difficult. Either the protein is explicitly labeled "drug-unavailable," or drug treatment leads to the selection of resistant versions of the protein and more invasive recurrence (Verdine and Walensky, 2007).

[0260] RNAi-mediated downregulation of fusion proteins is intended to overcome these problems because their expression is inhibited at the mRNA level. Specifically, in RMS cells, RNAi-mediated downregulation of PAX3-FKHR fusion protein expression had a direct effect on malignant phenotypes. Silencing of PAX3-FKHR fusions with siRNA against PAX3 or PAX3-FKHR reduced the proliferation, motility, and colony formation of RMS cell lines (Kikuchi et al., 2008; Liu, L. et al., 2012). Therefore, the inventors expected that effective downregulation of ARMS-specific fusion proteins by RNAi delivered to tumor cells via an established antibody-protamine carrier system in a stable and specific manner would yield therapeutic effects in vivo.

[0261] In RMS, IGF1R and epidermal growth factor receptor (EGFR) are candidate targets for our modular carrier. Our technology enables the differentiation of tumor cells from other cells through two independent features: (a) cell surface receptor decoration and (b) cellular oncogenesis mechanisms, thus providing two-layer specificity. We and others (Herrmann et al., 2010) have identified high-density surface expression of EGFR and IGF1R in different alveolar (and embryonic) RMS cell lines. Both of these cell surface receptors can function as target components of our system.

[0262] To check the targeting efficiency of antibody constructs in RMS cell lines, ERMS EGFR + The RD cell line was treated with an anti-EGFR antibody (cetuximab)-siRNA conjugate, and ARMS IGF1R +The RH-30 cell line was treated with an anti-IGF1R-siRNA complex (Figure 6). Both cell lines expressed IGF1R and EGFR at variable levels (Figure 6A). Due to their maximum expression, RD cells preferentially translocated anti-EGFR-Alexa488-siRNA (Figures 6B and C, upper panel), while RH-30 cells preferentially translocated anti-IGF1R-Alexa488-siRNA (Figure 6B, lower panel). Alexa488-siRNA translocated all EGFR via cetuximab-protamine. + The anti-IGF1R antibody was able to internalize as many as 90% of the RD cells (Figure 6C, center panel), but the anti-IGF1R antibody did not penetrate IGF1R + The effect was low in RH-30 cells (Figure 6B, lower panel).

[0263] To conduct proof-of-principle experiments for the specific targeting of PAX3-forkhead fusion oncogenes typical of RMS, various siRNAs targeting the breakpoint region of PAX3-FKHR (Figure 7D) were designed. In a colony formation assay, ARMS RH-30 cells were treated with these breakpoint-targeting siRNAs coupled to cetuximab-protamine. The breakpoint siRNAs significantly reduced colony formation in RH-30 cells compared to controls (Figure 7E), and colony formation in ERMS-type cells (RD) was impaired by NRAS transport combined with cMyc siRNA (Figures 7A and B) (all target genes are well-known oncogenes in ERMS). Consequently, in RD cells, NRAS oncogene expression was reduced in Western blot after treatment with anti-EGFR / NRAS siRNA (center column, Figure 7C).

[0264] These results illustrate that it is possible to target RMS cell lines using a modular antibody-siRNA system containing at least two different monoclonal antibodies, depending on the receptor modification of the RMS tumor, in order to induce oncogene inactivation, specifically transport selected nucleic acids, and thus induce oncogene inactivation.

[0265] Example 4: Targeting of oncogenes in Ewing sarcoma Ewing sarcoma is a bone tumor in children and young adults. Long-term complete remission in the metastatic phase is less than 35%, highlighting the urgent need for better treatment options (Paulussen et al., 1998; Paulussen et al., 2008). In these tumor cells, the central genetic event is the development of a chromosomal translocation t(11;22) resulting in the formation of the fusion protein EWS-FLI1 (Arvand and Denny, 2001). Ewing sarcoma cells express large amounts of IGF1R on their surface. Therefore, we intended to apply a modular therapy using an anti-IGF1R antibody, e.g., clone ImcA12 (thixtumumab) or teprotumumab, as an SMCC-protamine conjugate to deliver EWS-FLI1 breakpoint-specific siRNA. As proof of principle, we used the commercially available anti-IGF1R mouse antibody GR11L (Merck) to demonstrate that Ewing cells are targeted. These results were published in (Baumer, N. et al., 2016) and are illustrated in Figure 8.

[0266] To make this treatment option available, two different IGF1R antibodies were cloned, expressed, and purified using HPLC in CHO-S cells. These were clones of thixumumab (referred to herein as "A12") and teprotumumab (referred to herein as "Tepro"). Both were produced in sufficient quantities and coupled to SMCC-protamine (Figure 9A), both bound to siRNA (Figure 9B), and the siRNA was transported to IGF1R-positive cells SKNM-C (Figure 9C).

[0267] When cells were incubated with these IGF1R-mAB-protamine conjugates as complexes with siRNA against EWS-FLI1 and seeded on semi-solid soft agar, colony formation was significantly reduced (Figure 10A and B).

[0268] Therefore, it can be concluded that our modular system can be applied to the use of anti-IGF1R antibodies and sarcoma cells, specifically for the knockdown of fusion protein-specific siRNAs, such as EWS-FLI1-siRNA.

[0269] Example 5: Targeting of oncogenes in a lymphoma model Diffuse large B-cell lymphoma (DLBCL) is a common lymphoma subtype. DLBCL cells express CD20 on their surface. The standard first-line treatment for affected patients is a combination of chemotherapy and the anti-CD20 antibody rituximab. Rituximab binds to the CD20 molecule, inhibits it, and causes antibody-dependent cell-mediated cytotoxicity (ADCC). This approach can cure approximately 65% ​​of patients. Patients who are refractory to first-line treatment or who relapse after an initial response are characterized by extremely low survival rates, indicating an urgent need for novel therapeutic approaches. Therefore, we aimed to combine rituximab, a first-line drug as a cell-targeting antibody, with siRNAs targeting different oncogenes identified in genetically diverse lymphoma cells (Figure 15).

[0270] The inventors first chemically coupled the CD20 antibody rituximab to SMCC-protamine in different ratios to compare the effectiveness of each complex for binding to siRNA (Figure 13). Interestingly, despite high excesses of 80 moles or 120 moles of unbound SMCC-protamine, siRNA binding was almost identical to that when 1 mole of antibody was coupled to 40 moles of SMCC-protamine (Figure 13). Therefore, the inventors concluded that a minimum amount of SMCC-protamine was sufficient and returned to the routine antibody:SMCC-protamine ratio of 1:32 (Figure 14). As previously done, the binding ability of rituximab-protamine to siRNA was first checked, and coordination binding between siRNA and the carrier system (approximately 8 moles / mol) was observed, similar to that found with other carrier antibodies (Figure 14B).

[0271] Subsequently, different DLBCL cell lines were determined to be positive for CD20 and CD33 surface expression (Figure 15, upper panel). Therefore, we conducted internal distribution studies using anti-CD20 mAB rituximab and anti-CD33-mAB gemtuzumab.

[0272] To obtain further target molecules other than BTK, DLBCL cell lines were subjected to B cell receptor axis molecule screening by antibody-mediated siRNA knockdown (Figure 15). Using anti-CD33 antibody-siRNA targeting, significant inhibition of colony growth was achieved, particularly in HBL1 cells (Figure 15, lower panel).

[0273] Example 6: A complex formed by a carrier antibody-protamine and a low molecular weight polyanionic drug having a different chemical structure from siRNA. In another project, the inventors hypothesized that therapeutic monoclonal antibodies, such as rituximab or gemtuzumab, could be used as carrier molecules for low molecular weight (LMW) drugs. This strategy is clinically important because the pharmacokinetics and safety of many LMW drugs, such as kinase inhibitors, may be improved by targeted carriers compared to untargeted forms. Accordingly, the inventors hypothesized that with regard to the use of such antibody-inhibitor conjugates, (i) antibodies can be administered at lower doses because they help enrich the inhibitor in intended target cells, and (ii) antibodies inhibit the inhibitor from being taken up by unintended cells and inducing unintended toxic responses.

[0274] In the first experimental setup, the inventors synthesized a negatively charged small molecule having a charge of 4-, which is a derivative of a known growth inhibitor referred to herein as small molecule 1 (SM-1). Thus, by adding a negatively charged red fluorescence RF, the uncharged small molecule inhibitor was converted into a strongly anionic compound (referred herein as "SM-1 / RF"), and then conjugated to a protamine-based carrier system by electrostatic force to form an antibody-inhibitor conjugate.

[0275] In addition to the strong polyanionic charge of the red fluorescent dye, this conjugate had the advantage of being easily traceable in vitro and in vivo in the form of red fluorescence.

[0276] Subsequently, the same experiment was performed on the binding of SM-1 / RF to two carrier systems, rituximab (CD20)-protamine and the more reliable cetuximab (EGFR)-protamine. Both carriers showed strong co-assembly of SM-1 / RF and, due to their lower molecular weight (approximately 13 kDa) compared to siRNA, exhibited extremely high molar / molar electrostatic saturation, exceeding 100 moles of SM-1 / RF per mole of carrier mAB (Figure 17).

[0277] Corresponding conjugates, rituximab-protamine and cetuximab-protamine, loaded with a 20-fold excess of subcritical SM-1 / RF were incubated with CD20-expressing and EGFR-expressing cell lines, and intracellular enrichment of SM-1 / RF was analyzed. In both cases, intracellular enrichment of the fluorescence signal was demonstrated at typical red fluorescence excitation / emission wavelength combinations (Figure 18). Therefore, modified SM-1 / RF compounds can be internalized into cells and thus exert their effects.

[0278] Example 7: Remarkable characteristics of an effective antibody-protamine-siRNA formulation The precise conjugation technique for all antibodies used can be divided into two steps: firstly, amino-terminal conjugation of protamine to sulfo-SMCC, followed by a size exclusion process to remove excess conjugation crosslinkers; and secondly, cysteine-directed conjugation of the activated protamine-SMCC to the IgG backbone. The resulting bioconjugates exhibit significant molecular weight shifts in both the heavy and light chains of IgG, as can be seen from SDS-PAGE electrophoresis. Approximately 60–80% of the IgG was converted to contain the protamine tag, and the residual amount of excess protamine was always visible.

[0279] As shown in Figure 19A, unbound protamine was depleted from the reaction mixture of the EGFR-mAB cetuximab-protamine conjugate by protein G interaction chromatography. The protamine-conjugated antibody was bound to a protein G matrix, allowing for initial elution of unbound protamine, followed by elution of purified IgG-protamine complexes that were free of protamine (see fractions 29-31). Surprisingly, although this material was conjugated with protamine, it could not bind to siRNA in a classical band shift assay (see the right half of Figure 19B), while the unpurified mAB-protamine complex bound to siRNA in the typical 1:16 molar ratio.

[0280] To further investigate the efficacy of protamine-containing and protamine-depleted preparations, EGFR-expressing KRAS-dependent NSCLC cell lines, A549 and SK-LU1, were treated with both preparations transporting KRAS-siRNA and control siRNA. Only the preparation containing free protamine (see Figures 19A and B, "Anti-EGFR-mAB coupled to 32x SMCC-protamine") effectively reduced colony growth of the cell line by KRAS-siRNA, as expected due to its oncogene-dependent nature (Figures 20A and B).

[0281] The exact same purification method was used for anti-CD33 mAB gemtuzumab, which was used for the experimental treatment of AML, and the same effect was observed: the conjugate preparation, from which unbound protamine was depleted by HPLC, did not bind to the siRNA in the desired amount (Figure 21B, lower panel), while the unpurified preparation bound accurately (Figure 21B, upper panel).

[0282] Furthermore, in contrast to the unpurified material, the carrier without unbound SMCC-protamine did not retain the inhibitory efficacy of anti-DNMT3A-siRNA against OCI-AML2 cells in the colony formation assay (Figure 21C). This observation was inconsistent with the previous molecular assembly hypothesis of the carrier system (Figure 3A) and challenged the previous hypothesis in general.

[0283] To find an explanation for these perplexing and unexpected observations, the inventors conducted several experiments.

[0284] Considering the results from Figure 19, the inventors hypothesized that the presence of unbound SMCC-protamine in the CD20-mAB-protamine-SM-1 / RF-protamine adduct is as important as in the siRNA adduct, and therefore, as previously done, protamine was depleted from the rituximab-CD20 mAB preparation by affinity chromatography. As hypothesized, the depleted preparation (Figure 22A, fraction 25) was unable to bind and coordinate with polyanionic SM-1 / RF to the same extent as the SMCC-protamine-containing preparation (Figure 22B, right) (Figure 22B, left).

[0285] The same findings were obtained by using the anti-IGF1R monoclonal AB IMCA-12 conjugate (Figure 23). The antibody-protamine conjugate with depleted SMCC-protamine was unable to electrostatically bind to the siRNA.

[0286] In Figure 24, the ability of an A12 carrier antibody depleted of SMCC-protamine (Figure 23) to effectively deliver siRNA that inactivates oncogenes to SKNM-C Ewing sarcoma cells was tested. Non-depleted A12-SMCC-protamine loaded with effective siRNA reduced colony growth, but the depleted preparation (see Figure 23, fractions 19-21) did not reduce colony growth.

[0287] Example 8: Deciphering the role of free SMCC-protamine in the antibody-SMCC-protamine / free SMCC-protamine complex. Previous results showed that targeting does not function in the absence of free SMCC-protamine. Therefore, we wanted to find out the role that free SMCC-protamine plays in the complex. Naturally, we had to rule out the possibility that the main function is achieved by free SMCC-protamine. Accordingly, a series of experiments were conducted with free SMCC-protamine and other negative controls.

[0288] First, a colony formation assay was performed using the IGF1R-positive, EGFR-negative Ewing sarcoma cell line SKNM-C, which is dependent on the EWS-FLI1 translocation product (Figure 25). As a positive control, treatment of cells with an anti-IGF1R-mAB-protamine complex conjugated to anti-EWS-FLI1(E / F)-siRNA inhibited the EWS-FLI1 translocation product, resulting in a significant decrease in colony proliferation of SKNM-C cells (Figure 25). Conversely, transport of anti-EWS-FLI1-siRNA using anti-EGFR-mAB-protamine as a carrier, both with and without free SMCC-protamine, did not result in a decrease in colony formation compared to the control siRNA (Figure 25). This indicates that IGF1R-mediated targeting is specific and not mediated by free SMCC-protamine. Furthermore, SMCC-protamine alone at the same concentration (60 nM) as the anti-EGFR antibody failed to induce inhibition of colony formation (Figure 25).

[0289] Next, a typical targeting mixture containing an anti-IGF1R antibody conjugated to SMCC-protamine, the same amount of free SMCC-protamine present in the anti-IGF1R-mAB-protamine complex (60 nM of the carrier conjugated to 30-fold excess SMCC-protamine is equivalent to ≤1800 nM of possible free SMCC-protamine), and effective anti-EWS-FLI1-siRNA was administered to SKNM-C Ewing sarcoma cells (Figure 26A). When SKNM-C cells were treated with only free SMCC-protamine + effective siRNA at the same concentrations as the complete mixture, without targeting anti-IGF1R-mAB A12, no decrease in colony growth was observed compared to the control scr-siRNA (Figure 26A). This strategy was also tested in AML cell lines OCI-AML-2 (Figure 26B) and A549 NSCLC cells (Figure 26C), always omitting targeted mABs (anti-CD33 or anti-EGFR, respectively) and providing normally effective siRNA. As with SKNM-C, free SMCC-protamine loaded with effective siRNA remained ineffective, similar to the control siRNA.

[0290] This led to the assumption that while the correct antibody is required for the detection of the intended target cell surface molecule, two additional prerequisites must be met for it to effectively bind and complex with siRNA and target it to the oncogenic molecule for therapeutic efficacy: (a) protamine conjugated to the targeting antibody, and (b) a sufficient amount of residual unbound SMCC-protamine present in the mixture. Free SMCC-protamine without a carrier coupled to the antibody failed to meet these requirements.

[0291] The next question to be answered was whether any of the modified aggregate structures of the inventors' carrier system could consistently explain all the in vitro and in vivo efficacy results observed in the inventors' studies.

[0292] Example 9: Detection and visualization of unexpected electrostatic macrostructures that form stable nanoparticles Intracellular antibody-protamine-siRNA complexes are readily identifiable in treated cell culture samples when the corresponding cell surface receptor or molecule is expressed, as illustrated in Figure 27. Here, cetuximab (anti-EGFR)-SMCC-protamine bound to siRNA is translocated into EGFR-expressing NSCLC cells and processed internally in early endosomes (white dots, left panel) but not in lysosomes (gray dots, center panel).

[0293] Example 10: Antibody-protamine-siRNA complexes without free SMCC-protamine, or free SMCC-protamine-siRNA alone, do not intermigrate into target cells. Interestingly, the typical internal migration of vesicle structures was observed only when residual SMCC-protamine from the conjugation protocol remained in the mixture (Figure 28, right hand), and not when protamine-SMCC was depleted by affinity chromatography (Figure 28, left hand; see also Figure 19 for chromatography results). Thus, visually, the presence of unbound protamine-SMCC is important for the efficiency of the conjugate.

[0294] This was also performed with other antibody-SMCC-protamine conjugates, comparing them to a counterpart depleted of free SMCC-protamine via HPLC, and to free SMCC-protamine: internal translocation into cell lines was not observed with antibody-protamine-siRNA conjugates without free SMCC-protamine, nor with free SMCC-protamine alone (Figures 29, 30, and 31).

[0295] Example 11: Formation of vesicle structures in vitro by antibody-protamine-siRNA complex When negative control experiments were conducted, i.e., when cells not expressing the EGF receptor were treated with an effective conjugate targeting the EGF receptor, extremely low cell targeting efficiency was always observed as a result (Figure 32B). However, the inventors were intrigued by the accumulation of fluorescent micelle structures extracellularly. These accumulations, presumably attached to a matrix-like structure on the surface of the treated dish, were only observed when no target for binding to the conjugate and for the conjugate's internal translocation was found on the cell. Furthermore, all of these accumulations were the same size and must have been much larger than the approximately 10-20 nm that describes one IgG + several protamines + eight attached siRNA monomers, because this size is not detectable as a particle in fluorescence optical microscopy. Fluorescence optical microscopy has a resolution of approximately half the emission wavelength, and therefore the particle size would be larger than 200 nm.

[0296] Therefore, the inventors hypothesized three components necessary for the formation of a stable macrostructure required for activity: (1) cetuximab-SMCC-protamine, (2) siRNA, and (3) unbound SMCC-protamine. To verify the existence of such a macrostructure responsible for the efficiency of IgG-protamine-siRNA, particle size detection by dynamic light scattering (DLS) in a zeta counter (MALVERN) that correlates light diffusion caused by particles in solution was applied. The results were interesting: as a dynamic process, components with a perfectly plausible size (22 nm for the IgG-protamine-protamine-siRNA monomer) spontaneously assembled into nanostructures larger than 400 nm after several hours, but this process was undetectable in the protamine-depleted preparation (Figure 33).

[0297] This process is time-dependent, with larger structures forming only after a certain incubation period (Figure 34). A time frame of 2–6 hours is sufficient for these macrostructures to form, and these macrostructures begin to partially decompose again after 24 hours in an unprotected PBS environment at room temperature.

[0298] Based on these measurements, the inventors hypothesized that the antibody-protamine / free SMCC-protamine / siRNA complex is formed extracellularly and independently of the cellular context. To visualize these complexes, different complex compositions were incubated overnight in a cell-free environment using Alexa488-siRNA on coated chamber slides, and the developed structures were fixed the following day. Fluorescence microscopy revealed that vesicular structures are formed only when the three components—(1) antibody-SMCC-protamine, (2) free SMCC-protamine, and (3) siRNA—come into contact with each other (see Figure 35).

[0299] All antibody-protamine complexes containing free SMCC-protamine formed vesicular nanostructures, but those without free SMCC-protamine, or SMCC-protamine alone, did not form nanostructures (Figure 36).

[0300] In detail, the nanostructure formed by the three components—mAB-SMCC-protamine, unconjugated SMCC-protamine, and siRNA labeled with Alexa488—resembles the shape of a micrometer-sized spheroid (Figure 37). Its structure is verified by fluorescence microscopy and laser-scanned confocal microscopy. The spheroid structure was found to be completely filled with the Alexa488 signal from the siRNA compound.

[0301] The results are summarized in the table below. TIFF2023553038000012.tif60161

[0302] Example 12: Vesicular structures are generated in vitro at different temperatures. We also tested whether the formation of vesicle structures depended on a specific temperature. In fact, they were formed at 4°C, room temperature (approximately 22°C), and 37°C (Figure 38).

[0303] Example 13: In vitro formation of functional vesicle structures by antibody-protamine-siRNA complexes depends on the amount of free SMCC-protamine. To further elucidate the functions of SMCC-protamine coupled to the antibody within the complex and as a free molecule, the amount of SMCC-protamine added to the antibody (in this case, the anti-EGFR antibody cetuximab) was titrated. A constant amount of cetuximab was used, and SMCC-protamine was added in molar ratios of 1:1 to 1:100 (see Figure 39A for details). Subsequently, the conjugation efficiency was checked by Coomassi-stained SDS-PAGE, and it was found that the coupling of the antibody's light chain (LC) and heavy chain (HC) did not appear to be optimal when incubating antibody:SMCC-protamine ratios of 1:1 to 1:10 (Figure 39B). The conjugation process appeared to saturate at an antibody:SMCC-protamine molar ratio of 1:32 and was not further enhanced at 1:50 and 1:100 (Figure 39B).

[0304] The siRNA binding ability of these different conjugations was analyzed by routine band-shift assays (Figures 40A-F). siRNA binding was detectable at conjugation ratios of 1:32 to 1:100 (Figures 40D-F), while efficient siRNA binding was undetectable at lower ratios (Figures 40A-C).

[0305] The characteristics of the different conjugation products were further analyzed by their ability to form cell-free vesicle structures when incubated with Alexa488-control siRNA (Figures 40G-L), and also incubated with EGFR-positive A459 cells (Figures 40M-R). When cetuximab was conjugated to SMCC-protamine in ratios of 1:1 to 1:10, efficient cell-free vesicle formation was not observed (Figures 40G-I), while vesicle formation was extremely abundant at a ratio of 1:32 (Figure 40J), and decreased at ratios of 1:50 and 1:100 (Figures 40K-L). The internalization ability of these complexes was highest with a conjugation ratio of 1:32 (Figure 40P) and decreased with a conjugation ratio of 1:10 (Figure 40O). No internal translocation was observed at ratios of 1:1 (Figure 40M), 1:3.2 (Figure 40N), or 1:50–1:100 (Figures 40Q–R). This suggests that a 1:32 complex formation between cetuximab and SMCC-protamine is optimal for the most efficient conjugation, cell-free vesicle formation, and internal translocation into cells.

[0306] As a functional assay, the efficiency of different conjugation products in inhibiting colony formation in A549 cells by knockdown of the oncogene KRAS was compared. To elucidate the effect of unbound SMCC-protamine alone, it was also compared with an equal amount of free SMCC-protamine not conjugated to cetuximab (Figure 40S-X). Surprisingly, only the conjugated cetuximab:SMCC-protamine 1:32 conjugated with KRAS-siRNA resulted in a significant reduction in colony formation compared to scrambled control siRNA (Figure 40V). SMCC-protamine alone could not induce inhibition of colony formation via KRAS knockdown at any concentration (Figure 40S-X). Notable toxicity of SMCC-protamine as a conjugate with scr-siRNA and KRAS-siRNA was observed only at the highest concentration (Figure 40W-X).

[0307] Example 14: It is possible to re-add free SMCC-protamine to an SMCC-protamine-depleted antibody-protamine conjugate to form a vesicle structure in vitro, and to replace free SMCC-protamine with free protamine. To further elucidate the functions of SMCC-protamine coupled to the antibody within the complex and SMCC-protamine as a free molecule, the amount of SMCC-protamine added to antibody-protamine conjugates from which free SMCC-protamine had been depleted by HPLC was titrated. These antibody-protamine conjugates could not form vesicular structures containing fluorescent siRNA, as shown in Figure 36F. Therefore, the inventors investigated whether the function could be achieved by re-adding free SMCC-protamine, and whether SMCC-protamine could be substituted with protamine that does not contain sulfo-SMCC. Different amounts of free SMCC-protamine and protamine alone were added to anti-EGFR-mAB-P (Figure 41). Adding 1x or 10x SMCC-protamine relative to the antibody was not effective in forming vesicle structures (Figures 41A and B), but adding 32x SMCC-protamine resulted in highly effective vesicle formation (Figure 41C). This assay suggests that free SMCC-protamine can be replaced with chemically coupled sulfo-SMCC-free protamine (Figure 41F).

[0308] Example 15: Formation of vesicle structures in vitro by antibody-protamine-siRNA and / or SM-1 / RF complexes To test this new and unexpected nanostructure model, we used the molecule SM-1 / RF (see Example 8), which is structurally completely different but has the same electrostatic charge, and complexed it with an antibody-protamine conjugate (Figures 42-45).

[0309] When the results of cell-free assembly of mAB-protamine-SM-1 / RF-conjugates with and without additional siRNA were examined, significant differences were observed in the quantity and size of the respective nanostructures: siRNA complexed with mAB-protamine + free SMCC-protamine and assembled with SM-1 / RF were considerably larger and more frequent than those without siRNA (Figures 42C and F, and 43D and H). This phenomenon is explained by the hypothesis that mixed particles consisting of all four components form stable nanostructures. In detailed fluorescence microscopy images, the nanostructure of the largest particles can be revealed as siRNA forming the boundary of a spheroid micelle, with SM-1 / RF filling the lumen of this sphere (see Figures 44 and 45, enlarged view).

[0310] This phenomenon, in which mixed antibody-protamine particles were more frequent and much larger than those in which only SM-1 / RF was complexed with mAB-protamine, was observed when the carrier antibody was anti-CD20-mAB rituximab (Figure 44) and anti-EGFR-mAB cetuximab (Figure 45).

[0311] That is, while negatively charged SM-1 / RF can form small vesicles with the antibody-protamine complex (Figures 42E and 43F), siRNA, being a linear and highly negatively charged molecule, can function as a kind of electrostatic "glue" between the antibody-protamine / free SMCC-protamine complex. This can be observed as a circular glow in very large vesicles that appear to be filled with red fluorescent SM-1 / RF (Figures 44 and 45).

[0312] The large micelle structures shown in Figures 44 and 37 are also visible in standard optical microscopy analysis under phase contrast conditions (see Figure 46).

[0313] Furthermore, this observation was confirmed by laser scanning microscopy (LSM, Figure 47). Here, confocal analysis of vesicles formed in a cell-free environment showed that green fluorescent siRNA formed a ring (Figure 47A a-c and Figure 47B d-f), and for very large vesicles, such as those formed by anti-CD20-mAB-P, the lumen of these vesicles was found to be filled with red fluorescent SM-1 / RF (Figure 47B d and f).

[0314] Example 16: Proposed Model In summary, the principle of anionic cargo molecule binding via carrier-antibody-protamine + unbound protamine can be applied to cargo molecules other than siRNA nucleic acids. Here, it is important to modify the cargo molecule to give it polyanionic properties, and to leave unbound protamine-SMCC in the preparation to enable strong electrostatic coordination bonding and self-assembly of the reactants.

[0315] This observation strongly supports the possibility that novel, unexpected polymer nanostructures may be necessary and sufficient for the in vitro and in vivo pharmacokinetic efficacy of our carrier system.

[0316] Accordingly, the inventors hypothesize a combination of components—(1) antibody-protamine, (2) siRNA / anionic small molecule inhibitor, and (3) unbound (SMCC-)protamine—to form a nanoparticle-like macrostructure that is responsible for the stability of siRNA and can effectively deliver siRNA and / or anionic small molecule inhibitors to intended cells, which is a completely unexpected observation. An exemplary idealized model of this nanostructure assembly is shown in Figure 11.

[0317] In conclusion, the minimum common feature requirement is polyanionicity, and experiments using various chemically different effector payloads that do not have other structural similarities provide experimental evidence that our novel unexpected nanostructure model is the basis for the in vitro and in vivo pharmacokinetic features of the antibody-SMCC linker-protamine siRNA carrier and antibody-SM-1 / RF systems.

[0318] Having dual specificity for (1) transport and specific delivery of siRNA / anionic small molecules to target cells, and (2) specific intracellular oncogene inactivation, this modular nanostructure system can be used for various disease groups, such as cancer.

[0319] Example 17: Coupling of antisense oligonucleotides to antibody-protamine conjugates To check whether antibody-protamine nanoparticles could also be used to transport single-stranded oligonucleotides, which are currently used as an alternative tool for knocking down gene expression, it was hypothesized that these synthetic antisense single-stranded oligonucleotides ("ASOs") are as short as siRNAs and would bind to αEGFR-mAB-protamine conjugates in a similar manner. Therefore, when a band shift assay was performed using control ASOs, it was found that 1 mole of αEGFR-mAB-protamine conjugate could bind to at least 8–32 moles of ASO after incubation at room temperature for 1 hour or at 37°C for 5 minutes (Figure 12).

[0320] Example 18: Synthesis of the low molecular weight polyanionic drug ibrutinib-Cy3.5 ("RMA561") Ibrutinib is a covalent conjugate of Bruton's kinase. Used in several lymphoma subtypes, ibrutinib inhibits downstream signaling of the B cell receptor by covalently adding cysteine ​​to the ATP-binding pocket of soluble Bruton's kinase. Because ibrutinib targets BTK not only in lymphoma cells but also in normal cells, it can have serious side effects such as infection, pneumonia, or arrhythmias (Wilson et al. 2015). This can lead to higher doses, interference by unrelated cells, and adverse effects that may be partly due to bystander effects against targets other than BTK (Byrd et al. 2013). Furthermore, prolonged ibrutinib administration can lead to the development of resistance (Lenz 2017). Here, we first attempted to conjugate ibrutinib to rituximab, a suitable carrier antibody that targets CD20 and is part of the standard treatment for DLBCL, using advanced linker chemistry. The conjugation was successful, but it was found that it altered the solubility of the conjugate, and therefore could not be further utilized.

[0321] Therefore, uncharged ibrutinib was converted to the strongly anionic compound Cy3.5-RMA561 (referred to herein as ibrutinib-Cy3.5) and bound to a protamine-based carrier system by electrostatic force to form an antibody-inhibitor complex. The cyanine dye Cy3.5 exhibits strong anionic characteristics by presenting four sulfonic acid groups as a possible binder (Figure 48). From our perspective, to form a nanocarrier, it is preferable to concentrate the anionic charge at one site of the molecule and have an overall linear shape. Furthermore, the cyanine dye allows the use of fluorescence readings at all stages of evaluation. Following published data (Kim et al. 2015; Turetsky et al. 2014), amino-functionalized ibrutinib derivative 5 was synthesized starting from commercially available pyrazolopyrimidine 1. Pyrazolopyrimidine 1 was iodized and substituted with 4-phenyloxybenzeneboronic acid via Suzuki coupling to form the main moiety 2 of the ibrutinib core structure. (S)-N-Boc-3-hydroxypiperidine, important for high binding affinity, was added via a stereocontrolled Mitsunobu reaction to form compound 3. After deprotection of the piperidine moiety, an α,β-unsaturated linker 4 (Michael acceptor) was introduced for irreversible binding to the target. The resulting Boc-protected amine 5, under basic conditions, represents a lead structure for labeling with different anionic moieties, such as the cyanine dye Cy3.5 (Lumiprobe), giving the corresponding amido ibrutinib-Cy3.5 (Cy3.5-RMA561). The final product was purified using a C18-SPE cartridge (purity >98% (HPLC)) and verified by high-resolution mass spectrometry.

[0322] Derivative 5 protected with Boc (8.2 mg, 0.014 mmol, 1.05 equivalents) was dissolved in 0.5 mL of anhydrous dichloromethane (dehydrated with molecular sieve 4A), and a 4 M hydrogen chloride dioxane solution (41 μL, 0.166 mmol, 12 equivalents) was added. The reaction mixture was stirred at room temperature until 5 was completely converted to a free amine (TLC: silica, solvent: 10% MeOH / Â, detection: tracking by UV254 and ninhydrin staining). The reaction mixture was evaporated under vacuum while heating to 35°C. The residual white solid was dissolved in 0.5 mL of anhydrous dimethylformamide, and to this solution, the NHS ester of Cy3.5 (sulfo-Cy3.5 NHS ester by Lumiprobe; 15 mg, 0.014 mmol, 1.0 equivalent) dissolved in 0.5 mL of anhydrous dimethylformamide and N,N-diisopropylethylamine (72 μL, 0.414 mmol, 30 equivalents) was added. The reaction mixture was stirred at room temperature in the dark until the reaction was complete, controlled by TLC analysis (RP C-18, solvent: MeOH / H2O / AcOH 10 / 0.5 / 0.2 v / v / v, detection: UV-VIS and ninhydrin staining). The reaction mixture was evaporated under vacuum while being heated to 35°C, and the residue was ground with pentane, diethyl ether, and ethyl acetate. The mixture was vacuum-dried at room temperature to obtain 21 mg of the crude product (Cy3.5-RMA561) in the form of a purple solid.

[0323] Analytically pure samples were prepared by chromatographic purification of the crude product in a 12 g C18 SPE cartridge. The cartridge was preconditioned by washing with water (10 mL). To remove impurities and reaction by-products, the crude product was divided into two parts, each dissolved in 0.5 mL of water, loaded onto the cartridge, and then washed with water (10 mL) and further washed with acetonitrile (10 mL). The product was then eluted with a mixture of ACN / H2O 1:1 (v / v) into fractions exclusively containing pure Cy3.5-RMA561. After lyophilization, 2 × 8 mg of pure Cy3.5-RMA561 was obtained as a purple solid.

[0324] In addition to the strong polyanionic properties of the Cy3.5 dye, the conjugate had the advantage of being easily traceable in vitro and in vivo in the form of red fluorescence.

[0325] Example 19: Analysis of antibody-protamine / protamine complex formation with ibrutinib-Cy3.5 in vitro First, experiments were conducted using band shift assays to characterize the binding of ibrutinib-Cy3.5 to both antibodies (rituximab and cetuximab) conjugated to protamine by two carrier systems, the bifunctional crosslinker sulfo-SMCC, namely rituximab (anti-CD20-mAB)-protamine containing unbound protamine-SMCC and cetuximab (anti-EGFR-mAB)-protamine containing unbound protamine-SMCC. Both carrier-conjugates containing unbound protamine-SMCC showed potent co-aggregation of ibrutinib-Cy3.5 derivatives and exhibited extremely high molar / molar electrostatic saturation of more than 100 moles of ibrutinib-Cy3.5 per mole of carrier mAB due to its lower molecular weight (approximately 13 kDa) compared to siRNA (Figure 50). In all further experiments, the composition of the chemically conjugated antibody-protamine remained unchanged; that is, the resulting product still contained unbound protamine-SMCC in addition to the antibody-protamine conjugate.

[0326] The corresponding conjugates, rituximab-protamine and cetuximab-protamine, both containing unbound protamine-SMCC and loaded with a subcritical 20-fold excess of ibrutinib-Cy3.5, were incubated with CD20-expressing and EGFR-expressing cell lines, and intracellular enrichment of ibrutinib-Cy3.5 was analyzed. In all cases, intracellular enrichment of the fluorescence signal was demonstrated at typical Cy3.5 excitation / emission wavelength combinations (Figure 51). Therefore, modified ibrutinib-Cy3.5 compounds can still translocate into cells and thus still exert their effects if they bind to the target BTK.

[0327] Next, an ibrutinib-Cy3.5 derivative coupled to a rituximab carrier antibody was administered to DLBCL cell lines, the cells were lysed, and the lysates were subjected to SDS-PAGE analysis. Subsequently, the gel was irradiated with UV light, and the emission from the Cy3.5 chromophore was scanned. Indeed, a single 70 kDa protein band emitting Cy3.5 fluorescence was found, which was later identified as Bruton's kinase BTK by Western Bot analysis (Figure 52).

[0328] In conclusion, chemical modification of the ibrutinib core structure to a polyanionic derivative does not alter the efficiency of the conjugate binding to Bruton's kinase BTK.

[0329] Next, a functional assay was planned to identify the efficacy of the antibody-inhibitor conjugates. DLBCL tumor cells were seeded on methylcellulose to induce colony growth without a scaffold, serving as a surrogate marker for tumorigenicity. The assay was performed with each antibody-inhibitor conjugate combination and compared to an appropriate control group. CD20-highly expressing HBL-1 cells were found to form only 30% of the colonies when treated with rituximab-protamine / protamine containing ibrutinib-Cy3.5 compared to the control group without carrier mAB. In contrast, unconjugated rituximab had only a mild effect on colony growth. Furthermore, in EGFR-highly expressing, CD20-lowly expressing A549 NSCLC cells (Figure 53B), the cetuximab carrier was significantly superior to the rituximab carrier, demonstrating the intended receptor-specific uptake mechanism.

[0330] As can be seen from the results of antibody-protamine / free protamine-SMCC / siRNA conjugation experiments, we hypothesized that the presence of unbound / free protamine-SMCC in the αCD20-mAB-protamine-ibrutinib-Cy3.5-protamine adduct may be as important as in the siRNA adduct. Therefore, as previously done, we depleted free protamine-SMCC from the rituximab-αCD20 mAB preparation by affinity chromatography. As expected, the depleted preparation (Figure 54A, fraction 25) was unable to bind and coordinate to polyanionic ibrutinib-Cy3.5 to the same extent as the protamine-SMCC-containing preparation (Figure 54B, right) (Figure 54B, left). CD20-mAB-P, which does not contain free protamine-SMCC, does not inhibit colony formation when complexed with ibrutinib-Cy3.5, making it comparable to the αCD20-mAB-protamine / free protamine-SMCC complex after depletion of free protamine-SMCC (Figure 54C).

[0331] Example 20: Analysis of antibody-protamine / free protamine-SMCC complex formation with ibrutinib-Cy3.5 in vivo To further characterize the in vivo therapeutic efficacy of rituximab-protamine / free protamine / ibrutinib-Cy3.5 carrier compared to all necessary component controls, in vivo treatment experiments as shown were performed (see Figure 55A). For this purpose, 107 HBL-1 DLBCL cells were subcutaneously transplanted into immunodeficient NSG mice and 200 mm 3Tumor growth was observed until the average size was reached, and mice were randomly assigned to groups of 10 each. Treatment was initiated with a standard concentration of 4 mg / kg body weight calculated for rituximab equivalent to 0.625 nmol of rituximab conjugate per dose, rituximab-protamine / free protamine-SMCC / ibrutinib-Cy3.5(1:20) + 18 μg or 12.5 nmol of ibrutinib-Cy3.5 equivalent to 0.625 nmol of rituximab conjugate per dose, as well as equal amounts of uncoordinated ibrutinib (12.5 nmol) and ibrutinib-Cy3.5 (12.5 nmol), and a PBS control. Treatment with ibrutinib-Cy3.5 did not show a therapeutic effect on tumor growth, but application of an equivalent dose of ibrutinib-Cy3.5 bound to a rituximab-protamine carrier resulted in significantly slower tumor growth compared to all other groups (Figure 55C). This also translated into animal survival analysis (Figure 55B).

[0332] Therefore, the rituximab-protamine / free protamine / ibrutinib-Cy3.5 1:20 complex demonstrated significantly superior targeting and therapeutic profiles compared to all appropriate component controls in an in vivo model. Furthermore, the single dose of ibrutinib applied was 20 times lower (12.5 nmol ibrutinib corresponds to 0.720 mg / kg in mice, compared to the standard dose of 12 mg / kg in Nod-SCID mice (Chen et al. 2016; Zhang et al. 2017)).

[0333] To test this hypothesis, organs were prepared from sacrificed mice and subjected to ex vivo fluorescence detection of incorporated ibrutinib-Cy3.5 (Figure 56). As a result, tumors derived from mice treated with rituximab-protamine / ibrutinib-Cy3.5 showed a significant accumulation of Cy3.5-derived fluorescence signals, which increased with the treatment cycle. In contrast, tumors derived from mice treated with ibrutinib-Cy3.5 administered without rituximab coordination showed little to no detectable signal (Figure 56), and this group showed a tendency toward scattered background signals, which were observed in most organs (Figure 57).

[0334] Furthermore, no specific fluorescence was detected in the analyzed organs (Figure 57). It can be concluded that the rituximab-protamine / free protamine-SMCC / ibrutinib-Cy3.5 conjugate is specifically enriched in CD20-positive tumors.

[0335] Example 21: Formation of vesicle structures in vitro by antibody-protamine / free protamine-siRNA and / or ibrutinib-Cy3.5 complexes To further characterize the new nanostructures, electrostatically charged green fluorescent siRNA and red fluorescent ibrutinib-Cy3.5 were used and conjugated with antibody-protamine / free protamine-SMCC conjugates (Figures 58-60).

[0336] When the results of cell-free assembly of mAB-protamine / free protamine / ibrutinib-Cy3.5 conjugates with and without additional siRNA were examined, significant differences were observed in the quantity and size of the respective nanostructures: those assembled with siRNA complexed by mAB-protamine + free protamine-SMCC and those assembled with ibrutinib-Cy3.5 were considerably larger and more frequent than those without siRNA (Figures 58C and F, and 59D and H). This phenomenon can be explained by the hypothesis that mixed particles consisting of all four components form a stable nanostructure. In detailed fluorescence microscopy images, the nanostructure of the largest particles can be revealed to be such that siRNA forms the outer edge of the spheroid micelle (Figures 60, A and C), and ibrutinib-Cy3.5 more fills the lumen of this nanostructure (Figures 60B and D).

[0337] This phenomenon, in which mixed antibody-protamine particles were more frequent and much larger than those conjugated solely with ibrutinib-Cy3.5 and the mAB-protamine / protamine carrier, was observed both when the carrier antibody was αCD20-mAB rituximab (Figure 60C-D) and when it was anti-EGFR-mAB cetuximab (Figure 60A and B).

[0338] That is, while the negatively charged ibrutinib-Cy3.5 can form small vesicles with the antibody-protamine complex (Figures 58E and 59F), siRNA, being a linear and highly negatively charged molecule, can function as a kind of electrostatic "glue" between the antibody-protamine / free protamine-SMCC complex. This can be observed as a circular glow in very large vesicles that appear to be filled with red fluorescent ibrutinib-Cy3.5 (Figure 60).

[0339] To further characterize this structure, particle size measurements were performed using a ZetaView® nanoparticle tracking video microscope. Particles ranging from 1 to 1000 nm were detected and analyzed for their size and number (Figure 61). The addition of control (scr)siRNA, ibrutinib-Cy3.5, or both, resulted in the detection of the largest stable particles 1 hour after the onset of complex formation (Figures 61A, B, C, D). The use of equal volumes of antibody-free protamine-SMCC (=1800nM=60nm, 30x molar ratio used for anti-CD20-mAB coupling) consistently resulted in the formation of smaller particles (Figure 61A, bottom panel, and Figure 61E). Interestingly, the formation of extremely large mixed particles, as seen in Figure 60, was not observed in the ZetaView data due to technical limitations.

[0340] Example 22: Conjugation of anionic small molecule drugs using carrier-antibody-protamine fusions or antibody-protamine conjugates Regarding the complexation of anionic small molecules, band shift assays using ibrutinib-Alexa488 in different ratios up to 1:2 with αCD20-mAB-protamine revealed that the αCD20-mAB rituximab-protamine / free protamine-SMCC(αCD20-mAB-P / P) conjugate bound to ibrutinib-Alexa488. Due to the limited anionic charge of the Alexa488 molecule (Figure 62, B), the interaction between the polycationic protamine fusion and Alexa488 was found to be weaker than that with Cy3.5, which has a net charge of -4 (see next example). Thus, a coupling ratio of only 2:1 was achieved with ibrutinib conjugated to Alexa488 and the protamine conjugate. However, the conjugation of ibrutinib-Alexa488 with αCD20-mAB rituximab-protamine / free protamine-SMCC (αCD20-mAB-P / P) was still successful.

[0341] Under conditions similar to those reported for other nanoparticles, the construction of antibody-inhibitor conjugates in the form of stable nanoparticles, which are stable in serum (Figure 62E, G, F, H), could be detected by fluorescence microscopy (Figure 62C-H). Importantly, ibrutinib-Cy3.5 is detectable by fluorescence, which provides excellent traceability for all downstream applications.

[0342] When incubated in vitro, ibrutinib-Cy3.5-loaded αCD20-mAB-P / P resulted in an aggregate of electrostatically stabilized nanoparticles emitting red Cy3.5 fluorescence (Figure 65). Fluorescence microscopy initially detected regularly shaped vesicle structures (Figure 62C, D), followed by smaller particles and later, irregularly shaped aggregates larger than 2 μm. This process was not observed (not shown) when unmodified αCD20-mAB was used to complex with ibrutinib-Cy3.5, or when modified αCD20-mAB-P / free protamine was used to complex with hydrophobic ibrutinib (trade name: Imbruvica). The electrostatic particles observed by optical microscopy (Figures 65A and B) were also confirmed by electron microscopy (Figure 65C), and since a large number of smaller particles in the range of <100 to 200 nm were detected (Figure 65C), the inventors chose the term "nano" carrier.

[0343] Regarding the comparison of anionic charged small molecules and uncharged small molecules for complexation with protamine conjugates, it was found that charged ibrutinib-Cy3.5 formed stable nanoparticles with protamine-conjugated mAB, while uncharged ibrutinib (trade name: imbruvica) did not. Each antibody carrier conjugated to protamine was loaded with either charged ibrutinib-Cy3.5 or uncharged ibrutinib. Notably, only the ibrutinib sample conjugated with Cy3.5 showed high-density nanoparticle formation, while uncharged ibrutinib did not (Figure 63). This suggests that the net charge of the polyanionic material, as well as certain polyanion structures, is important for proper electrostatic interaction with protamine.

[0344] Example 23: Proposed Model In summary, the principle of binding anionic cargo molecules by a carrier consisting of antibody-protamine + unbound protamine can be applied to cargoes other than siRNA nucleic acids, such as small molecules, for example, the kinase inhibitor ibrutinib. Here, it is important to modify the cargo molecule to give it polyanionic characteristics, and to leave unbound protamine-SMCC in the preparation to enable strong electrostatic self-assembly of the components into nanostructures.

[0345] This observation strongly supports the idea that novel, unexpected polymer nanostructures are responsible for the in vitro and in vivo pharmacokinetic efficacy of our carrier system.

[0346] Therefore, the inventors predict a combination of components—(1) antibody-protamine, (2) siRNA / anionic small molecule inhibitor, and (3) unbound protamine (-SMCC)—to form a nanoparticle-like macrostructure that is responsible for the stability of siRNA and can effectively deliver siRNA and / or anionic small molecule inhibitors to intended cells, which is a completely unexpected observation. An idealized model of this nanostructure assembly is shown in Figure 64.

[0347] In conclusion, the minimum common characteristic requirement is polyanionicity, and experiments using various chemically different effector payloads that do not have other structural similarities provide experimental evidence that our novel unexpected nanostructure model is the basis for the in vitro and in vivo pharmacokinetic characteristics of the nanocarrier-siRNA carrier and nanocarrier-ibrutinib-Cy3.5 systems.

[0348] Having dual specificity for (1) transport and specific delivery of siRNA / anionic small molecules to target cells, and (2) specific intracellular oncogene inactivation or pharmacological activity, this modular nanostructure system can be used for various disease groups, such as cancer.

[0349] Example 24: Functional analysis of αCD20-mAB-P / P-ibrutinib-Cy3.5 nanocarrier in vitro Next, we investigated the effectiveness of this αCD20-mAB-P / P-ibrutinib-Cy3.5 nanocarrier in different cell model systems.

[0350] First, we investigated the internal translocation to CD20-positive DLBCL cells via Cy3.5 fluorescence. Lymphoma cells HBL1 and TMD-8 treated overnight with uncoupled ibrutinib-Cy3.5 showed valid red fluorescence marking of the cells (white in Figure 66E), which was enhanced when ibrutinib-Cy3.5 was conjugated with αCD20-mAB-P / P and transported (Figure 66F). This indicated that the process of internal translocation via the CD20 receptor is beneficial compared to the untargeted uptake mechanism of the ibrutinib-Cy3.5 anion without carrier antibody implementation (Figure 66E). Next, 72-hour treatment of cells with the conjugate showed a single band of covalent Cy3.5 marking of the 70kDa protein in SDS-PAGE electrophoresis, indicating the binding and functionality of the modified ibrutinib-Cy3.5 compound (Figure 66G). To detect BTK fluorescence, the gel had to be significantly overloaded to ensure equal loading of the lanes and to identify BTK. Therefore, the gel was then blotted for immunodetection of BTK after fluorescence detection. Indeed, the band representing BTK appeared at the same position as that seen in Cy3.5 fluorescence, indicating, as expected, that ibrutinib-Cy3.5 exclusively covalently bound to BTK (Figure 66G).

[0351] Furthermore, HBL1 cells were incubated with ibrutinib-body pie for 2 hours, washed, and treated with αCD20-mAB-P / P-ibrutinib-Cy3.5. While the cells took up ibrutinib-body pie (Figures 66N and P), Cy3.5 fluorescence appeared only in unpre-treated cells (Figure 66L) and not in cells pre-treated with ibrutinib-body pie (Figure 66P). Some intracellular red vesicles showed CD20-mediated internal translocation of ibrutinib-Cy3.5 (Figure 66P), but no pattern suggestive of BTK binding developed (see Figure 66L for ibrutinib-Cy3.5 and Figures 66N and P for ibrutinib-body pie). This is true both after 24 hours of αCD20-mAB-P / P-ibrutinib-Cy3.5 treatment and after pre-incubation with non-fluorescent ibrutinib and subsequent washing.

[0352] The functional effect of ibrutinib's covalent targeting of BTK is the inhibition of BTK autophosphorylation. Therefore, the phosphorylation status of BTK in DLBCL cells after ibrutinib-Cy3.5 treatment was analyzed both with and without complexation on the αCD20-mAB / P / P nanocarrier (Figure 67A). Cells were treated with PBS, uncomplexed ibrutinib-Cy3.5, and the αCD20-mAB-P / P / ibrutinib-Cy3.5 complex for 72 hours, lysed, and subjected to Western blot analysis. In HBL1 cells (Figure 67A, left panel) and TMD8 cells (data not shown), treatment with ibrutinib-Cy3.5, regardless of whether it was complexed or not, significantly reduced BTK phosphorylation at tyrosine 223, as detected by a specific phosphorylated BTK antibody. This was consistent with BTK binding as illustrated in Figure 66G. Total BTK expression was mildly affected (Figure 67A). The synthesized ibrutinib-Cy3.5 conjugate was concluded to retain full functionality in terms of both binding to the target molecule BTK and inactivating BTK autophosphorylation.

[0353] Interestingly, in all lymphoma cell lines tested, the lymphoma-specific αCD20-mAB-P / P / ibru-Cy3.5 nanocarrier system significantly inhibited colony growth in soft agar cultures. This was observed to a much lower degree with ibrutinib or ibrutinib-Cy3.5 as monotherapy and not with unmodified rituximab (αCD20-mAB) (HBL1: Figure 67B). This colony assay is used to quantify anchorage-independent clonal cell proliferation and is a standard in vitro surrogate for in vivo tumorigenesis. Therefore, we assert that the robust therapeutic effect of ibrutinib-Cy3.5 is observed only when the anionic compound assembles onto stable electrostatic nanoparticles composed of a cationic αCD20-mAB-protamine / free protamine carrier complex and an anionic cargo effector.

[0354] Next, we investigated the functional significance of BTK inactivation by αCD20-mAB-P / P-ibrutinib-Cy3.5 in DLBCL cell lines, specifically in terms of apoptosis induction. Here, in both HBL1 cells (Figure 68) and TMD8 cells (data not shown), treatment with αCD20-mAB-P / P-ibrutinib-Cy3.5 showed excellent induction of apoptotic signals (Figure 68, rightmost bar), whereas treatment with uncomplexed ibrutinib-Cy3.5 showed only a mild effect compared to both targeted treatment and free ibrutinib treatment. Therefore, it is hypothesized that targeted treatment with αCD20-mAB-P / P-ibrutinib-Cy3.5 leads to the accumulation of active ibrutinib-Cy3.5 in cells, and thus results in more severe apoptosis induction than uncomplexed ibrutinib-Cy3.5. Furthermore, the anionic molecule ibrutinib-Cy3.5, when not complexed, appears to be less accessible to cells or at least less effective than hydrophobic free ibrutinib, as judged by lower induction of apoptosis compared to free ibrutinib.

[0355] Example 25: Systemic therapy using αIGF1R-mAB-protamine-siRNA-protamine nanocarrier inhibits the growth of Ewing sarcoma xenograft tumors by knockdown of oncogenic EWS-FLI1 translocation products. To test the in vivo efficacy of teprotumumab-protamine nanocarriers, 107 human SK-N-MC cells were subcutaneously transplanted (sc) into the flanks of CD1 nude mice, and a cohort of at least 7 mice was treated with either PBS, αIGF1R-mAB-P / P conjugated with scrambled control siRNA, or the aforementioned αIGF1R-mAB-P / P conjugated with EWS-FLI1-siRNA (Figure 69A-C). Treatment was initiated when the tumors reached an average size of 100-150 mm3. Tumors in the treatment group receiving Tepro-mAB-P / EWS-FLI1-siRNA / P nanoparticles showed significant, near-complete inhibition of growth compared to both control groups (Figure 69B and C). This suggests that EWS-FLI1 knockdown via Tepro-mAB-P / siRNA / P nanoparticles was successful after systemic in vivo application.

[0356] Example 26: Nanoparticles formed by carrier antibody-protamine / free protamine and siRNA exhibit a nearly neutral surface charge. The formation of nanoparticles from antibody-protamine / free protamine + siRNA was found to be rapid and reproducible, but dependent on the antibody preparation. For example, DLS analysis (Figure 70) and microscopic analysis showed that different α-IGFR-protamine preparations tended to produce larger particles than those formed by αEGFR-protamine or αCD33 preparations. Next, the surface charge varied only slightly in the weakly anionic range, resulting in nearly neutrally charged particles. It can be concluded that not only the properties of the antibody itself, but also the electrostatic balance between the anionic and cationic components, defines the attributes of the nanoparticles in terms of size and surface charge.

[0357] Example 27: Deciphering the prerequisites for effective nanoparticle formation between anti-EGFR-mAB-SMCC-protamine conjugate, free SMCC-protamine, and siRNA. Furthermore, we evaluated whether siRNA was required for vesicle formation. A constant amount of αEGFR-mAB-P and a constant 32x free SMCC-protamine were incubated with different amounts of Alexa488-control siRNA (Figure 71A-G, green fluorescence in the upper panel, phase contrast in the lower panel). Notably, nanoparticles were efficiently formed with an optimal molar excess of siRNA of 5-10x relative to the antibody (Figure 71D-E).

[0358] Example 28: Nanoparticles formed by αEGFR-protamine / free protamine-Alexa488-siRNA are stable under serum-containing conditions. For the systemic therapeutic application of targeted nanoparticles, stability under various challenging conditions is paramount; otherwise, the active substance will separate from the nanocarrier due to disintegration. Here, we tested the stability of αEGFR-mAB-protamine, free protamine, and Alexa488-siRNA in high concentrations of bovine serum albumin, and found that the nanocarrier remained stable even after 24 hours (Figure 72B).

[0359] Example 29: Serum stability of αCD20-mAB-protamine / free P-ibrutinib-Cy3.5 nanocarrier The αCD20-mAB-protamine / free P-ibrutinib-Cy3.5 antibody-inhibitor complex, in the form of stable nanoparticles, was detectable in serum for 24 hours (Figure 73B-C) and even 72 hours (Figure 73E-F) by fluorescence microscopy (Figure 73A-F).

[0360] Example 30: pH stability of siRNA nanocarriers constructed with three different targeting antibodies For systemic application of nanocarriers, it is crucial to determine the pH conditions under which the structure is stable in order to prevent premature degradation and loss of the coordinated siRNA effector molecule. Here, siRNA nanocarriers were formed under standard conditions using three different targeting antibodies and siRNAs, and their integrity was tested at pH conditions ranging from 4.8 to 8.0 (Figure 74), thus covering all pH conditions that the nanocarriers may encounter during therapeutic application. The nanocarriers, as determined by Alexa488 fluorescence of the complexed siRNAs, were found to be stable at pH conditions from 5.2 to 8.0 and showed a tendency to structure at lower pH levels, forming larger superstructures.

[0361] Example 31: pH stability of nanocarriers constructed with αCD20-mAB-protamine / free protamine and ibrutinib-Cy3.5 Here, ibrutinib-Cy3.5 nanocarriers were formed using αCD20-mAB-protamine / free protamine under standard conditions, and their integrity was tested at pH ranges of 4.8–8.0, thus covering all pH conditions that the nanocarriers may encounter during therapeutic application (Figure 75). The nanocarriers of the complexed ibrutinib-Cy3.5, as determined by Cy3.5 fluorescence, were found to be stable at pH conditions of 5.8–8.0 and to have a tendency to disintegrate at lower pH levels.

[0362] Example 32: Immunolabeling of targeting IgG antibodies in αEGFR-mAB-P / free protamine-siRNA nanocarriers and αIGF1R-mAB-P / free protamine-siRNA nanocarriers The self-assembly process of cationic antibody-protamine / free protamine preparations with siRNA results in nanoparticle structures with a distinct configuration: here, αEGFR-mAB-protamine / free protamine-siRNA nanoparticles (Figure 76) and αIGF1R(teprotumumab)mAB-protamine / free protamine / siRNA nanoparticles (Figure 77) were subjected to immunodetection of human IgG signals. To visualize the position and orientation of human IgG within the nanocarrier, α-human IgG-Alexa647 was used. The signal was observed only at the outer edge of the nanoparticle micelle structure (Figures 76B and 77B), and not in the lumen. Instead, the signal for fluorescently labeled siRNA was found in the lumen of the structure (Figures 76A and 77A). Thus, it was concluded that bulky IgG molecules are oriented outward from the nanoparticle micelles and therefore must ultimately be able to access the extracellular domains of cell surface molecules and receptor tyrosine kinases, which are their protein targets.

[0363] Example 33: Visualization of free protamine in nanocarrier composites The location of important free protamine within the nanocarrier had remained unknown until now. Therefore, the inventors addressed this point by substituting the free protamine in a predetermined αEGFR-protamine preparation with protamine conjugated to Cy3-NHS ester (Figure 78A), and combining this with non-fluorescent siRNA to form a nanocarrier structure (Figure 78B). Subsequently, when the nanocarrier was subjected to fluorescence microscopy, a staining pattern was revealed in which protamine-Cy3 was located in the lumen of the nanocarrier (Figures 78C-E), and the IgG portion stained with anti-human IgG-Alexa647 was located in the peripheral section of the nanocarrier (Figures 78E-F).

[0364] Example 34: Synthesis of cyanine-conjugated inhibitors, gefitinib, gemcitabine, and venetoclax. To this end, we will synthesize three new compounds conjugated to two different cyanine dyes, sulfo-Cy3.5(trademark) (excitation 591 nm / emission 604 nm) and sulfo-Cy5.5(trademark) (excitation 684 nm, emission 710 nm). Both cyanine dyes share an identical core fluorophore structure exhibiting four strongly anionic sulfonyl groups necessary for the coordination bond of the cationic peptide protamine, but differ only in the number of conjugated double bonds, which results in discriminable fluorescent dye attributes. Similar to ibrutinib, the three different drug-dye conjugates will be synthesized in comparable overall molecular shapes. Gefitinib (EGFR inhibitor), gemcitabine (cell division inhibitor), and venetoclax (BLCL-2 inhibitor) were selected as potential candidates because, in all cases, they retain their ability to bind to target molecules after conjugation with the dye, enabling the application of fluorescence imaging (Wu et al. 2020; Zhu et al. 2018; Gonzales et al. 2018). They are conjugated to cyanine dyes by adding a PEG4 spacer and using commercially available reactive NHS ester or azide-functionalized dyes (see Figure 79).

[0365] First, starting with commercially available gefitinib 1, it is demethylated, and the resulting phenol is converted by nucleophilic attack with azido-PEG4-mesylic acid to synthesize a gefitinib analog. The resulting azido is reduced to amine 2 and labeled with sulfo-Cy3.5 or sulfo-Cy5.5 to obtain a gefitinib conjugate for further complexation with nanosupports.

[0366] For gemcitabine 3, the hydroxyl group is protected, a leaving group is added to cytosine, and alkyne 4 is obtained after nucleophilic attack with propargylamine (Solanki et al. 2020). After labeling with the corresponding azide-functionalized cyanine dye by a click reaction, the desired conjugate is obtained.

[0367] For the third example, venetoclax, we start with the synthesis of the known venetoclax core structure 5 (Giedt et al. 2014). Using the previously mentioned mesyl-PEG4-azide, we reach sulfonamide 6 in three steps, and after conjugation with 5, the corresponding venetoclax conjugate for further evaluation is obtained by reduction of the azide and subsequent labeling with a cyanine dye (NHS-ester).

[0368] Example 35: The concept is extended to simpler and less expensive polyanionic molecular parts and to other therapeutic interventions such as PDT and radiotherapy. Following the conversion and evaluation of the electrostatic coupling principle to other anticancer drugs with different binding motifs and targets, the intention is to transform the required anionic features from the cyanine dyes used here (which were important for initial optical characterization and fluorescence imaging) into more readily available electrostatic connectors, in terms of (1) easier and cheaper synthesis, in order to facilitate translation into clinical evaluation. Candidates include polysulfated monosaccharides, disaccharides, and branched oligosaccharides, or monophosphates, diphosphates, and triphosphates, which could pave the way for large-scale synthesis (Figure 80).

[0369] The present invention as described herein exemplary may be appropriately implemented in the absence of any components or limitations not specifically disclosed herein. Furthermore, the terms and expressions used herein are for illustrative purposes only, not limitation, and the use of such terms and expressions is not intended to exclude any equivalents of the exhibited and described features or any part thereof, and it should be recognized that various modifications are possible within the scope of the present invention as described in the claims. Accordingly, although the present invention is specifically disclosed by exemplary embodiments and optional features, it should be understood that modifications and variations of the present invention as disclosed herein and embodied therein may be used by those skilled in the art, and that such modifications and variations are considered to fall within the scope of the present invention.

[0370] The present invention is described generically in this specification. Each of the narrower species and subgeneric groups included in the generic disclosure also forms part of the present invention. This includes the generic descriptions of the present invention with conditions or negative limitations that remove any subject matter from a genus, whether or not the material to be removed is specifically enumerated herein.

[0371] Other embodiments are included in the following claims.

[0372] Non-patent references TIFF2023553038000013.tif240161TIFF2023553038000014.tif251161TIFF2023553038000015.tif247161TIFF2023553038000016.tif221161

Claims

1. (c) contacting the antibody with a composition comprising a first conjugate (A), the first conjugate comprising a positively charged polypeptide conjugated to a bifunctional linker, the composition being characterized in that it is essentially free of unconjugated bifunctional linkers, thereby obtaining a second conjugate (B), the second conjugate comprising a positively charged polypeptide, a bifunctional linker and an antibody; and (d) contacting the second conjugate (B) with the positively charged polypeptide and the negatively charged molecule, thereby forming nanoparticles.

16. A method for producing nanoparticles comprising:

2. Prior to step (c), (a) conjugating a positively charged polypeptide to a bifunctional linker; (b) Removing unconjugated bifunctional linkers 2. The method of claim 1, comprising:

3. 3. The method of claim 1 or 2, wherein in step (c), the molar ratio of the first conjugate (A) to the antibody is at least about 10:

1.

4. The method according to any one of claims 1 to 3, wherein in step (d), the molar ratio of the positively charged polypeptide to the second conjugate (B) is at least about 10:

1.

5. The method of any one of claims 1 to 4, wherein the antibody is specific for a cell surface molecule.

6. The method of any one of claims 1 to 5, wherein the negatively charged molecule is a nucleic acid.

7. The method of any one of claims 1 to 6, wherein the positively charged polypeptide is a protamine or a histone. (a) the antibody is an anti-CD33 antibody, the positively charged polypeptide is protamine, and / or the negatively charged molecule is DNMT3A-siRNA; (b) the antibody is an anti-IGF1R antibody, the positively charged polypeptide is protamine, and / or the negatively charged molecule is EWS / FLI1-siRNA; or (c) the antibody is an anti-EGFR antibody, the positively charged polypeptide is protamine, and / or the negatively charged molecule is KRAS-siRNA; The method of any one of claims 1 to 7.

9. The method described in claim 8, wherein the anti-CD33 antibody is gemtuzumab, the anti-IGF1R antibody is teprotumumab or cixutumumab, or the anti-EGFR antibody is cetuximab.

10. Nanoparticles obtainable by the method according to any one of claims 1 to 9.

11. (a) a positively charged polypeptide; (b) a second conjugate (B) comprising an antibody conjugated to a positively charged polypeptide; (c) one or more negatively charged molecules; Nanoparticles comprising:

12. 12. The nanoparticle of claim 10 or 11, wherein the second conjugate is concentrated in the outer portion of the nanoparticle.

13. The nanoparticle of any one of claims 10 to 12, wherein the one or more negatively charged molecules are concentrated in an interior portion of the nanoparticle.

14. The nanoparticles of any one of claims 10 to 13, having an average diameter of about 0.05 μm to about 10 μm.

15. (a) the antibody is an anti-CD33 antibody, the positively charged polypeptide is protamine, and / or the negatively charged molecule is DNMT3A-siRNA; (b) the antibody is an anti-IGF1R antibody, the positively charged polypeptide is protamine, and / or the negatively charged molecule is EWS / FLI1-siRNA; or (c) the antibody is an anti-EGFR antibody, the positively charged polypeptide is protamine, and / or the negatively charged molecule is KRAS-siRNA; The nanoparticles according to any one of claims 10 to 14.

16. The nanoparticle described in claim 15, wherein the anti-CD33 antibody is gemtuzumab, the anti-IGF1R antibody is teprotumumab or cixutumumab, or the anti-EGFR antibody is cetuximab.

17. A composition comprising the nanoparticles of any one of claims 10 to 16.

18. A pharmaceutical composition for the treatment of a disease, comprising the nanoparticles described in any one of claims 10 to 16 or the composition described in claim 17.

19. The pharmaceutical composition of claim 18, wherein the disease is cancer.

20. The pharmaceutical composition of claim 18 or 19, wherein the disease is leukemia, Ewing's sarcoma, or a solid tumor.

21. A kit comprising the nanoparticles of any one of claims 10 to 16 or the composition of claim 17.